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Background: Chronic constipation affects 1–2% of adults and significantly affects quality of life. Beyond the
use of laxatives and other basic measures, there is uncertainty about management, including the value of
specialist investigations, equipment-intensive therapies using biofeedback, transanal irrigation and surgery.
Objectives: (1) To determine whether or not standardised specialist-led habit training plus pelvic floor
retraining using computer-assisted direct visual biofeedback is more clinically effective than standardised
specialist-led habit training alone, and whether or not outcomes of such specialist-led interventions are
improved by stratification to habit training plus pelvic floor retraining using computer-assisted direct visual
biofeedback or habit training alone based on prior knowledge of anorectal and colonic pathophysiology using
standardised radiophysiological investigations; (2) to compare the impact of transanal irrigation initiated with
low-volume and high-volume systems on patient disease-specific quality of life; and (3) to determine the
clinical efficacy of laparoscopic ventral mesh rectopexy compared with controls at short-term follow-up.
Design: The Chronic Constipation Treatment Pathway (CapaCiTY) research programme was a
programme of national recruitment with a standardised methodological framework (i.e. eligibility,
baseline phenotyping and standardised outcomes) for three randomised trials: a parallel three-group
trial, permitting two randomised comparisons (CapaCiTY trial 1), a parallel two-group trial (CapaCiTY
trial 2) and a stepped-wedge (individual-level) three-group trial (CapaCiTY trial 3).
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Setting: Specialist hospital centres across England, with a mix of urban and rural referral bases.
Participants: The main inclusion criteria were as follows: age 18–70 years, participant self-reported
problematic constipation, symptom onset > 6 months before recruitment, symptoms meeting the
American College of Gastroenterology’s constipation definition and constipation that failed treatment
to a minimum basic standard. The main exclusion criteria were secondary constipation and previous
experience of study interventions.
Interventions: CapaCiTY trial 1: group 1 – standardised specialist-led habit training alone (n = 68);
group 2 – standardised specialist-led habit training plus pelvic floor retraining using computer-assisted
direct visual biofeedback (n = 68); and group 3 – standardised radiophysiological investigations-guided
treatment (n = 46) (allocation ratio 3 : 3 : 2, respectively). CapaCiTY trial 2: transanal irrigation initiated
with low-volume (group 1, n = 30) or high-volume (group 2, n = 35) systems (allocation ratio 1 : 1).
CapaCiTY trial 3: laparoscopic ventral mesh rectopexy performed immediately (n = 9) and after 12 weeks’
(n = 10) and after 24 weeks’ (n= 9) waiting time (allocation ratio 1 : 1 : 1, respectively).
Main outcome measures: The main outcome measures were standardised outcomes for all three trials.
The primary clinical outcome was mean change in Patient Assessment of Constipation Quality of Life
score at the 6-month, 3-month or 24-week follow-up. The secondary clinical outcomes were a range of
validated disease-specific and psychological scoring instrument scores. For cost-effectiveness, quality-
adjusted life-year estimates were determined from individual participant-level cost data and EuroQol-5
Dimensions, five-level version, data. Participant experience was investigated through interviews and
qualitative analysis.
Results: A total of 275 participants were recruited. Baseline phenotyping demonstrated high levels
of symptom burden and psychological morbidity. CapaCiTY trial 1: all interventions (standardised
specialist-led habit training alone, standardised specialist-led habit training plus pelvic floor retraining
using computer-assisted direct visual biofeedback and standardised radiophysiological investigations-
guided habit training alone or habit training plus pelvic floor retraining using computer-assisted direct
visual biofeedback) led to similar reductions in the Patient Assessment of Constipation Quality of Life
score (approximately –0.8 points), with no statistically significant difference between habit training
alone and habit training plus pelvic floor retraining using computer-assisted direct visual biofeedback
(–0.03 points, 95% confidence interval –0.33 to 0.27 points; p = 0.8445) or between standardised
radiophysiological investigations and no standardised radiophysiological investigations (0.22 points,
95% confidence interval –0.11 to 0.55 points; p = 0.1871). Secondary outcomes reflected similar levels
of benefit for all interventions. There was no evidence of greater cost-effectiveness of habit training
plus pelvic floor retraining using computer-assisted direct visual biofeedback or stratification by
standardised radiophysiological investigations compared with habit training alone (with the probability
that habit training alone is cost-effective at a willingness-to-pay threshold of £30,000 per quality-
adjusted life-year gain; p = 0.83). Participants reported mixed experiences and similar satisfaction in all
groups in the qualitative interviews. CapaCiTY trial 2: at 3 months, there was a modest reduction in the
Patient Assessment of Constipation Quality of Life score, from a mean of 2.4 to 2.2 points (i.e. a reduction
of 0.2 points), in the low-volume transanal irrigation group compared with a larger mean reduction of
0.6 points in the high-volume transanal irrigation group (difference –0.37 points, 95% confidence interval
–0.89 to 0.15 points). The majority of participants preferred high-volume transanal irrigation, with
substantial crossover to high-volume transanal irrigation during follow-up. Compared with low-volume
transanal irrigation, high-volume transanal irrigation had similar costs (median difference –£8, 95%
confidence interval –£240 to £221) and resulted in significantly higher quality of life (0.093 quality-
adjusted life-years, 95% confidence interval 0.016 to 0.175 quality-adjusted life-years). CapaCiTY trial 3:
laparoscopic ventral mesh rectopexy resulted in a substantial short-term mean reduction in the Patient
Assessment of Constipation Quality of Life score (–1.09 points, 95% confidence interval –1.76 to –0.41
points) and beneficial changes in all other outcomes; however, significant increases in cost (£5012, 95%
confidence interval £4446 to £5322) resulted in only modest increases in quality of life (0.043 quality-
adjusted life-years, 95% confidence interval –0.005 to 0.093 quality-adjusted life-years), with an
incremental cost-effectiveness ratio of £115,512 per quality-adjusted life-year.
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Conclusions: Excluding poor recruitment and underpowering of clinical effectiveness analyses, several
themes emerge: (1) all interventions studied have beneficial effects on symptoms and disease-specific
quality of life in the short term; (2) a simpler, cheaper approach to nurse-led behavioural interventions
appears to be at least as clinically effective as and more cost-effective than more complex and invasive
approaches (including prior investigation); (3) high-volume transanal irrigation is preferred by
participants and has better clinical effectiveness than low-volume transanal irrigation systems; and
(4) laparoscopic ventral mesh rectopexy in highly selected participants confers a very significant
short-term reduction in symptoms, with low levels of harm but little effect on general quality of life.
Limitations: All three trials significantly under-recruited [CapaCiTY trial 1, n = 182 (target 394);
CapaCiTY trial 2, n = 65 (target 300); and CapaCiTY trial 3, n = 28 (target 114)]. The numbers analysed
were further limited by loss before primary outcome.
Trial registration: Current Controlled Trials ISRCTN11791740, ISRCTN11093872 and
ISRCTN11747152.
Funding: This project was funded by the National Institute for Health Research (NIHR) Programme
Grants for Applied Research programme and will be published in full in Programme Grants for Applied
Research; Vol. 9, No. 14. See the NIHR Journals Library website for further project information.
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Plain English summary
Constipation affects nearly everyone at some stage in their life. However, about 1 in 100 people inthe UK suffer chronic symptoms that fail to respond to simple treatments including exercise,
drinking more fluid, better diet and laxatives.
We call this ‘chronic constipation’, and it can be very difficult to treat, even by experts. We can give
stronger laxatives and newer drugs and provide nurse-led bowel retraining classes, bowel irrigation
and even surgery. However, we do not know what tests we should do first and what treatments we
should then use. The Chronic Constipation Treatment Pathway (CapaCiTY) programme enrolled
275 participants to three trials:
CapaCiTY trial 1 – how good are different types of specialist nurse-led bowel
retraining (182 participants)?
CapaCiTY trial 2 – what type of bowel irrigation via the anus should we use (65 participants)?
CapaCiTY trial 3 – how good is a type of surgical operation called laparoscopic ventral mesh
rectopexy for internal bowel prolapse (28 participants)?
Unfortunately, the studies did not recruit enough participants to tell us for sure which test or treatment
is best; however, we were able to draw some useful conclusions by combining symptom and quality-of-
life outcomes, costs of treatment and participant interview responses about their experience:
l All new treatments studied helped most participants.
l Simple nurse-led retraining programmes were at least as good as more costly, complex ones.
l Expensive tests did not help at an early stage.
l Participants prefer using higher-volume bowel irrigation than lower-volume bowel irrigation and it
has better results.
l Despite worries about mesh, laparoscopic ventral mesh rectopexy seems safe in the short term and
leads to a big drop in symptoms early after surgery. This was in very carefully chosen participants.
l The programme helped to ensure that we all use the same tests and nurse-led therapies. We also
published the most detailed reviews so far, to our knowledge, of different types of surgery for
chronic constipation.
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Constipation is common in adults and children, with up to 20% of the population reporting this symptom
depending on the definition used. Some people (1–2% of the population) suffer symptoms that are
chronic, disabling and refractory to basic treatments. Such people, who are most commonly female, are
usually referred to secondary care, with many progressing to tertiary specialist investigations. Patient
dissatisfaction and health-care and societal costs are high in this group.
Management of chronic constipation (CC) is generally stepwise, with first-line conservative treatment,
such as lifestyle advice and laxatives (primary care), followed by nurse-led bowel retraining programmes,
sometimes including focused biofeedback (secondary/tertiary care). Such treatments are poorly
standardised in the UK and far from universally successful. Patients with intractable symptoms and
impaired quality of life (QoL) may subsequently be offered irreversible surgical interventions that have
unpredictable results.
Objectives
The main aims of the Chronic Constipation Treatment Pathway (CapaCiTY) research programme were
to trial the effectiveness of three current and popular interventions for CC.
CapaCiTY trial 1:
l to determine whether or not standardised specialist-led habit training plus pelvic floor retraining
using computer-assisted direct visual biofeedback (HTBF) is more clinically effective than
standardised specialist-led habit training alone (HT) at 6 months’ follow-up
l to determine whether or not outcomes of such specialist-led interventions are improved by
stratification to HTBF or HT based on prior knowledge of anorectal and colonic pathophysiology
using standardised radiophysiological investigations (INVEST).
CapaCiTY trial 2:
l to compare the impact of transanal irrigation (TAI) initiated with a low-volume and a high-volume
system on patient disease-specific QoL after 3 months of treatment.
CapaCiTY trial 3:
l to determine the clinical efficacy of laparoscopic ventral mesh rectopexy (lapVMR) compared with
controls at short-term follow-up (24 weeks).
In addition, the programme sought to:
l detail the baseline phenotype of UK patients with CC to identify symptom burden and
psychological morbidity
l systematically review the outcomes of all current surgical interventions for CC
l synthesise results of all three trials with current evidence to produce a prototype treatment
pathway for health-care decision-makers.
DOI: 10.3310/pgfar09140 Programme Grants for Applied Research 2021 Vol. 9 No. 14
Copyright © 2021 Knowles et al. This work was produced by Knowles et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
xxi
Methods and results
Standardised methodological framework, recruitment and baseline phenotyping
Participants met stringent eligibility criteria. The main inclusion criteria were age 18–70 years,
symptom onset > 6 months prior to recruitment, symptoms meeting the American College of
Gastroenterology’s constipation definition and constipation that failed treatment to a minimum
basic standard. The main exclusions were secondary constipation and previous experience of
study interventions.
A total of 275 participants were recruited across three trials, representing a major shortfall in the required
sample sizes (n = 808). This reflected several major process challenges but also low uptake from the
733 patients screened (37.1%). About half of screen failures were because participants failed eligibility
and half were because participants declined. There were also problems of participant retention, with
higher-than-anticipated loss before primary outcome (actual loss 11–43% vs. anticipated loss 20%).
Trial participants were 90% female (100% in CapaCiTY trial 3) and were a mean age of 45 years
[interquartile range (IQR) 33–57 years]. Baseline phenotyping indicated high levels of comorbid
medical disorders (> 70%) and a history of previous abdominal and pelvic surgery (> 50%). Risk factors
such as psychiatric diagnoses and joint hypermobility were present in ≈ 20% of participants. Around
two-thirds of women were parous. Although the criteria for chronicity of constipation was 6 months’
duration, mean duration was 6 years and almost all participants with CC had constipation that proved
intractable to lifestyle modification and laxatives, which was reflected by referral pattern (80% of
referrals were from secondary or tertiary care). Almost 20% of these cases of CC were also refractory
to prokinetic drug therapy. Levels of symptom burden were high, with mean Patient Assessment of
Constipation Quality Of Life (PAC-QoL) and Patient Assessment of Constipation Symptoms (PAC-SYM)
scores of > 2.0 points at baseline. In addition, > 50% of participants had faecal incontinence symptoms,
> 30% had urinary symptoms and > 20% (100% in CapaCiTY trial 3) had pelvic organ prolapse
symptoms. Levels of psychological morbidity were high. Cut-off points on the self-reported Patient
Health Questionnaire-9 items (PHQ-9) and Generalised Anxiety Disorder-7 (GAD-7) scale suggest that
around one-third of participants would have met criteria for a depressive or anxiety disorder. These
rates are six times higher than those reported in the general population and are on the higher end of
mental comorbidity in patients with medical conditions.
Baseline data formed the basis of a subsequent standardised (for all three trials) panel of outcomes,
including several validated symptom-scoring instruments, cost-effectiveness variables [i.e. individual-
level patient costs from diaries and EuroQol-5 Dimensions, five-level version (EQ-5D-5L), scores to
calculate quality-adjusted life-years (QALYs)] and qualitative methodology to determine participant
experience (through a total of 45 interviews). The primary clinical outcome was mean change in
validated PAC-QoL score. Secondary clinical outcomes included a range of validated disease-specific
(PAC-SYM), generic [Measure Yourself Medical Outcome Profile 2 (MyMOP2)] and psychological
[GAD-7, PHQ-9, Brief Illness Perception Questionnaire for Chronic Constipation (BIPQ-CC)] scoring
instrument values.
CapaCiTY trial 1: habit training with direct visual biofeedback compared with habit training
alone in adults with chronic constipation
We sought to answer the question of whether or not, in unselected participants with CC, a more
time-consuming, expensive and invasive procedure (namely, instrument-directed visual biofeedback)
added benefit to that achieved by a more basic programme of nurse-led bowel education – namely,
habit training. We compared HT with HTBF. In addition, because of strongly held views (mainly in the
USA) that biofeedback works only for a subset of patients with CC who have dyssynergic defaecation
(a specific functional disorder), we used a battery of UK-standardised specialist tests of anorectal and
colonic function (INVEST) to stratify participants to one treatment or the other. Both treatments were
provided by trained NHS specialist colorectal nurses or physiotherapists.
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To answer both research questions concurrently required a sample size of 394 participants (based on
3 : 3 : 2 randomisation to HT, HTBF and INVEST treatment, respectively). Unfortunately, the CapaCiTY
trial 1 recruited only 182 participants, and only 103 participants provided primary outcome data at
6 months after cessation of therapy. With the caveat that all results were underpowered, there was no
evidence that HTBF conferred additional benefit over HT {HT: PAC-QoL score at baseline, 2.26 points
[standard deviation (SD) 0.69 points], vs. at 6 months post treatment, 1.49 points [SD 0.85 points];
HTBF: PAC-QoL score at baseline, 2.41 points [SD 0.81 points] vs. at 6 months post treatment, 1.65 points
[SD 1.03 points]; treatment difference –0.03 points, 95% confidence interval (CI) –0.33 to 0.27 points;
p = 0.8445}. Secondary outcomes also reflected equal beneficial effects of both HT and HTBF on a range
of symptom and QoL outcomes (e.g. mean PAC-SYM scores decreased from 2.2 points at baseline to
1.5 points at 6 months and weekly laxative use decreased fourfold). Global satisfaction was 65%, reflecting
participants who liked or disliked both interventions for a number of reasons. Similar results were obtained
for INVEST vs. no INVEST, with no difference in primary outcome [INVEST: mean PAC-QoL score at
baseline, 2.33 points (SD 0.74 points) vs. at 6 months post treatment, 1.56 points (0.93 points); no INVEST:
mean PAC-QoL score at baseline 2.36 points (0.78 points) vs. at 6 months post treatment, 1.81 points
(1.03 points); treatment difference 0.22 points, 95% CI –0.11 to 0.55 points; p = 0.1871]. Participants
provided reasons for liking INVEST, for example greater knowledge of their condition (and knowing that
their condition was not ‘all in their mind’), and described disliking the invasiveness of, and embarrassment
caused by, the tests. Given similar changes in EuroQol-5 Dimensions, five-level version (EQ-5D-5L), scores
for all interventions, cost-effectiveness analyses favoured the simpler (i.e. HT and no INVEST) strategies as
the dominant strategies. For both HTBF and INVEST, cost increases were significant (HTBF vs. HT: £239,
95% CI £133 to £354; INVEST vs. no INVEST: £543, 95% CI £403 to £685) and QoL was actually reduced
compared with HT (HTBF: –0.010 QALYs, 95% CI –0.053 to 0.03 QALYs; INVEST: –0.047 QALYs, 95% CI
–0.093 to –0.001 QALYs). The probability that HT is cost-effective was a p-value of 0.83 at a willingness-
to-pay (WTP) threshold of £30,000 per QALY.
CapaCiTY trial 2: pragmatic randomised controlled trial of low-volume compared with
high-volume initiated transanal irrigation therapy in adults with chronic constipation
A total of 65 participants were randomised (low-volume TAI, n = 30; high-volume TAI, n = 35) from a
target sample size of 300 participants. At 3 months, there was a modest reduction in PAC-QoL scores
in the low-volume TAI group, from a mean of 2.4 points to a mean of 2.2 points (SD –0.2 points); there
was a greater reduction in mean score in the high-volume TAI group, of 0.6 points (difference –0.37
points, 95% CI –0.89 to –0.15). Substantially greater crossover from low-volume to high-volume TAI
over the follow-up period (n = 18) than from high-volume to low-volume TAI (n = 6) indicated a
preference for high-volume TAI. Compared with low-volume TAI, high-volume TAI had similar costs
(–£8, 95% CI –£240 to £221) but was associated with significantly greater QoL (0.093 QALYs, 95% CI
0.016 to 0.175 QALYs). Qualitative analysis reflected the view that the increased clinical effectiveness
of high-volume TAI outweighed concerns about the slightly increased duration and discomfort.
CapaCiTY trial 3: stepped-wedge randomised controlled trial of laparoscopic ventral mesh
rectopexy in adults with chronic constipation
Seven high-quality systematic reviews of CC surgery with graded practice recommendations based
on European consensus were published in 2017 confirming lapVMR as an evidential need. A total of
28 participants were randomised from a target sample size of 114 participants, and lapVMR resulted in
substantial short-term reduction in PAC-QoL scores (–1.09 points, 95% CI –1.76 to –0.41 points) and
beneficial changes in all other outcomes that were maintained to 72 weeks. There were few adverse
events. However, significant increases in cost (£5012, 95% CI £4446 to £5322) resulted in only modest
increases in QoL (0.043 QALYs, 95% CI –0.005 to 0.093 QALYs), with an incremental cost-effectiveness
ratio of £115,512 per QALY at 48 weeks. Participant experiences were mixed, including participants who
were globally satisfied, participants experiencing partial or transient benefits and participants who felt
that it was not the ‘miracle’ cure they were looking for.
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Conclusions
Firm conclusions are limited by significant under-recruitment. However, synthesis of clinical
effectiveness and cost-effectiveness data with qualitative experience provides themes and suggestions
for a CC pathway of care:
l In unselected CC patients, HT helps the majority, and the more costly, time-consuming and invasive
intervention of HTBF should be reserved for special situations (specific diagnoses or perhaps
failure of HT).
l Expensive and invasive radiophysiological investigations cannot be recommended early in the
care pathway.
l The default for TAI should be high volume, with low volume reserved for special cases or
patient preference.
l Care needs to be exercised in recommending surgery because, although surgery reduces
constipation symptoms greatly in the short term, there was no evidence that surgery improved
general QoL beyond 1 year.
l Future interventions should focus on incorporating psychological methods alongside HT to address
psychological comorbidity.
Future research
It is not recommended that others try to repeat the CapaCiTY trials in their current form. First, it is
unlikely that the main conclusions would vary despite further recruitment; second, lessons learned in
respect of recruitment should deter others from trying to deliver parallel-group randomised controlled
trials in this population, even with less explanatory designs. Future research could focus on better
understanding the profound psychological comorbidity in the CC population and, if new interventions
are to be trialled (including those co-addressing psychological and behavioural problems), these might
be best suited to a design that incorporates experimental evaluations in a longitudinal cohort of
participants, for example trials within cohorts studies. Such trials should seek to maximise pragmatism
by sacrificing standardisation of specialist investigations and interventions in favour of uptake and
recruitment; they would also benefit from an expanded network of centres (including outside the UK)
to ensure timely recruitment and a greatly simplified and flexible follow-up regimen that could exploit
advances in technology for remote follow-up.
Trial registration
These trials are registered as ISRCTN11791740, ISRCTN11093872 and ISRCTN11747152.
Funding
The project was funded by the National Institute for Health Research (NIHR) Programme Grants for
Applied Research programme and will be published in full in Programme Grants for Applied Research;
Vol. 9, No. 14. See the NIHR Journals Library website for further project information.
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Constipation is common in adults and children, and up to 20% of the population (2–28% of adults
and 0.7–30.0% children) report this symptom depending on the definition used,1–3 with a much higher
prevalence in women.4–6 Chronic constipation (CC), usually defined as > 6 months of symptoms, is less
common7 but results in 0.5 million UK general practitioner (GP) consultations per annum. A proportion
(1–2%)8 of the population suffer more disabling symptoms, are very frequently female9 and are usually
referred to secondary care, with many progressing to tertiary specialist investigation. Patient dissatisfaction
levels are high in this group, with ≈ 80% feeling that laxative therapy is unsatisfactory;10 furthermore, the
effect of symptoms on quality of life (QoL) is significant.11 CC consumes significant health-care resources.
In the USA in 2004, a primary complaint of constipation was responsible for 8 million physician visits,12
resulting in (direct and indirect) costs of US$1.7B. Although detailed figures are lacking in the UK, it is
estimated that ≈ 10% of district nursing time is spent on constipation13 and that the annual spend on
laxatives exceeds £100M.14
Pathophysiological basis of chronic constipation
The act of defaecation is dependent on the co-ordinated functions of the colon, rectum and anus.
Considering the complexity of neuromuscular (sensory and motor) functions required to achieve
planned, conscious and effective defaecation,15 it is no surprise that disturbances to perceived ‘normal’
function occur commonly at all stages of life. Clinically, such problems commonly lead to de facto
symptoms of obstructed defaecation (e.g. straining; incomplete, unsuccessful or painful evacuation;
bowel infrequency), but symptoms such as abdominal pain and bloating are also very common. After
exclusion of a multitude of secondary causes (e.g. obstructing colonic lesions; neurological, metabolic
and endocrine disorders), the pathophysiology of CC can broadly be divided into problems of colonic
contractile activity, and thus stool transit, and problems of the pelvic floor. Thus, with specialist
physiological testing, patients may be divided into those who have slow colonic transit, evacuation
disorder, both or neither (e.g. no abnormality found with current tests). Evacuation disorders can be
subdivided into those in which a structurally significant pelvic floor abnormality is evident, such as
rectocele or internal prolapse (e.g. intussusception), and those in which there is a dynamic failure of
evacuation without structural abnormality, most commonly termed functional defaecation disorder.
Management of chronic constipation
Management of CC is a major problem because of its high prevalence and lack of widespread specialist
expertise. In general, a step-wise approach is undertaken, with first-line conservative treatment such
as lifestyle advice and laxatives (primary care) followed by nurse-led bowel retraining programmes,
sometimes including focused biofeedback and psychosocial support (secondary/tertiary care). Although
these treatments may improve symptoms in more than half of patients, they are far from universally
successful. Thus, patients with intractable symptoms and impaired QoL may be offered a range of
costly, irreversible surgical interventions with unpredictable results, sometimes resulting in major
adverse events (AEs) or a permanent stoma.
The research programme
An evidence-based pathway for the management of CC in adults is currently lacking, although National
Institute for Health and Care Excellence (NICE) guidance exists for the management of CC in children16–18
and for allied conditions (e.g. faecal incontinence) in adults. This arguably leads to variations in practice,
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particularly in specialist services. With a number of new drugs gaining NHS approval19–22 and new
technologies at a horizon-scanning stage,23–26 it is timely that the currently limited evidence base is
developed for resource-constrained NHS providers to have confidence that new and sometimes expensive
investigations and therapies are appropriate and cost-effective. A cost-conscious pathway of care may help
reduce health-care expenditures by appropriately sequencing the care provided while targeting more
expensive therapies at those most likely to benefit from them. Such data could inform the development
and commissioning of integrated care pathways.27
The overall rationale of the Chronic Constipation Treatment Pathway (CapaCiTY) research programme,
therefore, was to develop an evidence base for CC management through a series of three randomised
controlled trials (RCTs) that answered some of the important questions for sequenced patient care
(Figure 1). For each, the focus was on generating real-life evidence based on valid clinical outcome
measures, patient acceptability and cost.
The specific objectives were as follows:
l work programme (WP)1
¢ to develop a common methodological framework for subsequent studies
¢ to recruit a UK cohort of adults with CC based on strict eligibility criteria and detail the baseline
phenotype to identify disease risk factors, symptom burden, QoL and psychological morbidity.
l WP2 (CapaCiTY trial 1)
¢ to determine whether or not standardised specialist-led habit training plus pelvic floor retraining
using computer-assisted direct visual biofeedback (HTBF) is more clinically effective than
standardised specialist-led habit training alone (HT)
¢ to determine whether or not outcomes of such specialist-led interventions are improved by
stratification to HTBF or HT based on prior knowledge of anorectal and colonic pathophysiology
using standardised radiophysiological investigations (INVEST).
l WP3 (CapaCiTY trial 2)
¢ to compare the impact of transanal irrigation (TAI) initiated with a low-volume and a high-volume
system on patient disease-specific QoL after 3 months of treatment.
l WP4 (CapaCiTY trial 3)
¢ to systematically review the evidence for all common surgical procedures used for adults
with CC
¢ to determine the clinical efficacy of laparoscopic ventral mesh rectopexy (lapVMR) compared
with controls at short-term follow-up (24 weeks).
l WP5
¢ to synthesise clinical outcome, patient acceptability and cost data from CapaCiTY trials and to
develop an NHS pathway for the management of CC in adults based on data synthesis.
SYNOPSIS
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Response
Obvious clinical evidence of overt
pelvic organ prolapsecAnorectal function testing (balloon expulsion
test, rectal sensory testing and anorectal
manometry (±) defaecography)
Review lifestyle modif ication (e.g. f ibre, f luid, exercise)
Rational laxative use (PEG, stimulant laxative)b
Prokinetics if naive (1–2 mg of prucalopride daily or 290 µg of linaclotide or another secretagogues)
CC refractory to





Transanal irrigation Other surgical targets
and procedures
Posterior compartment prolapse syndrome
with high-grade intussusception (±) rectocoele
MDT meeting to discuss
surgical options
Re-evaluation of symptom-
investigation correlation to focus
on further pharmacology or
other untried interventions
Consider laparoscopic ventral rectopexy or






(±) adjunctive tests (e.g. urodynamics)
FDD
Dysynergic defaecation Other evacuation disorder




FIGURE 1 Overview of the CapaCiTY research programme. Green arrows indicate studied pathways in CapaCiTY trials 1–3 (numbered circles). a, Alarm features excluded and
secondary causes treated appropriately; b, in IBS-C, consider antispasmodics or neuromodulators in case constipation improves but abdominal pain persists and is dominant symptom;
c, examples of overt prolapse include anterior (stage 3 cystocele), middle (stage 3 rectocele, uterovaginal) and posterior compartments (grade IV/V intussusception); d, if not performed
previously; e, common adjuncts include sacrocolpopexy, hysterectomy, transvaginal tape and cystocele repair. FFD, functional defaecation disorder; IBS-C, constipation-predominant irritable











































































































































































































































































































To permit the synthesis of all data at the end of the programme, we defined eligibility criteria, outcome
measures and analytic methods that were common across all three trials. In addition, at the outset it
was envisaged that some participants could move sequentially through more than one trial if a prior
treatment had failed (although in practice this happened very infrequently because of delays in
recruitment to all studies).
Setting
Following scoping during the programme development phase, we pre-identified 10 UK specialist
centres that geographically encompass the north and south of England with a mix of urban and rural
referral bases. Other centres were recruited for specific studies, especially in CapaCiTY trial 3.
Target population
The programme addressed the NHS management of CC in secondary and tertiary care, rather than the
broader patient population with relatively short-lived or mild symptoms, receiving self-care or primary
care management. This focus was pragmatic, given the concentration of expertise, diagnostics and
biofeedback equipment in hospital settings. Based on well-established epidemiological data28,29
(see SYNOPSIS, Background), the main target population was women of mean age 50 years.
Ethics approvals
The three trials had the following registration details and approvals:
l CapaCiTY trial 1
¢ Research Ethics Committee (REC) reference 14/LO/1786
¢ Integrated Research Application System (IRAS) 160709
¢ ISRCTN11791740
¢ date of REC approval: 6 December 2014.
l CapaCiTY trial 2
¢ REC reference 15/LO/0732
¢ IRAS 172401
¢ ISRCTN11093872
¢ date of REC approval: 6 July 2015.
l CapaCiTY trial 3
¢ REC reference 15/LO/0609
¢ IRAS 171006
¢ ISRCTN11747152
¢ date of REC approval: 6 July 2015.
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Eligibility assessments
Patients were recruited at the time of clinical consultation at physician- and nurse-led clinics, and also
at the time of investigation in gastrointestinal physiology units. All patients expressing initial interest
were referred to the local lead investigator to screen case notes for eligibility.
Good clinical practice-trained local investigators determined eligibility by interview on the basis of
defined inclusion/exclusion criteria. Participants were recorded on a screening log and each allocated a
unique participant identifier (ID) number. Eligible subjects were then provided with an adequate explanation
of the aims, methods, anticipated benefits and risks of the programme, and a participant information sheet.
Special emphasis was placed on the long-term nature of the programme, time commitments and number
of assessments required. Patients were telephoned 1 week later (or given an appointment) to allow
appropriate time for them to consider their participation.
Inclusion and exclusion criteria
Inclusion criteria
Chronic constipation was defined according to pragmatic criteria, broadly, those employed for recent
pivotal trials of prokinetics19,22 and US guidance:30
l age 18–70 years
l patient self-reported problematic constipation
l symptom onset > 6 months prior to recruitment
l symptoms meeting American College of Gastroenterology definition of constipation (‘unsatisfactory
defaecation characterized by infrequent stool, difficult stool passage or both for at least previous
3 months’)30
l constipation that has failed treatment to a minimum basic standard according to the NHS Map of
Medicine31 (lifestyle and dietary measures and two or more laxatives or prokinetics tried)
l ability to understand written and spoken English (for questionnaire validity).
Exclusion criteria
Exclusions included major causes of secondary constipation and specific factors precluding participation
in study interventions:
l significant organic colonic disease (red flag symptoms e.g. rectal bleeding previously investigated);
inflammatory bowel disease; megacolon or megarectum (if diagnosed beforehand); or severe
diverticulosis, bowel stricture or birth defects deemed to contribute to symptoms (incidental
diverticulosis not an exclusion criterion)
l major colorectal resection surgery
l current overt pelvic organ prolapse (e.g. bladder, uterus, rectum) or disease requiring obvious
surgical intervention
l previous pelvic floor surgery to address defaecatory problems [posterior vaginal repair, stapled
rectal resection (STARR) and rectopexy] or previous sacral nerve stimulation
l rectal impaction (as defined by digital and abdominal examination, which form part of the NHS Map
of Medicine basic standard)31
l significant neurological disease deemed to be causative of constipation (e.g. Parkinson’s disease),
spinal injury, multiple sclerosis or diabetic neuropathy (uncomplicated diabetes alone not an
exclusion criterion)
l significant connective tissue disease – scleroderma, systemic sclerosis and systemic lupus
erythematosus (hypermobility alone not an exclusion criterion)
l significant medical comorbidities and activity of daily living impairment (based on a Barthel index32
score of > 11 in apparently frail patients)
l major active psychiatric diagnosis (e.g. schizophrenia, major depressive illness and mania)
WORK PROGRAMME 1: COMMON METHODOLOGICAL FRAMEWORK AND PARTICIPANT RECRUITMENT
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l chronic regular opioid use (at least once-daily use) where this is deemed to be the cause of
constipation based on temporal association of symptoms with onset of therapy, and all regular
strong opioid use
l pregnancy or intention to become pregnant during study period
l previous experience of specific therapies included in the programme.
Trial-specific inclusion criteria
l CapaCiTY trial 1:
¢ vision sufficient to undertake visual biofeedback.
l CapaCiTY trial 2:
¢ sufficient manual dexterity of patient/carer to use TAI.
l CapaCiTY trial 3:
¢ failure of non-surgical interventions (minimum of nurse-led behavioural therapy)
¢ internal rectal prolapse, as determined by clinical examination and INVEST, fulfilling two
diagnostic criteria – (1) intra-anal or intrarectal intussusception with or without other dynamic
pelvic floor abnormalities (e.g. rectocele, enterocele, perineal descent) and (2) deemed (by expert
review) to be obstructing on defaecating proctogram (i.e. trapping contrast and/or associated
with protracted or incomplete contrast evacuation using normal ranges).33
Baseline clinical evaluation
In addition to screening questions, clinical examination and information obtained by baseline
standardised outcome assessments, participants completed a structured interview to document other
comorbidities and risk factors (e.g. metabolic, endocrine and neurological disease; obstetric and
gynaecological history; joint hypermobility; past surgical history). Clinical examination of the perineum/
anus/rectum/vagina was carried forward to baseline from the last clinical consultation to prevent
unnecessary repetition of intimate examinations.
Specialist radiophysiological investigations
All three trials required, at least in part (depending on the trial), the results of a number of well-
established specialist investigations of anorectal and colonic functions. These investigations were
nationally standardised during National Institute for Health Research (NIHR) programme development
work, including a consensus meeting (London 2013) highlighting universally discordant current
practice; remarkably, no UK centre at that time had the same protocol for any of the four main tests:34
1. Anorectal manometry using high-resolution methods35–37 to determine defined abnormalities of
rectoanal pressure gradient during simulated evacuation.38–40
2. Balloon sensory testing using standardised methods41,42 (2 ml of air per second to a maximum of
360 ml) to determine volume inflated to first constant sensation, defaecatory desire and maximum
tolerated volumes. Rectal hyposensation and hypersensation defined in accordance with sex-specific
normative data on 91 healthy adults.43 The rectoanal inhibitory reflex elicited by 50 ml rapid
inflation (if necessary, in 50-ml aliquots up to 150 ml).
3. Fixed-volume (50 ml) water-filled rectal balloon expulsion test38,39,44,45 in the seated position on a
commode. Abnormal expulsion is defined as failure to expel within 1.0 minute of effort for men and
1.5 minutes of effort for women.46
4. Whole-gut transit study using serial (different shaped) radio-opaque markers over 3 days, with a
single, plain radiograph at 120 hours.47,48
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5. Fluoroscopic evacuation proctography using rectal installation of barium porridge to defaecatory
desire threshold (or a maximum of 300 ml) and evacuation on a radiolucent commode33,35–37,49
with pre-opacification of the small bowel (for enterocele). Radiation dose, proportion of contrast
evacuated and time taken are recorded, as well as ‘functional’ features (i.e. pelvic floor dyssynergia)
and ‘structural’ features (e.g. rectocele, enterocele and intussusception) deemed obstructive to
defaecation.38,43 Although magnetic resonance proctography is now used in some UK centres, with
the advantage of no radiation dose, it was not widespread at the time of developing the CapaCiTY
programme. There are also differences in sensitivity between fluoroscopic and magnetic resonance
proctography, especially if the latter is carried out on a supine patient,50 that could prove difficult
for standardisation.
Standardised radiophysiological investigations were performed if results were not already available
for participants from tests in the preceding 12 months. In some participants, individual missing investigations
were performed. Routine NHS practice (e.g. 10-day NHS rule related to menstrual cycle) was applied in
respect of women between menarche and menopause. Participants who could potentially be pregnant had
a serum or urine pregnancy test performed as per routine care. Participants were given the results of
investigations by the physiologist or radiologist.
Programme outcomes
A common ‘standardised outcome framework’ was used throughout. All questionnaires contained written
instructions to be completed by the participant in an undisturbed environment without prompting. Online
and postal options were provided for participants who chose not to attend in person.
The plan at the start of the programme was that all outcomes would be recorded for each intervention
at baseline, 3 months and 6 months before participants could progress to a further intervention WP.
For participants not changing therapy, further outcomes were recorded at 6-month intervals to the
end of the programme (to a theoretical maximum of 4 years). Participants who progressed from one
intervention to another had a new ‘baseline’ recorded on recruitment. In practice, few participants
progressed from one WP to another and follow-up was limited by delays in recruitment to a maximum
of about 18 months.
Primary clinical outcome
Patients with CC complain of a multitude of symptoms including infrequent defaecation, pain, bloating,
straining, passage of hard stool, incomplete evacuation and systemic symptoms. The relative importance of
these varies between patients so that a single symptom, such as bowel frequency, does not adequately
describe treatment effect in a population.51 Symptom diaries have a poor record as primary outcome
measures, suffering from incomplete data, retrospective completion, tolerance or sensitisation.52,53
A number of composite scoring systems have been developed, but only one, the Patient Assessment of
Constipation Quality Of Life (PAC-QoL), has been robustly developed and psychometrically validated to
a high level, including a comprehensive assessment of effect size.54–56 The PAC-QoL includes 28 items
covering four domains, each item is scored (0–4 points) and items and domains are aggregated to a
composite score (0–4 points).
Minimum clinically important differences have been defined for PAC-QoL scores and informed an
analysis of responders to treatment. Treatment effects have been characterised using cumulative
distribution curves and a 1.0-point reduction has been confirmed as a robust measure of a responder.57
Furthermore, a minimum clinically important difference can be defined by a 10% change (i.e. 0.4 points
in the scale), as reported broadly in the literature. These definitions were used to ensure that the
primary outcome measure in each trial was based on magnitude, risk and cost of intervention.
Thus, for trials 1 and 2, a ≥ 0.4-point reduction in PAC-QoL score was considered to be a minimally
important mean difference between groups, whereas in CapaCiTY trial 3 (surgery) a ≥ 1.0-point
difference was chosen to reflect the more costly and potentially harmful intervention posed by surgery.
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Secondary clinical outcomes
Given the questionnaire format of most available CC outcome assessments and multiple time points of
assessment, we carefully selected and justified each outcome to keep the number and length of assessments
to an achievable level (for compliance). The choice of Patient Assessment of Constipation Symptoms
(PAC-SYM) and Measure Yourself Medical Outcome Profile 2 (MyMOP2) was specifically informed by
qualitative research performed during our NIHR programme development stage on 50 participants with CC:
l PAC-QoL score – binary responder analyses using 0.4-point and 1.0-point cut-off points
l PAC-SYM score – individual domains and total score (as continuous variables)
l 2-week patient diary (for 2 weeks prior to each assessment) to record bowel frequency and
whether or not each evacuation was ‘spontaneous (no use of laxatives) and/or complete’; the journal
also captured concurrent medication, health contacts and time away from normal activities
(including work) since the patient’s last visit
l a validated patient problem-specific measure, MyMOP2, which incorporates the two worst
volunteered symptoms and a measure of well-being58 (lower scores represent less symptomatology)
l a validated QoL cost-effectiveness questionnaire – EuroQol-5 Dimensions (EQ-5D), EuroQol-5
Dimensions, five-level version (EQ-5D-5L), and EuroQol Visual Analogue Scale (EQ-VAS)59 (higher
scores indicate better QoL)
l Patient Health Questionnaire-9 items (PHQ-9)60 – nine items measuring level of depression (lower
scores indicate less depression)
l Generalised Anxiety Disorder-7 (GAD-7)61 scale (lower scores indicate less anxiety)
l avoidant and ‘all or nothing’ behaviour subscales of the Chronic Constipation Behavioural Response
to Illness Questionnaire (CC-BRQ)62 and Brief Illness Perception Questionnaire for Chronic
Constipation (BIPQ-CC)63 (specific analyses required for interpretation)
l global participant satisfaction (five-point scale from ‘not at all satisfied’ to ‘completely satisfied’)
and a global participant improvement score (0–100% visual analogue scale) comparing how the
participant feels today compared with before the study (higher scores indicate greater satisfaction).
Health economic outcomes
Resource use at the participant level was captured using trial case report forms (CRFs) at scheduled clinical
visits and contacts. Intervention costing was specific to each trial and was detailed in the reporting of
findings. Assessments were carried out at 0, 3, 6 and 12 months’ follow-up, augmented by telephone calls
(every 12 weeks for the CapaCiTY trial 3). Participant use of prescription drugs related to their condition
was recorded and costed using Prescription Cost Analysis (PCA) data.64 Health service contacts were
recorded by asking participants to recall GP, district nurse, pharmacy, accident and emergency department
(A&E), outpatient and inpatient visits. Health-care resource use was costed using published national
reference costs. Individual patient costs were estimated in 2018 Great British pounds (GBP) as the sum of
resources used weighted by their reference costs. Time away from work or usual activities was recorded
and costed using national average weekly earnings,65 contributing to a broader societal costing (Table 1).
Generic health-related QoL was assessed using the EQ-5D questionnaire: a participant-completed
two-page questionnaire consisting of the EQ-5D-5L and the EQ-VAS. The EQ-5D-5L includes five
questions addressing mobility, self-care, usual activities, pain/discomfort and anxiety/depression, with
each dimension assessed at five levels, from ‘no problems’ to ‘extreme problems’. EQ-5D-5L scores
were converted to health status scores using the mapping function developed by van Hout et al.,71
providing a single health-related index including 0 (death) and 1 (perfect health), for which negative
scores are possible for some health states. Scores were captured in trial CRFs during clinic visits or
contacts at baseline, 3 months, 6 months and 12 months for CapaCiTY trials 1 and 2, and at 12-week
intervals from the screening visit up to 72 weeks for CapaCiTY trial 3. Using the trapezoidal rule, the
area under the curve (AUC) of health status scores was calculated, providing participant-level quality-
adjusted life-years (QALYs) estimates for the cost-effectiveness analyses. Because AUC estimates are
predicted to correlate with baseline scores (and thus potential baseline imbalances), AUC estimates
were adjusted for baseline scores in regression analyses.
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TABLE 1 Unit costs (£, 2018) applied to patient resource use
Resource Unit Cost (£) Source
Health-care contacts
GP Per visit 39.00 PSSRU66
District nurse Per visit 41.00 aPSSRU67
Pharmacist Per visit 14.00 NHS CPCS68
A&E Per visit 114.00 NHS Improvement69
Outpatient Per visit 135.00 PSSRU66
Inpatient Per visit 631.00 PSSRU66
Other resources
Prescription drugs Per item b NHSD-PCA70
Time off work Per day 92.00 ONS65
CapaCiTY trial 1
INVEST Per procedure 462.00
Staff time Per procedure 192.00 NHS Improvement69
Anal manometry Per test 50.00 Personal communicationc
Rectal sensation Per test 4.00 Personal communicationc
Balloon expulsion test Per test 4.00 Personal communicationc
Gut transit study Per study 66.00 NHS Improvement69 and personal commmunicationc
Evacuation proctography Per test 141.00 NHS Improvement69 and personal commmunicationc
Cleaning/sterilisation Per procedure 5.00 Personal communicationc
Habit training (with/without biofeedback)
Training sessions Per hour 135.00 PSSRU66
Biofeedback Per session 70.00 d
CapaCiTY trial 2
Low-volume TAI Per use 3.93 eNHSD-PCA70
Per 30-day use 118.00 eNHSD-PCA70
High-volume TAI Per use 7.57 fNHSD-PCA70
Per 30-day use 227.00 fNHSD-PCA70
Training/support sessions Per hour 135.00 PSSRU66
CapaCiTY trial 3
LapVMR surgery Per procedure 4941.00 NHS Improvement69
CPCS, Community Pharmacist Consultation Service; NHSD-PCA, NHS Digital Prescription Cost Analysis; ONS, Office
for National Statistics; PSSRU, Personal Social Services Research Unit.
a Item reflated to 2018 costs following table 15 in Unit Costs of Health and Social Care 2018.66
b Because of incomplete recording of prescribing data, in each instance the British National Formulary chemical name
was identified and the net ingredient cost per item was applied assuming full usage at typical dose in the follow-up
period. This provided an upper bound on prescribing costs.
c S Mark Scott, Queen Mary University of London, 2020, personal communication.
d Assuming a £18,000 cost for high-resolution manometer with a 7-year life, 200 uses per year, annual warranty
and catheter replacement at £11,000, annual service contract at £2700, future costs discounted at 3.5% and £5
sterilisation/cleaning cost per use [Charlie Birkett, LABORIE/Medical Measurement Systems B.V. (Enschede,
the Netherlands), personal communication].
e Qufora® IrriSedo Mini (low-volume) system (MacGregor Healthcare Ltd, Tranent, UK): £118 (30 days), £3.93 per day.
f Qufora IrriSedo Cone (high-flow) system (15 irrigation set) (MacGregor Healthcare Ltd): £101.66 (15 days); Qufora
IrriSedo Cone accessory set: £59 (additional 15 days), £5.35 per day. Peristeen® Anal Irrigation System (high volume)
(Coloplast A/S, Humlebæk, Denmark): £76.90 (90 days); Peristeen® Anal Irrigation System accessory unit: £134.02
(15 days), £9.79 per day. The system used was not recorded, so an average of the systems was assumed.
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Patient and health-care professional experience
Qualitative data were obtained to aid the interpretation of outcomes and the development of an
authoritative clinical pathway that recognised informational needs of both clinicians and patients.
Face-to-face, digitally recorded, semistructured interviews (duration up to 1 hour) were conducted by
an experienced nurse with a social science background and involved a purposive, diverse sample of
patients and health-care professionals throughout the programme, with participant recruitment reflecting
a range of ages, geographical locations and, when possible, other pertinent attributes such as ethnicity and
sex, continuing until data saturation when no new themes emerged. All participants were told that they
might be invited for interview when they were informed about each trial, but provided separate informed
consent for interview (in those agreeing to be approached). A topic guide for each interview, informed by
existing literature and patient advisors, was developed and piloted prior to commencement.
Adverse events and other work package-specific data
Adverse events were recorded throughout the programme using an AE log to record the nature, seriousness,
causality, expectedness, severity, relatedness and outcome. All serious adverse events (SAEs) that were
related or unexpected were reported to the sponsor, REC, quality assurance manager and local research and
development (R&D) departments and the participant followed-up until conclusion. Safety was monitored by
the Data Monitoring and Ethics Committee (DMEC) and reported to the REC in the annual progress reports.
Other important data such as treatment logs and perioperative courses wereWP specific.
Common analytical framework
General
The Pragmatic Clinical Trials Unit (PCTU; a UK Clinical Research Collaboration registered and NIHR-
funded clinical trials unit in the Institute of Population Health Sciences, Queen Mary University of
London) managed the three trials, including the development and management of secure databases in
accordance with standard operating procedures. Automated validation checks were carried out at
source data entry and further checks were performed on receipt by the study statistician and data
manager. Data queries were addressed to the data manager and participating centres as appropriate.
The centrally held database was locked for analysis once the data quality and completeness were
assured and on sign-off of the final statistical analysis plan (SAP).
Sample size calculations
Detailed individual justifications for each trial are included in Appendix 1. In brief, sample sizes were
calculated using the primary clinical outcome: change in PAC-QoL score based on pre-defined scalar
changes. All calculations were performed at 90% power at a 5% significance level and, thence, allowed
for 10% drop-out after randomisation.
Baseline characteristics
Numbers and percentages of patients with important baseline characteristics are presented by trial
group. Continuous variables (e.g. age) are summarised by treatment group using mean and SD [median
and interquartile range (IQR) if non-normally distributed]. No statistical testing was performed.
Clinical outcomes
All analyses were performed by the study statistician after the SAP was reviewed by the DMEC
and signed off by the chief investigator and senior statistician. Although exact analyses for each trial
differed according to study design, primary outcomes were analysed on an intention-to-treat (ITT)
basis at defined time points (3 or 6 months) using linear mixed regression models [using Stata 14.2
(Stata Corp LP, College Station, TX, USA) xtmixed] with a random effect for centre and fixed effects
for intervention, sex, baseline PAC-QoL score and breakthrough medication. Secondary outcomes were
analysed on an ITT basis. For each outcome, descriptive statistics (as appropriate) by trial group are
presented; continuous variables (e.g. PAC-QoL score) are summarised by treatment group using mean,
SD, median and IQR. For categorical variables, numbers and percentages of patients reporting each
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response option were presented by trial group. Given the lower than target number of patients recruited
to the trials, adjusted analyses were performed on PAC-QoL-derived secondary outcomes in CapaCiTY
trial 1 only (logistic regression models for categorical outcomes). Unadjusted treatment differences and
respective 95% confidence intervals (CIs) are presented for all other secondary outcomes. Results
obtained using the CC-BRQ and BIPQ-CC have been omitted pending further analysis.
Subgroup analyses
Originally planned subanalyses were restricted after poor recruitment to a small number of specific
analyses for major baseline characteristics in the CapaCiTY trial 1 only. A p-value of < 0.05 was taken
to indicate statistical significance.
Cost-effectiveness
The economic analysis of the three interlinked CapaCiTY trials followed ITT principles and a prospectively
agreed analysis plan. Using the standardised outcome framework for each trial, treatment effects were
summarised at the patient level as overall cost and QALYs.Within-trial patient cost-effectiveness analyses
were conducted comparing alternative treatments in each trial. Primary analyses took an NHS perspective.72
Follow-up of trial participants is problematic, particularly over longer periods, making incomplete data
a routine challenge. Consequently, the planned base-case analysis for each trial assumed the use of
multiple imputation to account for missing data. For each trial, the base-case analysis is presented as
the imputed and adjusted within-trial incremental costs and QALYs gained. Supportive sensitivity
analyses included participants with complete data; unplanned sensitivity analyses are added if informative.
Imputation and estimation were conducted according to good practice guidance73 using the multiple
imputation framework in Stata. Multiple imputation provides unbiased estimates of treatment effects if
data are missing at random (MAR) (i.e. causes of missingness are captured in observed variables). This
assumption was explored in the data using logistic regression of the missingness of costs and QALYs against
baseline variables.74 Patient prognostic variables and trial stratification variables were assessed as potential
missingness predictors for use in the imputation, which included outcome measures and costs (at each time
point) as predictors and imputed variables. Imputation models used fully conditional (Markov Chain Monte
Carlo) methods (multiple imputation by chained equations), which are appropriate when correlation occurs
between variables. Multiple imputation ‘draws’ each provide a complete data set, which probabilistically
reflects the distributions and correlations between variables. Burn-in traces for imputation variables were
visualised to assess the independence of draws. Predictive mean matching drawn from the five k-nearest
neighbours (k-NN) was used to enhance the plausibility and robustness of imputed values, as normality may
not be assumed. Analysis of multiple draws was conducted with Stata’s multiple imputation framework
providing estimation adjusted for Rubin’s rule.75 In the imputation, missing costs and EQ-5D-5L scores were
imputed for each period of follow-up and aggregated to overall patient costs and QALYs for each draw. All
imputed variables acted as predictive variables, supplemented by trial baseline variables if significant and
plausible predictors of missingness. Analysis of costs and QALYs was conducted primarily using bivariate
regression. Multiple imputation estimation models were bootstrapped to provide non-parametric estimates.
To minimise the information loss of finite imputation sampling, the fraction of missing information (FMI)
was used to ensure that the number of imputed draws exceeded the FMI percentage. The distributions of
imputed and observed values were compared to establish the consequences of estimation.
The (bootstrapped) median incremental cost-effectiveness ratio (ICER) and CI were estimated from the
bivariate analysis.Value for money was determined by comparing the ICER with two willingness-to-pay
(WTP) thresholds: the NICE-recommended upper threshold for ‘regular’ approvals of £30,000 per QALY76
and a lower value of £15,000 per QALY, reflecting uncertainty about the true value appropriate to the
NHS.77 The chosen threshold represents theWTP for an additional QALY: an intervention with a lower ICER
value than the threshold could be considered cost-effective for use in the NHS.To assess the robustness
of findings, base-case assumptions were explored using a range of supportive sensitivity analyses.
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Net monetary benefit (NMB) succinctly describes the resource gain (or loss) when investing in a new
treatment when resources can be used elsewhere at (or up to) the same WTP threshold. It is calculated as:
NMB =QALY × threshold – cost, (1)
where NMB is estimated across a range of WTP thresholds such as from £0 per QALY to £100,000 per
QALY.Where an intervention ICER is cost-effective (i.e. lower than theWTP threshold) the incremental NMB
will be positive. NMB is routinely estimated from a bivariate regression to help generate a cost-effectiveness
acceptability curve (CEAC).The CEAC visualises the likelihood that treatments are cost-effective as theWTP
threshold varies.78 Univariate regression of NMB has several advantages over the bivariate approach: it may be
more robust approach with sparse data; it transforms the cost/outcomes data from a ratio into a continuous
variable, allowing for easier manipulation and interpretation; it manages the correlation between costs and
QALYs; it easily manages covariate imbalances; and repeated estimations explore theWTP threshold.79
However, it does not allow the cost-effectiveness plane to be visualised, and the univariate distribution varies
by threshold. Univariate regression was used as a confirmatory analysis where patient numbers were low or
distributions were highly non-normal.
The expected value of perfect information (EVPI) is the upper limit of the value to a health-care system
of further research to eliminate uncertainty.80 Findings from cost-effectiveness analyses remain uncertain
because of the imperfect information they use. If a wrong adoption decision (e.g. to make a treatment
available) is made, this will bring with it costs in terms of health benefit forgone: the NMB framework
allows this expected cost of uncertainty to be determined and guide whether or not further research
should be conducted to reduce uncertainty.
Analyses and modelling were undertaken in Stata 16.1 using the portal provided at Queen Mary
University of London. Reporting follows the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) statement.81
Patient experience
Interviews were digitally recorded, anonymised, transcribed verbatim and analysed using a pragmatic
thematic analysis. Data analysis was developed as outlined by Fereday and Muir-Cochrane82 in the first
instance by mapping key concepts derived from the transcripts (‘charting’) and extracting emergent themes
from the transcripts. The topic guide was used for the pre-determined codes and supplemented with
additional codes that arose from the data. The final analysis combined inductively and deductively derived
codes. The qualitative researcher (Tiffany Wade) conducted independent analyses and then compared and
refined resulting codes and themes in discussion with the qualitative research study lead (CN). Three
members of the patient and public involvement (PPI) panel were shown the qualitative results and
participated in an online discussion to refine the messages. Emergent themes formed the basis of analytical
interpretation. Challenges to delivering the three trials were also enquired about during the qualitative
interviews with participants and research staff, using the qualitative methods described.
Patient recruitment
Challenges to recruitment
Recruitment was poor and negatively affected the whole programme (i.e. all three trials). This reflected
several issues with the process and some of the design. Thus, the programme as a whole suffered from
the following:
l Long-term staff [i.e. specialist NHS nurses and Clinical Research Network (CRN)-funded research
nurses] sickness and retirements and difficulty in recruiting staff led to shortage of staff to deliver
interventions. This was reflected by significant recruitment only at sites where research staff from
the directly funded core research team took over delivery (e.g. Barts and the London School of
Medicine and Dentistry, Queen Mary University of London, in CapaCiTY trial 1 and County Durham
and Darlington NHS Foundation Trust in CapaCiTY trial 2).
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l R&D delays to get the study up and running at many sites (range 6–9 months), with five sites
never opening.
l Lack of funding to cover excess treatment costs (ETCs) [e.g. high-resolution anorectal manometry
(HRAM) devices; Clinical Commissioning Groups (CCGs) to allow prescription of irrigation kits].
l Recruitment targets too high, demotivating staff and pressurising them to start recruitment before
they were prepared (according to interviews).
l Some treatments were available as part of clinical practice immediately if patients refused entry
into research, and with some delay if patients agreed to participate. Patients often had a significant
burden of symptoms and were unwilling to delay treatment.
Other issues were trial specific. In CapaCiTY trial 1, delays due to infection control variations in approval
of HRAM protocol and device cleaning (e.g. local views differed from published national standards and
would require the purchase of expensive sterilisation equipment) hindered INVEST. Trial 1 also suffered
criticism that the number of outcome questionnaires may have been off-putting to some patients (see
Work programme 5, Patient and public involvement). In CapaCiTY trial 2, we underestimated the number of
patients who would not be willing to try the irrigation device and the additional staff time above clinical
need, making staff reluctant to recruit (both points highlighted in interviews). CapaCiTY trial 3 was
seriously hindered by the evolving serious mesh controversy on national and international media.83
Patients became unwilling to try the intervention and some hospitals were instructed by their lawyers to
stop the intervention. A further problem in CapaCiTY trial 3 related to NHS bed pressures: the stepped-
wedge design meant that one group of patients was randomised to have surgery caried out in 4 weeks.
Some sites were unable to secure a bed in this time frame even with proscribed tolerance.
We took a number of measures to try to mitigate these issues:
l We provided almost all sites with refresher site initiation visits and guidance in reviewing referral
letters to identify suitable patients.
l We provided all sites with a refresher investigator meeting in December 2017 to get all research
staff together from all our sites with the aim to provide them with refresher training on protocol,
exchange experience on overcoming recruitment barriers and encourage everyone to recruit.
l We changed the design of the studies in January 2016 to shorten the time between the follow-up
visits from 24 months to 12 months to lessen the burden of the follow-up visits on both patients
and research staff, and removed two lengthy questionnaires to reduce file size.
l We made protocol amendments to make the protocol more compatible with routine practice
where possible.
l We provided sites with support in data entry and administrative work, which would free up the
research nurse to do the screening and recruitment.
l We launched an advertising campaign in summer 2016 to find suitable patients
through newspapers.
l We provided HRAM devices to sites on loan in an effort to help sites meet the requirements of
study device (CapaCiTY trial 1). We undertook competitive procurement and assisted sites with
business cases to secure funding for HRAM equipment.
l We secured funding from irrigation device company McGregor Healthcare Ltd (Macmerry, UK) to
sponsor sites affected by the lack of prescription funding (CapaCiTY trial 2).
l We engaged with NIHR to try to encourage CCGs to meet their obligations to fund ETCs. We had
letters from the Department of Health and Social Care in this regard but both it and the CRN were
unable to mandate ETCs (CapaCiTY trial 2).
l We requested recruitment extensions for all three trials in an effort to boost recruitment.
l We regularly presented at national speciality meetings (e.g. the Pelvic Floor Society).
l We made use of incentives – prizes, a newsletter, social media and professional
development opportunities.
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Final programme recruitment
A total of 275 patients was recruited across three trials, representing a major shortfall in relation to the
required cumulative sample size (n = 808). These patients were recruited from a total of 733 screened
(37.1%); this recruitment rate was lower than the 50% recruitment rate we anticipated. About half of
screen failures were due to failed eligibility and about half were due to the patient declining. There was
also a problem of patient retention in all trials, with higher than anticipated drop-out rates before
primary outcome (actual range 11–43% vs. anticipated range 20%).
A total of 90% of participants were female (100% in CapaCiTY trial 3) and participants had a mean
age 45 years (IQR 33–57 years). The majority (70%) of participants were of white ethnicity. Baseline
phenotyping indicated high levels of comorbidity in > 70% of patients and a history of previous abdominal
and pelvic surgery in > 50%. In terms of other risk factors, psychiatric diagnoses (insufficient for exclusion)
and joint hypermobility were each present in ≈ 20% of patients. Approximately two-thirds of participating
women were parous. Although the criteria for chronicity of constipation was 6 months’ duration, mean
duration was 6 years and almost all patients with CC had constipation that proved intractable to lifestyle
modification and laxatives, which was reflected by referral pattern: 80% of referrals were from secondary
or tertiary care. Almost 20% had also failed prokinetic therapy. Symptom burden was high, with mean
PAC-QoL and PAC-SYM scores of > 2.0 points at baseline. In addition, > 50% of patients had faecal
incontinence symptoms, > 30% had urinary symptoms and > 20% had pelvic organ prolapse symptoms
(100% in CapaCiTY trial 3).
In CapaCiTY trial 1, data from the PHQ-9, which measures depression, showed that 32.9% of participants
scored > 9 points, suggesting that one-third of the sample would meet case criteria for major depressive
disorder (MDD). A further 33% had scores indicative of mild depression, suggesting that, overall, around
two-thirds of the sample were distressed or depressed. This compares with a point prevalence of MDD in
the general population of 5%. The prevalence of MDD is, on average, at least twice as high in people with
chronic medical diseases than in those without a chronic medical condition, but, even taking this into
account, the rates in the current study are at the high end.84 The findings for anxiety were similar, with
one-third of the cohort (33.6%) scoring above the GAD-7 cut-off point for an anxiety disorder, and a
further 25.1% reporting mild symptoms of anxiety.
Interview participants
A total of 45 patients and 23 staff members were interviewed:
l CapaCiTY trial 1. A total of 24 participants (men, n = 3; women, n = 21) were interviewed: nine
participants were allocated to INVEST and 15 participants were allocated to no INVEST, to
elucidate the experience of undergoing tests and being given an explanation of results or their
feelings about not being tested; 11 participants were allocated to HT and 13 participants were
allocated to HTBF, both improved and not improved (at 6 months) for perceptions of treatment.
A total of 15 staff members were interviewed: five therapists involved in HT/HTBF to determine
the comparative ease of delivery of the two therapies, three research nurses, four CapaCiTY research
teammembers, one biofeedback physiologist, one clinical trials associate and one trainee clinical scientist.
l CapaCiTY trial 2. A total of 11 patients (men, n = 4; women, n = 7) undergoing TAI were
interviewed: seven received high-volume TAI, three received low-volume TAI and one received both
high-volume and low-volume TAI. Most (n = 10) patients were continuing to use TAI at the time of
interview; however, one had discontinued use by the interview date.
l CapaCiTY trial 3. A total of 10 patients (all female) were interviewed. Nine patients were
interviewed ≈ 1 year after their lapVMR to gain an understanding of what their experiences were
prior to, immediately after and 1 year after the operation. One patient who declined surgery was
also interviewed. A total of eight staff members (i.e. three surgeons, three research nurses, one
gastroenterologist and one research team member) were also interviewed about both the
interventional and research element of the study.
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Work programme 2: CapaCiTY trial 1 –
randomised trial of habit training
compared with habit training with
direct visual biofeedback in adults with
chronic constipation
Specific background and rationale
In most UK practices, patients with CC are first referred to specialist nurses for a variety of nurse-led
behavioural interventions to improve defaecatory function. A range of cohort studies,85 RCTs,86–91
reviews,92 guidelines93 and meta-analyses94 attest to the general success of this approach. However,
opinion varies greatly concerning the complexity of intervention required and UK survey evidence
(performed as part of this programme) indicates that there is remarkable variability of practice.95
A simple form of behavioural therapy is habit training. This involves optimising dietary patterns to
maximise gastrocolic response and the morning clustering of high-amplitude propagated colonic
contractions that propel contents towards the rectum for subsequent evacuation. Dietary advice to
optimise intake of liquid and fibre is given, as well as advice about frequency and length of toilet visits
and posture. Patients are also instructed on basic gut anatomy and function, and gain an appreciation
of how psychological and social stresses may influence gut functioning. Simple pelvic floor and balloon
expulsion exercises are often included.
More complex forms of therapy include instrument-based biofeedback learning techniques.85–91
Favoured in the USA and by about half of UK centres, these provide direct visual computer-based
biofeedback of pelvic floor activity. Although small RCTs suggest an additive value of biofeedback over habit
training alone in the management of selected patient subgroups of CC (e.g. dyssynergic defaecation),87,96–98
there has been no multicentre or adequately powered RCT in unselected patients, despite the uncertainty
having significant resource implications. Aside from the issue that there is now considerable disagreement
regarding the very diagnosis of dyssynergic defaecation (including from our own study using HRAM),99 most
publications advocating biofeedback have come from specialist centres with considerable ‘investment’ in
these techniques, with reports much less favourable when biofeedback is the ‘de-vested’ comparator.100,101
The controversy following a Cochrane review that drew attention to the limitations of the evidence base102
attests to the polarity of opinion on this subject and the need for a more definitive (i.e. a larger,
higher-quality) RCT.
This underpinned our first trial-specific research question:
l In unselected (i.e. no-INVEST group) adults with CC, is HTBF more clinically effective than HT as
measured by PAC-QoL score at 6 months’ follow-up?
A further unanswered question regards the utility of behavioural therapies in different subgroups
of patients with CC. Well-regarded international consensus (e.g. the Rome VI Criteria)103 supports a
view that biofeedback significantly benefits only a subgroup of patients with a form of functional
defaecation disorder termed ‘dyssynergic defaecation’ (see Figure 1). This poses the question whether
or not further tests are required at an early stage (i.e. before behavioural therapy to select patients for
biofeedback). There are significant differences of expert opinion on this subject: some advocate early
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complex and expensive investigations to guide treatment in most patients,8 whereas others advocate
undertaking such tests only in resistant cases or in those progressing to surgery.104 The advantage
of guiding treatment105,106 is balanced against the invasive nature of some tests, radiation exposure,
embarrassment and cost (≈ £600–1200 NHS tariff); most also necessitate an escalation of care
(i.e. from secondary to tertiary centre). The need to resolve this question has been consistently
highlighted38,107 but, to our knowledge, prior to the programme no RCT had stratified treatment
selection on this basis.
This underpinned our second trial-specific research question:
l Is the impact of such specialist-led interventions improved by stratification to HTBF or HT based on
prior knowledge of anorectal and colonic pathophysiology using INVEST as measured by PAC-QoL
score at 6 months follow-up?
Both research questions were embedded in a single experimental design with three parallel trial
groups and required a total sample size of 394 patients. For a full description of this trial, including
interventions, trial-specific design procedures and all results and analyses, see Appendix 1. Only the
main results and conclusions are summarised in this report.
Results
Recruitment started on 26 March 2015 (first intervention 21 May 2015) and ended 30 June 2018.
A total of 182 participants (of the target 394 participants) were randomised out of 502 screened
(36.3%) from 10 sites. Two sites opened but failed to recruit; the remainder randomised between 7 and
71 participants. A total of 68 participants were randomised to HT, 68 participants were randomised
to HTBF and 46 participants underwent INVEST-guided therapy (HT or HTBF based on results) [the
Consolidated Standards of Reporting Trials (CONSORT) flow diagram is shown in Figure 2]. A total of
178 participants provided PAC-QoL data at one or more time points (Figure 3). The primary outcome
(PAC-QoL score) was available at both baseline and 6 months for only 103 participants. There was no
evidence of an additive effect of HTBF over and above HT (Table 2).
A range of secondary outcomes covering symptoms and QoL improved in both the HT group and the
HTBF group (e.g. mean PAC-SYM score reduced from 2.2 points at baseline to 1.5 points at 6 months
and weekly laxative use reduced fourfold). Interventions led to small reductions in depression but no
significant differences between the intervention types. Overall, about 65% of participants were globally
satisfied or very satisfied with both interventions and this was reflected by participant experience
reported at interview (i.e. similar proportions of participants liked, and a minority disliked, both
interventions for a number of reasons).
Similar results were obtained for INVEST versus no-INVEST, with no evidence of a difference in primary
outcome (see Table 2): participants provided reasons for liking INVEST (e.g. greater knowledge of
their condition and knowing that it was not ‘all in their mind’) and disliking the invasiveness and
embarrassment of the tests.
Given similar changes in EQ-5D-5L scores for all interventions, cost-effectiveness analyses favoured
the simpler strategies (i.e. HT and no INVEST) as the dominant strategies. In both instances, cost
increases were significant (HTBF vs. HT: £239, 95% CI £133 to £354; INVEST vs. no INVEST: £543,
95% CI £403 to £685) and QoL reduced (HTBF: –0.010 QALYs, 95% CI –0.053 to 0.03 QALYs;
INVEST: –0.047 QALYs, 95% CI –0.093 to –0.001 QALYs). The probability that HT is cost-effective was
a p-value of 0.83 at a WTP threshold of £30,000 per QALY.
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FIGURE 3 Overall PAC-QoL scores. (a) All participants (n= 178 at baseline); and (b) participants with no missing data to
12 months (n = 54). Both figure parts show reductions in score (i.e. improvement) over time.
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Conclusions
Taking together the results from clinical effectiveness, cost-effectiveness and patient experience data,
the following conclusions may be drawn while accepting the major caveat of under-recruitment:
l Included adults with CC had high levels of symptom burden and long durations of symptoms that
had been refractory to previous treatments and could therefore be considered ‘hard to treat’. These
symptoms were associated with a substantive effect on QoL and psychological well-being. Patient
experience reflected the misery of the condition and fear that treatments would be ineffective.
l Our analysis of clinical effectiveness showed that all interventions trialled (i.e. HT, HTBF with
INVEST and HTBF with no INVEST) reduced symptom burden and improved disease-specific QoL.
The observed magnitude of these PAC-QoL score changes (≈ 0.8 points) can be considered to be
clinically meaningful and represented a greater reduction than the minimum clinically important
difference sought between groups by design (mean change 0.4 points). The findings from the
primary outcome were coherent with a panel of secondary outcomes, and, overall, such
improvements are unlikely to have occurred spontaneously in a condition that is generally
considered chronic and stable.
l Confidence intervals rule out clinically important differences between HT and HTBF for the primary
outcome and all main secondary outcomes. The same was true of INVEST and no INVEST.
l Standardised specialist-led habit training alone and no INVEST are strongly supported by cost-
effectiveness analyses. Despite under-recruitment (182 out of a planned 394 participants), participant-
level data provided the most robust evidence to date on the first step of care for patients referred
to hospital for CC. Neither a complex specialist-led intervention (e.g. pelvic floor retraining using
biofeedback) nor stratification to complex or standardised therapy based on prior knowledge of
anorectal and colonic pathophysiology (INVEST) were more cost-effective than HT. Analysis suggests
that HT is the dominant strategy (i.e. lower cost and greater QoL) at a WTP threshold of £30,000
per QALY.
l All procedures were safe and well tolerated by patients.
l Interviews suggested that patient experience was mixed. Some regretted not being allocated to
INVEST or HTBF (because they believed that they would have less knowledge of their condition
and less likelihood of treatment success), whereas others felt that the tests and biofeedback were
embarrassing and intrusive. Most participants reported a positive interaction with staff and at least
some symptom benefit. Most would recommend trying the intervention they received to other
people with CC.
l Staff were mostly supportive, but some found that adhering to the agreed intervention protocol
constrained their clinical flexibility and they would have preferred to individualise the intervention.
The biofeedback element added time to consultations, or limited what they could cover in HT.
TABLE 2 Overall PAC-QoL score by randomised group and mean differences between HT and HTBF groups and
no-INVEST and INVEST groups for those included in the final analysis model
Intervention
PAC-QoL score (points), mean (SD)
Treatment differencea (95% CI) p-valueBaseline 6 months
HT vs. HTBF
HT (n = 38) 2.26 (0.69) 1.49 (0.85) Reference
HTBF (n= 30) 2.41 (0.81) 1.65 (1.03) –0.03 (–0.33 to 0.27) 0.8445
No INVEST vs. INVEST
No INVEST (n = 68) 2.33 (0.74) 1.56 (0.93) Reference
INVEST (n = 22) 2.36 (0.78) 1.81 (1.03) 0.22 (–0.11 to 0.55) 0.1871
a Adjusted for sex, baseline PAC-QoL score and breakthrough medication (i.e. use of oral and/or rectal laxatives).
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l Because these patients had significant psychological comorbidity, and there is evidence that
psychological treatments such as cognitive–behavioural therapy have significant and sustained
benefits on symptoms, mood and QoL in people with irritable bowel syndrome (many of whom also
experience severe constipation), future work should focus on incorporating psychological methods
alongside HT.108,109
l Taken together, the cost-effectiveness data (in the absence of differences in clinical effectiveness,
patient experience and safety) promote the adoption of the simpler pathway (i.e. HT without
INVEST). A revised prototype pathway is provided on this basis in the final conclusions of the
synopsis (see Figure 8).
Reflections on work programme 2
This WP was severely hampered by poor recruitment, with many of the general challenges listed in
SYNOPSIS. It is not the place here to repeat well-rehearsed arguments about the frailties of delivering
a complex research intervention in a resource-strained NHS, but these certainly affected this trial. That
noted, with the benefit of hindsight, and even after simplifying the trial design at the award approval
stages, the study was probably overambitious in design. We tried to answer two research questions
concurrently with one experimental design (HT vs. HTBF and INVEST-stratified vs. no INVEST-stratified
treatment). This was laudable and based very clearly on nationally agreed research priorities at the time
(e.g. from the American Gastroenterology Association).93 However, it might have been better to have
simplified the design to one that compared only HTwith HTBF in a two-group trial without INVEST. This
would have not only reduced the sample size (and general complexity) but also avoided some of the issues
of equipment shortages and approvals (including infection control procedures) that delayed many centres
from opening for as long as 1 year (with some never opening). We considered this option at the second
review stage but felt that it was too great a departure from our original application. An alternative design
(based on our qualitative data) might have been preference based. Another issue was the complexity of
inclusion criteria and the number and complexity of outcome instruments. Despite PPI input at the
outset, and changes made (with PPI) during the programme, outcome collection was still burdensome.
Although the type of strict inclusion criteria and outcome panel we employed seem to still be the norm
in recent pivotal trials, a more pragmatic (relaxed) approach to inclusion and a smaller outcome booklet
would (with hindsight) have been preferable.
Despite these challenges, the trial undoubtedly brought together a fragmented community of experts
from around the UK and led to the standardisation of practice. Two publications from early in the
programme highlight the previous lack of understanding of what actually constitutes biofeedback95 and
what investigations tests should be performed and how.34,110 The former was borne out by our qualitative
data (i.e. many practitioners preferred to tailor their approach to each patient). The latter led to an
international effort to introduce technical standards on performing and interpreting diagnostic tests of
anorectal function, in which the CapaCiTY team were leaders, and these have been published.111
Finally, it must be recognised that, despite under-recruitment, CapaCiTY trial 1 is, to our knowledge,
nevertheless the largest RCT to date in which biofeedback is one of the trialled interventions. A total of
182 patients were randomised; sample sizes in 17 previous RCTs included in a Cochrane review102 ranged
from 21 to 119 (and it is noted that the trial with 119 patients101 was focused on surgery with biofeedback as
the comparator). Therefore, it is acknowledged that among many UK practitioners there will be a sentiment
that the results of CapaCiTY trial 1 do still provide an answer to a major question – namely, that the sort of
specialist-led biofeedback practice advocated by a small but very vocal group of experts in the USA is less
likely to work in an NHS pathway.The main points are as follows: (1) there is insufficient human resource
(trained specialist nurses) and equipment (manometry catheters) to provide it (CapaCiTY trial 1 had three to
four sessions; in the USA five to seven sessions are prescribed); and (2) there is a general disbelief (reinforced
by the findings of the study and a prior Cochrane review)102 that direct visual biofeedback offers much to
patients over and above the panoply of approaches encompassed by HT (including holistic elements of
patient support as well as didactic training) when it comes to the average patient (i.e. widespread adoption
would be protracted if possible at all).
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Research recommendations
The primary outcome effect size was almost identical for all groups and it is unlikely that another trial,
even with a much greater sample size, would detect a clinically important difference between interventions.
Certainly, the CI for the effect comparing HT and HTBF excludes the difference we initially set as the
minimum clinically important difference in our sample size calculation.Thus, it is hard to recommend further
investment, even with a more simplified trial design.We cannot comment on whether or not the US
expert view is correct; perhaps limitation to highly selected patients with proven dyssynergic defaecation
and specialist equipment in the hands of very expert medical practitioners (undertaking multiple sessions
of therapy) does result in better outcomes (we did not trial this). However, we believe that this would be
difficult to trial successfully in the NHS for the reasons outlined, and were it to produce the same results
as CapaCiTY trial 1 it would still be unlikely to influence international opinion owing to the financial
reimbursement drivers that promote the US approach. As noted, there may be rationale to include some
form of psychological therapy alongside habit training for the large proportion of patients with significant
psychological morbidity (akin to trials for patients with irritable bowel syndrome). This is an area for
further research.
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Work programme 3: trial 2 – pragmatic
randomised trial of low-volume
compared with high-volume initiated
transanal irrigation therapy in adults
with chronic constipation
Specific background and rationale
Transanal irrigation, for which there are a variety of commercially available devices, has been rapidly
disseminated internationally since about 2000, first in CC patients with neurological injury112,113 and
subsequently in other groups CC groups.114,115 Despite a lack of published data other than from small
selected case series, TAI is now available on drug tariff (at a cost of ≈ £2500 per patient per annum)
and is generally considered to be the next step for patients failing other nurse-led interventions. TAI
has permeated the UK market without robust efficacy data and with ongoing concerns regarding
longevity of treatment and complications.112,116 Retrospective clinical audit data and review116,117 by the
applicants suggest a continued response rate after 1 year of ≈ 50%, with patients thus avoiding or
delaying surgical intervention, but an accurate assessment of response rate and acceptability of this
intervention required confirmation in a trial. In addition, two alternative systems for delivery of TAI
exist: low-volume systems delivering ≈ 70 ml per TAI, and high-volume systems delivering up to 2 l of
TAI (although typically only 0.5–1.5 l is required per TAI). The theoretical benefit of higher-volume TAI
is greater efficacy – simply put, more washout. However, the low-volume system is cheaper, costing
≈£750 per annum, based on alternate-day use, compared with a cost of £1400–1900 per annum for
high-volume TAI, and it may also be less traumatic and more acceptable to patients.
This underpinned our first specific research question:
l In patients with CC who have failed conservative treatment (HT or HTBF), what is the impact on
disease-specific QoL of TAI initiated with a low-volume and a high-volume system measured by
PAC-QoL score at 3 months’ follow-up?
Transanal irrigation is an invasive therapy that requires, every day or every couple of days, insertion of
the device into the anus followed by a period spent filling the rectum with fluid and then evacuating it.
It is reasonable to suppose that patients would discontinue therapy that they felt was ineffective or
unacceptable, or switch between low-volume and high-volume systems (permissible in the trial design).
This underpinned our second trial-specific research question:
l What is the survival rate of therapy of TAI initiated with a low-volume and a high-volume system
and do patients prefer one system to another?
Both research questions were embedded in a single, pragmatic, two-group parallel design (Figure 4) and
required a total sample size of 300 patients (150 per group). Patients used one system only (plus defined
‘rescue therapies’) for a minimum of 3 months. After this time point they could switch to the other
system if their initial therapy was ineffective/unsatisfactory. This allowed identification of response rates
to each system in the short term (3 months) and, thereafter, a comparison between treatment strategies
(TAI initiated with low-volume therapy or high-volume therapy) rather than a pure comparison of the
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two techniques. This was a patient-centred study design aiming to limit the time that patients spent
using ineffective therapy without being allowed to try an alternative. Reasons for switching were
captured qualitatively.
For a full description of this trial, including interventions, trial-specific design procedures and all results
and analyses, see Appendix 1. Only the main results and conclusions are summarised in this report.
Results
High-volume compared with low-volume transanal irrigation
First recruitment and intervention took place on 11 November 2015; recruitment ended 30 June 2018.
A total of 65 patients (target 300 patients) were randomised from 150 screened (21.7%) from seven sites.
Three sites opened but failed to recruit; the remainder randomised between 1 and 33 patients, with
approximately half of the patients recruited from secondary care and half recruited from tertiary care.
A total of 30 patients were randomised to low-volume TAI and 35 to high-volume TAI (see Figure 4).
The primary outcome (PAC-QoL score) was available at baseline and 3 months for only 43 patients.
At 3 months there was a modest reduction in mean PAC-QoL score from 2.4 points to 2.2 points
(SD –0.2 points) in the low-volume TAI group and a larger reduction of –0.5 points in the high-volume
TAI group (Table 3). Although this difference was not large there was consistency of findings across



































FIGURE 4 The CapaCiTY trial 2 CONSORT flow diagram.
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and EQ-VAS score showed greater improvement in the high-volume TAI group. These results were
based on an ITT analysis even though two patients crossed over (from low-volume to high-volume TAI)
before the 3-month outcome (possibly diluting the difference in effect).
Some further evidence of the greater benefit of high-volume TAI could be inferred from the fact that,
over the follow-up period (with the majority after 3 months), 18 patients switched from low-volume to
high-volume TAI but only six patients switched from high-volume to low-volume TAI, and two of these
six switched back again to high-volume TAI.
Despite under-recruitment, patient-level data from the trial still provided the most robust evidence
available to inform the pathway of care. Despite differences in initial purchase prices of the basic devices,
initiating high-volume TAI did not increase study cost but resulted in higher patient QoL, suggesting a
dominant interventional strategy (cost-effective at a WTP threshold of £30,000 per QALY; p = 0.99).
The interventions were generally well tolerated considering the invasive nature of the procedure.
A total of 16 out of the 65 patients (25%) reported AEs, with a total of 68 AEs. Of these, 40 AEs (59%)
were mild and 20 (29%) were moderate. There were six SAEs, of which three were expected. All resolved
with no sequelae.
Survival rate of transanal irrigation therapy
In the absence of a sham control (impossible to devise), and with the inability to compare with standard
therapy, it was reasonable to use treatment continuation as a marker of efficacy. The treatment is
burdensome, and it can be argued that patients who are not receiving benefit would not continue with
it. There was no encouragement from research or clinical staff for patients to continue to use ineffective
therapy. The 1-year survival rate of the treatment of 76% (Figure 5) implied significant continued effect.
A comparison of survival rate plots of low-volume and high-volume TAI that allows for crossover has
not been presented at the time of publication. This analysis is planned but was outside the SAP.118
TABLE 3 The CapaCiTY trial 2 primary outcome: PAC-QoL score, low-volume TAI vs. high-volume TAI
Intervention
Baseline 3 months
Difference in means (95% CI)Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Low-volume
TAI (n= 19)
2.4 (0.8) 2.4 (1.9–2.9) 2.2 (0.8) 2.0 (1.5–2.8) Reference
High-volume
TAI (n= 25)
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FIGURE 5 The CapaCiTY trial 2 survival rate of treatment as a surrogate of ongoing benefit: Kaplan–Meier plot for time
to cessation of treatment.
DOI: 10.3310/pgfar09140 Programme Grants for Applied Research 2021 Vol. 9 No. 14
Copyright © 2021 Knowles et al. This work was produced by Knowles et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
25
Conclusions
Taking together the results from clinical, cost-effectiveness and patient experience data, the following
conclusions may be drawn while accepting the major caveat of under-recruitment:
l The population studied represented a typical hospital-derived cohort of patients with severe CC
that had not responded to conservative therapies.
l We did not carry out statistical significance tests owing to under-recruitment. Despite this, there is
preliminary evidence that high-volume TAI may be more effective than low-volume TAI. Although
effect sizes were small for both primary and secondary outcome measures (especially global
improvement scores), dominant crossover from low-volume to high-volume TAI and health
economic analysis point in the same direction of favouring high-volume TAI.
l Survival rate data were suggestive of a persisting benefit in the majority of patients, with three-quarters
of patients still using TAI at 12 months. Overall, there were fewer patients on low-volume TAI at
12 months than on high-volume TAI. A survival rate analysis allowing for crossover is yet to
be undertaken.
l Some AEs were reported, but, of six SAEs, none was related or life threatening. The most common
AEs were rectal bleeding and anal pain (48 events in 16 patients).
l Despite under-recruitment, patient-level data from the trial still provided the most robust evidence
currently available to inform the pathway of care. Initiating high-volume TAI did not increase overall
cost (despite slightly higher basic device pricing) and resulted in higher patient QoL, suggesting a
dominant interventional strategy (cost-effective at a WTP threshold of £30,000 per QALY; p = 0.99).
l Although cost-effectiveness base-case findings were robust to the complete-case and sensitivity
analyses conducted, the findings should be treated with caution. Small absolute numbers of patients
and high levels of missing data as follow-up progressed placed great reliance on the imputation
process and output. As with CapaCiTY trial 1, although substantial efforts were made to deliver a
robust imputation process, it not possible to prove that a MAR process has been attained. Actual
level of TAI use (the predominant cost) was not directly recorded and was instead approximated
from available variables.
l A final consideration in support of high-volume TAI concerns convergence. Health-care costs are
similar comparing the two groups, suggesting that differences in health-care costs beyond 12 months
are small. However, QoL diverges between groups over 12 months, suggesting that QALY gains may
continue to accrue for some time beyond 12 months. Although speculative, any modelling of future cost
and benefits would further increase the cost-effectiveness of high-volume TAI.
l Transanal irrigation often caused initial anxiety, was not always easy to learn and was time-consuming.
Ongoing staff support was much appreciated, especially as results were not always immediate. Some
found it of no benefit, but many persevered and found that, although not necessarily a pleasant
experience, it had an impact (sometimes large) on their symptoms and QoL. Staff were possibly more
enthusiastic than patients initially, and this enthusiasm was picked up by patients in some cases and
helped them to persevere.
Reflections on work programme 3
Poor recruitment (65/300; 22%) was a disappointment and reduced the inferential quality of the study.
As well as the usual difficulties as discussed for CapaCiTY trial 1, we failed to recognise an important
constituent: that the patients offered TAI had (1) a severe burden of illness and (2) already tried all
the usual conservative measures (which had failed). They were resorting to TAI often in a state of
desperation. The difficulty, then, was that recruitment to the trial resulted in a delay in treatment while
baseline assessments and investigations were undertaken. At the same time, patients were aware that
they could access the treatment immediately if they remained outside the trial. With hindsight, it
should have been clear that this would lead to difficulties. To overcome this would have required a
waiting list for non-trial treatment or a pragmatic approach in which investigations and baseline diaries
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were dispensed with (as they are dispensed with in emergency medicine trials). Further issues, such as
the failure to obtain funding for the therapy in several UK regions, proved beyond our control despite
extensive discussion with relevant CRNs and at a national level. Ironically, we received letters stating
that funding would not be provided because the therapy lacked evidence from a randomised trial.
Despite gross under-recruitment, we believe that the trial provided some meaningful evidence that
high-volume TAI may be more effective than low-volume TAI for the majority of patients. The CI for
the effect size appeared to rule out a clinically important difference of 0.4 in favour of low-volume TAI
and not in favour of high-volume TAI. This finding promotes a care pathway in which high-volume TAI
might be initiated as a default for patients when there is not a compelling reason or preference for
low-volume TAI. This is a useful conclusion, but it lacks identification of a more definite means of
stratifying patients to one treatment or the other based on baseline phenotype. Ideally, we would have
liked to study the efficacy of TAI per se, but there was no way of designing a sham control. A waiting
list comparison was considered but rejected because waiting times were not long enough to provide
meaningful data. A cohort design was also proposed, but the grant review panel encouraged a RCT.
The appeal of considering low-volume and high-volume TAI was the ability to relate responders in the
different treatment cohorts to symptoms (urge vs. no urge) and selected physiology results (notably,
presence or absence of blunted rectal sensation). We could potentially have learned something about
the physiology and mechanism of action of these treatments by doing this. However, with very low
recruitment numbers, these additional analyses (covariates of response to each or both therapies)
could not be undertaken.
It was interesting to note from the staff interviews that specialist nurses providing the treatment
already had strong views that high-volume TAI was a better treatment. It is possible that some bias
might have been affected by these opinions.
Research recommendations
It does not seem necessary to recommend repeating the trial on the basis of inadequate recruitment
because any future trial will face many of the same challenges, even with the changes proposed here.
Furthermore, a more basic question still remains: what is the value of any type of anal irrigation? There
have been a significant number of retrospective observational studies and occasional prospective ones.
The difficulty would be in establishing a control, as already stated here. It may be possible to develop a
prospective cohort study of patients with CC that, while being monitored prospectively, might adopt
TAI as an alternative to usual care. A trials within cohorts (TwiCs) design could be considered if
patients would consider secondary randomisation against continuing usual care.
The qualitative evidence has been very illuminating and further analysis of this will be undertaken to
understand drivers for continuing and discontinuing therapy (to guide patient selection and encourage
compliance). As new equipment is developed (including devices activated by mobile telephones) there
may be a desire to assess equivalence and safety. In addition, there is a need to understand the merits
of contraindications such as mild colitis and pregnancy.
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Work programme 4: CapaCiTY trial 3 –
stepped-wedge randomised trial of
laparoscopic ventral mesh rectopexy in
adults with chronic constipation
Specific background and rationale
When non-surgical therapies fail, a decision must be made about whether or not to offer surgical
interventions. Decision-making is greatly influenced by local expertise, commissioning and personal
enthusiasm for particular interventions25,119,120 balanced against poor results in some patients.25 Currently,
there is large and difficult-to-justify variation in surgical practice according to need and type of procedure.
The need to reduce variations in practice, based on available evidence, is a perpetual theme of national
specialty group discussions, with various initiatives proposed. Multidisciplinary team (MDT) processes have
been established in the UK with the aim of reducing potential for inadequately informed and potentially
harmful interventions in poor surgical candidates.25 However, when these MDT processes occur, decision-
making is not helped by a near void of high-quality evidence.
At the time of starting the CapaCiTY research programme, lapVMR was considered a very effective
procedure for the management of selected patients with CC. This procedure was first described for the
treatment of external rectal prolapse in 2000121–123 and then for patients with internal prolapse and/or
rectocele presenting with CC.124–131 Its popularity, based on its lesser invasiveness and perceived small
detrimental effect on bowel function,132 soared 15-fold in the UK between 2001 and 2012133 but
rapidly declined during the CapaCiTY research programme (2016 to present) when concerns regarding
the use of pelvic mesh surfaced in the media83 and the courts.134
The evidence for efficacy of lapVMR was limited to observational data, the majority of which derived
from single-centre case series. It is clear that complications can be limited by good technique and
perhaps choice of mesh, but complications will not be eradicated. Thus, it can be argued that the future
of lapVMR depends not on the very small observed differences in long-term mesh complications (e.g. in
1.0–2.0% of patients) but on a fundamental evaluation of whether or not the procedure is actually
clinically beneficial (i.e. whether or not these complication rates would be deemed acceptable, provided
patients are consented to the risk, if the patient benefit was sufficiently large).
This underpinned the specific research question:
l In selected adults with CC who have failed conservative treatment (i.e. HT or HTBF with or without
TAI) and who have high-grade internal rectal prolapse, what is the clinical efficacy of lapVMR
compared with controls at short-term (i.e. 24-week) follow-up.
In addition, this WP included the delivery of a series of high-quality systematic reviews for all main
surgical procedures employed to treat CC to define benefits and harms and provide prototype graded
practice recommendations (including for lapVMR).
We used a stepped-wedge randomised trial design to permit observer-masked data comparisons
between patients awaiting intervention and patients who have undergone surgery. Contrary to most
stepped-wedge trials, individual patients (as opposed to clusters) were randomised. In brief, eligible
participants were randomised to three groups with different delays before surgery (Figure 6). In all
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groups there was a period of 4 weeks post eligibility assessment to arrange the logistics of surgery
[time (weeks) since randomisation (T) –4 (T–4) to T0] and ensure that patients have returned to their
normal life routine after various assessments. lapVMR was performed in group 1 at T0, in group 2
at T12 and in group 3 at T24. Unavoidably, participants were aware when surgery was undertaken
and thus met one of the assumptions of a stepped-wedge design (i.e. no effect of treatment expected
until surgery has been performed). Efficacy outcome data were collected at equally stepped time
points (T0, T12, T24, T36 and T48). PAC-QoL and PAC-SYM total scores were analysed using a mixed
linear regression model, adjusting for a random effect of participant and a fixed effect of time since
randomisation (see Figure 6). The effects of the intervention at 12, 24, 36, 48, 60 and 72 weeks post
surgery were modelled as fixed effects. For example, the intervention effect at 12 weeks post surgery
was included in the regression model using a dummy variable set to 1 in those cells of Figure 6 where
surgery occurred 12 weeks previously [i.e. at T12 in group 1 (when surgery was at T0), T24 in group 2
(when surgery was at T12) and T36 in group 3 (when surgery was at T24). This was the expected
difference in outcome between a patient who had surgery 12 weeks previously and a patient who had
not had surgery. This was similar for intervention effects at T24, T36, T48, T60 and T72 weeks post
surgery. The analysis included a Kenward–Roger correction to correct for the small sample size, and
was performed in Stata using the ‘mixed’ command with the options ‘reml dfmethod(kroger)’.
The choice of design (in effect a modification of a standard, parallel-group, waiting-list control design)
had several advantages. First, a stepped-wedge design is more efficient and thus improves recruitment
feasibility (the major hurdle of nearly all surgical trials). Despite the multicentre approach of this study,
the problems of recruitment were manifest. Simulation demonstrated that a parallel-group design
required a much larger sample size than that proposed for the current study at the same power.
Second, the trial design meant that there was only a one in three chance (rather than a one in two
chance as in a parallel-group design) of waiting almost 6 months for surgery, which was more acceptable
to patients (according to a 100-patient survey during the programme development phase). Using this
design required a sample of 114 patients with 95% power (purposely chosen to reflect the magnitude
and risk of intervention) at a 5% significance level.
For a full description of this trial, including interventions, trial-specific design procedures and all results
and analyses, see Appendix 1. Only the main results and conclusions are summarised in this report.
Results
Stepped-wedge randomised trial
The first recruitment was on 1 March 2016, with the first intervention on 15 June 2016. Recruitment
ended on 31 January 2019. A total of 28 patients (target 114 patients) were randomised out of
81 screened (34.5%) from nine sites. Two sites opened but failed to recruit and one site failed to
randomise; the remainder (n = 6) randomised 1–11 patients each. Nine patients were randomised to
immediate surgery, 10 were randomised to a 12 weeks’ waiting time and nine were randomised to a
24 weeks’ waiting time. The CONSORT flow diagram is shown in Figure 7. One patient was randomised
but did not undergo surgery. However, this patient remained in the study on ITT principles. Two
patients dropped out of the study before the primary end point and a further five failed to complete
the primary outcome (PAC-QoL score at 24 weeks), which was therefore undertaken in 19 patients.
Laparoscopic ventral mesh rectopexy resulted in substantial improvement in symptoms, with the mean
PAC-QoL score reducing from 2.63 points at baseline to 1.26 points at 24 weeks, and a similar
reduction in PAC-SYM score from 2.24 points at baseline to 1.19 points at 24 weeks (Table 4).
Secondary outcomes also indicated improvement over time, with PAC-QoL and PAC–SYM scores
showing maintained reductions compared with baseline up to the 72-week time point (accepting
potential attrition bias). Improvements in total score reflected improved scores across all domains of
the instruments. Positive directional effects were observed for nearly all other secondary outcomes,
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FIGURE 7 The CapaCiTY trial 3 CONSORT flow diagram. a, One patient did not undergo surgery; this patient continued
to participate and was included in analysis on ITT principles.
TABLE 4 Total PAC-QoL and PAC-SYM scores at baseline and follow-up points post surgery, with 95% CI and p-value for













Baseline 26 2.63 – – –
12 weeks 23 1.35 –1.04 –1.54 to –0.55 0.0001
24 weeks 19 1.26 –1.09 –1.76 to –0.41 0.0019
36 weeks 19 1.47 –0.98 –1.87 to –0.10 0.0296
48 weeks 17 1.43 –1.07 –2.16 to 0.02 0.0552
60 weeks 9 1.22 –1.26 –2.56 to 0.05 0.0587
72 weeks 5 1.11 –1.38 –2.94 to 0.19 0.0840
PAC-SYM
Baseline 26 2.24 – – –
12 weeks 23 1.15 –0.97 –1.41 to –0.53 0.0000
24 weeks 18 1.19 –0.92 –1.52 to –0.32 0.0029
36 weeks 19 1.25 –1.03 –1.80 to –0.26 0.0094
48 weeks 17 1.36 –0.97 –1.92 to –0.02 0.0444
60 weeks 9 1.19 –1.16 –2.28 to –0.03 0.0448
72 weeks 5 0.82 –1.51 –2.87 to –0.16 0.0289
All estimates are adjusted for time.
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with some quite substantial improvements in measures [e.g. > 25% scalar improvements in psychological
measures (e.g. PHQ-9, GAD-7), St Mark’s Incontinence Score and EQ-VAS]. Global patient satisfaction
was 2.7 points at 24 weeks (nearest to ‘very satisfied’), although this dropped to 2.2 points (‘moderately
satisfied’) at 48 weeks. This result was mirrored in the global patient improvement score (EQ-VAS score
0–100 points between ‘no effect’ and ‘complete cure’), which was 72.2 points at 24 weeks and 56.5 points
at 48 weeks.
Comparing pre-surgery and post-surgery periods, intervention led to a significant increase in cost
(£5012, 95% CI £4446 to £5322), similar to the cost of surgery, and a modest and imprecise increase
in QoL (0.043 QALYs, 95% CI –0.005 to 0.093 QALYs). The ICER was £115,512 per QALY. At the NICE
threshold of £30,000 per QALY, the probability that surgery is cost-effective within 48 weeks of
surgical intervention is 0%. The EVPI (per subject) reflects the opportunity loss of ongoing uncertainty
and suggests no requirement for further research.
Laparoscopic ventral mesh rectopexy was shown to be a safe procedure. There were 30 AEs reported
by 16 patients, 20 of which were considered to have possible causality related to surgery and none of
which had any long-term sequelae. There were five SAEs, of which four were deemed to be related to
surgery. Three of these were for postoperative pain, which was entirely to be expected in a proportion
of patients; one was for a chest infection and none resulted in long-term patient harm.
Patient experience of lapVMR was, on the whole, positive. Some patients did not find surgery to be the
miracle cure that they were looking for and some reported negative experiences in the perioperative
period, but for the most part these were not related to the operation itself. Some patients also found
benefit from the dietary and behavioural changes that they initiated as a result of advice that they
were given as part of the perioperative care package.
The media scrutiny of the use of mesh undoubtedly affected both patient and surgeon perception and
willingness to take part in the study. Some centres paused or abandoned lapVMR totally in the light of
the mesh scandal, and there was a perception that for others the heightened scrutiny of practice in the
protocol also negatively affected recruitment.
Systematic reviews
An aim of the programme was to systematically review outcomes from current surgical approaches to
CC, with the aim of integrating new data with old data at the programme conclusion. On this basis, a
series of workshops and rounds of Delphi consensus were undertaken, leading to seven major open
access publications; these included an introduction and methods paper,135 five reviews of major procedure
classes136–140 and a summary paper with European graded practice recommendations covering patient
selection, benefits and harms of all procedures.141 These papers have been cited 102 times in the scientific
literature and also referenced in major textbooks and the national press; they represent a unique,
contemporary and valuable open access resource for clinicians and researchers worldwide. The review of
rectopexy confirmed that lapVMR evidence was confined to 18 studies, all of which contained poor-quality
(Oxford Centre for Evidence-Based Medicine grade IV) observational data (case series and poor-quality
cohort studies); these data provided the rationale for CapaCiTY trial 3.
Conclusions
Taking together the results from clinical effectiveness, cost-effectiveness and patient experience data,
the following conclusions may be drawn while accepting the major caveat of under-recruitment:
l Included patients had a high symptom burden and long duration of symptoms that had been
refractory to previous treatments, including a minimum of bowel habit training by a specialist
practitioner. Patients had been thoroughly investigated and, therefore, could be considered both
‘hard to treat’ and ‘carefully selected’ for surgical intervention.
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l Our analysis of clinical effectiveness showed a reduced symptom burden and improved disease-
specific QoL. The magnitude of the effect of surgery (estimated reduction of 1.09 points in PAC-QoL
at 24 weeks) was greater than the minimum clinically important difference sought by design (mean
change 1.0 points) and this change was statistically significant. In addition, significant and clinically
important improvements in PAC-SYM score and bowel frequency provided further evidence of the
benefit of surgery.
l The findings of the primary outcome showed a continued improvement for the duration of the
study period (estimated 1.38-point reduction in PAC-QoL at 72 weeks), and this finding was
supported by a panel of secondary outcome measures, accepting inferential limitations posed by
potential attrition bias.
l Serious under-recruitment limited the scope to conduct economic analysis. To explore the potential
cost-effectiveness of lapVMR some assumptions were necessary: (1) the effect of surgery was not
affected by allocation (and thus delay to surgery); (2) growth curve analysis is a reliable method to
characterise pre-surgery and post-surgery costs and QoL; (3) pre-surgery non-surgery costs and
EQ-5D-5L scores are stable, making it possible to construct a single pre-surgery follow-up covering
the 48 weeks before surgery; and (4) benefits following surgery are limited to the first 48 weeks
following surgery. The weakest of these assumptions might be limiting benefit from surgery to
48 weeks; any future QALY gain and reduced burden from decreased use of the health-care system
for symptoms of CC would make surgery more cost-effective. Potential longer-term complications of
mesh insertion and removal were not considered, but if emergent would reduce cost-effectiveness.
l The base case suggests that lapVMR is not cost-effective (p = 0.00 at a WTP threshold of £30,000
per QALY). However, because this finding comes from an observational analysis of a stepped-wedge
design, and for the reasons described, it remains vulnerable to bias that might increase or decrease
cost-effectiveness.
l Although some adverse effects were reported, lapVMR was safe and well tolerated overall.
l Some patients described how their bowel function was better immediately after surgery and had
continued success, and these patients noted a better QoL both mentally and physically; others
found the benefit to be short-lived or did not feel any change. Pain was a significant issue for some
patients. The mesh controversy dominated staff experience.
Reflections on work programme 4
The study was severely hampered by under-recruitment. Difficulties in attracting centres to recruit
pre-dated the zenith of the mesh scandal and reflected wide variation in practice across the UK in
terms of both patient selection and lapVMR operative technique. The mesh scandal undoubtedly
compounded the recruitment problems faced by the study and yet paradoxically emphasised the
need for such a study to take place. It was, for instance, very clear that the attention we paid to
strict inclusion and exclusion criteria [actually based on guidance from the Pelvic Floor Society
(London, UK)134] led to increased scrutiny in many centres where such surgery was being undertaken
without rigorous application of these criteria. This regrettably (for the trial but not the patients concerned)
led to a rapid revision (manifest as a drop-off) in the number of patients available at several centres
for recruitment. Unfortunately, with the evolution of the media storm against placement of pelvic mesh
and worldwide class actions against surgeons and manufacturers of mesh, the issue of patient selection
has now made its way to the courts. Therefore, although it might be argued that the study design was
overzealous in its approach to inclusion and exclusion, the decision of our expert panel to rigidly maintain
the selection and procedural standards laid out in the protocol was undoubtedly the right one.
With the media storm blowing up and the Cumberlege report142 in preparation, there was never a
time when the results of this trial were more needed, and we were very disappointed by our failure
to keep the trial going. This was not for want of trying. With the strong support of the Association of
Coloproctology of Great Britain and Ireland, the Pelvic Floor Society wrote on our behalf to NHS
England seeking its support for a mandate to surgeons in England and Wales to continue surgery only
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in the context of research indemnity. This request, if granted, would have helped push recruitment and
prevented some hospitals from abandoning the operation, thus denying patients access to lapVMR and
the scientific community an answer to the main trial questions.
However, despite these setbacks, the main aim of the trial, namely to determine the effect size of surgery
for the first time in a high-quality experimental design, and thus improve on the level IV evidence provided
by 18 case series (as outlined in our systematic review),140 was addressed, albeit at a lower than desirable
level of statistical power. Being to our knowledge the only high-quality evidence in the field, our results
show substantial symptomatic benefit (more than we sought by design) to a cohort of highly selected
patients from lapVMR performed to a standardised technique.
Cost-effectiveness analysis was disappointing and, as with all expensive (surgical) interventions, we did
not show a cost benefit in the short term (to 48 weeks). Enthusiasts will say that the benefit of mesh
placement is economically apparent only in the long term. It is also difficult to demonstrate cost-
effectiveness in our multiply comorbid patients whose overall sense of well-being (as measured by the
EQ-5D-5L) is only partially affected by improvement in bowel-associated symptoms.
Research recommendations
The current COVID-19 pandemic has created a natural hiatus in the provision of nearly all non-urgent
benign surgery. This has coincided with the publication of the Cumberlege report142 and together these
provide a ‘pause for thought’ on the future use of lapVMR in patients with CC. Despite the underpowering of
our study, it is unlikely that such a trial will be repeated (at least in the UK). Rather, it is likely that enthusiasts
will cite the effect size in our study as mirroring that in observational trials, balancing this against the very
real risk of harm (notably the small proportion of patients with long-termmesh complications). The reduction
in anxiety surrounding the use of mesh as time passes and the production of updated consensus guidance
on patient selection and operative technique may make further study in this area feasible.
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Work programme 5: synthesis of trial
data and conclusions
A stated aim of the programme was to develop an NHS pathway for the management of CC inadults based on data synthesis. Specifically, we stated that ‘findings will be assimilated and
synthesised with previous research, and a national working group convened to develop a new
treatment pathway for management of CC in adults’. To this end each participant had a unique ID so
that they could be followed through each of the trials. Considerable under-recruitment, reflecting the
difficulties of recruiting the patient population, severely limited the scope for an integrated analysis or
pathway. However, with all the caveats noted, evidence from the CapaCiTY trials supports the value
of standard-care habit training and high-volume TAI and questions the value of habit-training with
biofeedback, INVEST procedures and low-volume TAI. The findings as they pertain to lapVMR are
mixed and lend some support to this procedure in a highly defined population with informed consent.
With these conclusions in mind, Figure 8 provides a revision of the pathway schematic presented in
SYNOPSIS. Here, patients receive a standardised intervention with habit training, and only if this fails
do they progress to INVEST. Thence, selected patients with the specific diagnosis of dyssynergic
defaecation can undergo direct visual biofeedback, and others can undergo TAI, this being initiated by
default with a high-volume device. Patients progressing to a MDT meeting for consideration of surgery
may be offered lapVMR if they meet the strict selection criteria, but the consent process must include
realistic data on the immediate and longer-term benefits (or otherwise) of this procedure, noting that
enhanced consent procedures with standardised proformas and patient information leaflets (provided
by the Pelvic Floor Society) are already best practice in relation to detailing long-term harms. Surgeons
could, for instance, cite a conservative interpretation of our data in relation to reduced bowel symptoms
but falling overall satisfaction with surgery over time, as well as little or no improvement in general QoL.
Reflections on the whole research programme and overall conclusions
How will the international community receive such a pathway? We feel that the answer to this in the
UK is with general positivity. Over the 6 years that the CapaCiTY research programme has run, from
initial meetings at national society conferences to the present, we have witnessed hugely positive
engagement from experts in the field through to more general audiences. Our ability to bring together
the specialist community, both specialists whose centres recruited and specialists whose centres were
unable, has proved a major triumph of the programme. Although this is not measurable in adequately
powered clinical-effectiveness data, it can be inferred by how many units have standardised their
approach to diagnostics and therapy by education through the programme. Furthermore, conclusions
from our systematic reviews have already entered major textbooks and have received national and
international platforms for presentation. Dissemination activity is ongoing, and there is no doubt that
we will be invited for national and international presentation of the conclusions of the three CapaCiTY
trials. These ‘softer’ end points will be the main enduring legacy of the CapaCiTY research programme
and the lives of people living with CC will be the better for it.
Lessons learned for future research
The considerable challenges to recruitment for all three trials have been noted. Table 5 outlines some
insights about how these problems might be mitigated in the future.
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Response
Obvious clinical evidence of overt
pelvic organ prolapsec
Anorectal function testing (e.g.  balloon
expulsion test, defecography, rectal sensory
testing and anorectal manometry)
Review lifestyle modif ication (f ibre, f luid, exercise)
Rational laxative use (PEG, stimulant laxative)b
Prokinetics if naive (1–2 mg of prucalopride daily or 290 µg of linaclotide or other secretagogues)
Chronic constipation refractory to
lifestyle modif ication and basic
pharmacological treatmenta
No response
Response No responseInitiated high-volume TAIe
Other surgical targets
and procedures
Posterior compartment prolapse syndrome
with high-grade intussusception with or
without rectocoele
MDT meeting to discuss
surgical options
Re-evaluation of symptom
investigation correlation to focus
on further pharmacology or
other untried interventions
Consider lapVMRf or alternative







with or without defaecographyd
with or without adjunctive tests
(e.g. urodynamics)Dysynergic defaecation Other evacuation disorder
Habit training
Direct visual biofeedback
FIGURE 8 Revised prototype pathways of care informed by results of the CapaCiTY research programme. a, Alarm features excluded and secondary causes treated appropriately; b, in IBS-C,
consider antispasmodics or neuromodulators in case constipation improves but abdominal pain persists and is dominant symptom; c, examples of overt prolapse include anterior (stage 3 cystocele),
middle (stage 3 rectocele, uterovaginal prolapse) and posterior compartments (grade IV/V intussusception); d, if not performed previously; e, unless patient preference is for low-volume TAI or
there are specific contraindications to high-volume TAI; f, may reduce specific symptoms but not have overall effect on QoL; g, common adjuncts include sacrocolpopexy, hysterectomy, transvaginal






































































Limit to one or two major RCTs in a
programme recommended
Alternative design
Although the teammade considerable efforts
to support each trial and we had sequential
start dates, the dilution of focus and effort was
probably a factor, especially with trying to
‘market’more than one trial per recruitment
centre. Disruption to the original planned
sequence occurred because of set-up delays.
The three-group design of study 1 was
certainly overambitious, with INVEST leading
to delays in recruitment to any group.With
hindsight, an alternative design that
incorporates experimental evaluations in a
longitudinal cohort of patients would have
been more appropriate, such as a TwiCs
design.TwiCs designs have become
increasingly popular during the period of the
research programme, including pragmatic
evaluations of complex interventions such as
surgery. ATwiCs design would have provided
a much greater cohort of patients with
longitudinal observations of symptoms, QoL
data and data on the effect of ongoing routine
clinical care; this would have proved a valuable
source of new learning in its own right
‘Fat file’ as a deterrent
to patients and local
investigators
Reduce outcome frequency and number.
Adhere to ‘one trial, one question’
One problem of clinical programmes is trying
to appease everyone’s interests, thus trying to
rigorously cover aspects of qualitative and
quantitative outcomes relevant to specialist
clinical, QoL, health economic and psychological
outcomes. This enthusiasm must be tempered




Increase pragmatism. Avoid or reduce
standardisation of complex interventions
We tried (rightly) to answer the ‘important
questions’, but the complexity of these led to
the need for standardisation. This constrained
clinicians to a point where many did not buy
in to the agreed protocol. A better balance of
standardisation vs. clinician-decisive care




attribution of costs and
NHS resources
Choose NHS interventions that reduce cost
and complexity. Think ‘what research
question can we answer’ before ‘what do
we want to answer’
Wewould advise future investigators to think
very carefully about embarking on a RCT that
requires complex interventions over and above
routine care.The staffing to deliver complex
research interventions in the NHS (even pre
COVID-19) is fragile andmost of our
recruitment came care of directly funded
research staff. ETCsmake this even less tenable.
In our experience, CRNs proved unable to
resolve issues when individual trusts viewed
research as a low priority compared with clinical
delivery. Surgery added the additional problem
of waiting-time inflexibility
continued
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Patient and public involvement
Patient representation in the CapaCiTY research programme supported all research activities. The
focus of the CapaCiTY research programme from a PPI perspective was to convene a Constipation
Research Advisory Group (CRAG) comprising eight patients and two carers from London, UK, and
Durham, UK. This group had geographical diversity (covering both north and south England) and a
disease-appropriate demographic (eight female and two male participants). PPI was managed by
two co-applicants and the CRAG had an active ‘contributory’ rather than ‘representative’ role.
The overarching functions of the CRAG included:
l managing the research (e.g. steering/advisory group)
l developing participant information resources
l advising on protocol revisions (in particular on recruitment and participant burden)
l disseminating of research findings.
Although CRAG members had patient knowledge of living with severe CC, they did not have the same
knowledge of clinical trial and medical research terminology as the research team. Because CRAG
members were invited (in rotation) to sit on the Programme Steering Committee (PSC), this put them
at a disadvantage. Therefore, training was provided to CRAG members at the start of the project in
2015 that included taking part in an activity in identifying barriers to recruitment in clinical trials and
potential solutions. This enabled the CRAG members to review all patient-facing documents including
the patient information sheet, patient diaries and patient journals at the beginning of the programme for
all three trials. It also enabled them to feel more comfortable when they attended a PSC meeting.
The CRAG was actively involved and effective in providing lay advice and guidance in areas of trial
feasibility, design, management, marketing, analysis, recruitment and reporting. Furthermore, CRAG
members reviewed all patient-facing material during the substantial amendment in 2016. The CRAG
was also consulted about reducing the length of follow-up from 24 to 12 months.
The CRAG reported and made recommendations to the PSC. It was agreed that normally CRAG
meetings would be held every 6 months prior to the PSC (ideally 1 month before). The CRAG would
feed recommendations back to the PSC. Therefore, the CRAG had a significant role in strategic
decision-making. For example, in 2017 the CRAG was provided with a detailed presentation as per
the PSC’s recommendation. The PSC asked that the CRAG answer whether or not the CRAG deemed
CapaCiTY trial 2 futile owing to under-recruitment. Although it was noted that the inclination of the
PSC was to continue, they were keen to consult with the CRAG. The group discussed at length the key
areas under consideration, which included the following: was it safe for the patients participating in the
trial? Was it cost-effective to continue? Would the research questions be answered?
TABLE 5 Lessons learned for future research (continued )
Problem Mitigation Notes
Set-up time in multiple
centres
Perform pre-trial recruitment feasibility
studies rather than relying on site surveys
We grossly underestimated delays in R&D
approval processes, with some experienced
sites (with a willing principal investigator)
taking up to 1 year to open from receiving
all study documentation, and this despite
intervention by the host CRN on our behalf.
Several never opened
Failure of early learning
from qualitative data
Perform some interviews (e.g. of staff)
early in programme
We did not include a process evaluation in
our programme but could have used some
of the eventual qualitative analysis from
staff and patients to troubleshoot some of
the recruitment issues that we encountered
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Though the group accepted that, ideally, more patients should be recruited to improve the accuracy
and validity of the data results, it was generally agreed that 100 patients was an acceptable milestone.
The CRAG also discussed financial matters. However, the main focus of the in-depth discussion was
whether or not the research questions would be answered. Owing to the smaller sample size it was
recognised that the primary research question could be compromised. However, the CRAG recognised
the importance of being able to answer many other questions in relation to high-volume and low-
volume TAI treatments. The CRAG discussed the value and importance of the secondary data that had
been captured to date and data that would continue to be collected if the trial was to continue. It was
evident that from a patient perspective these data were of significance. It was noted that the CRAG
wished to avoid any negative messaging and in particular did not wish to put off future patients from
entering a trial because of the possibility of cancellation.
This consultative approach between the PSC and CRAG, seeking to direct and support the three trials,
ensured that both researchers and patients had a mutual understanding of what was required. This
ensured that the findings of the three trials would be of benefit to participants in those clinical trials.
In addition, three members of the CRAG held a teleconference with Christine Norton and Shiva Taheri
to contribute to the interpretation of the interview data and to agree and support the main messages
for dissemination.
Overall, patient representation made a major contribution to design, conduct and recruitment of the
CapaCiTY research programme. The CRAG was involved in all major decisions that were made during
the programme, which meant that patient benefit was always put first in everything we did. The CRAG
will continue to support the CapaCiTY research programme in dissemination activities, including at the
Bowel Research UK annual Big Bowel Event.
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Appendix 1 Reports of studies not yet
published
CapaCiTY trial 1: habit training compared with habit training with direct
visual biofeedback in adults with chronic constipation – randomised
controlled trial
Intervention
Habit training was provided by a trained specialist (nurse or physiotherapist with clinical experience)
who had undertaken a standard 1-day (study-specific) training session. A standardised approach and
intervention were provided using an intervention manual (see Appendix 2, CapaCiTY trial 1: intervention
protocols), and at least one random observation visit was performed early in the study by lead
researchers for quality control.
The course of therapy included three or four sessions (with interval tolerance of every 3–5 weeks). The
first and last sessions were always face to face. Sessions were delivered by the same therapist if at all
possible and tailored to a participant’s individual needs.
Habit training with biofeedback included the steps of habit training plus direct visual biofeedback using
a portable HRAM manometry catheter connected to a computer monitor. Calibration, validation and
maintenance of the equipment were built in to the programme and training manuals were provided.
Training on the standardised system and protocol was performed and documented in the investigator
site file prior to sites commencing treatment. The outcomes of each session, including the ability to
expel the balloon, generate propulsion, increase rectal pressure, relax the anal canal and sense the
balloon at lower or higher volumes (relevant to hyposensate and hypersensate patients) over
successive sessions were recorded on an intervention CRF.
Trial design features
Basic design
A parallel, three-group, randomised trial design permitted two randomised comparisons: an overall
evaluation of the performance of a panel of INVEST in improving the selection of treatment and an
evaluation of treatment options (HT vs. HTBF) without INVEST. Thus, the overall evaluation addressed
whether or not INVEST-guided care led to more favourable outcomes than randomised allocation.
Sample size calculation
Sample size was calculated using the primary clinical outcome, change in PAC-QoL score. A 10% scale
difference or 0.4-point reduction in PAC-QoL score with a variance estimate conservatively set at
SD = 1 was considered clinically relevant. To detect a mean change of 0.4 points in PAC-QoL score
(SD = 1) with 90% power and 5% significance level, 132 participants per group or 264 participants in
total was required for the comparison of HT and HTBF (no-INVEST group).
For the secondary comparison of INVEST and no INVEST, a reduction of 0.4 points (SD = 1) was also
considered clinically meaningful. To detect an effect size of 0.4 points with 90% power and 5%
significance level required 90 participants in the INVEST group, assuming 264 participants were
recruited to the no-INVEST group.
Allowing for 10% loss to follow-up, a sample size of 147 participants was needed in both the HT and
HTBF groups and 100 participants in the INVEST group. A total sample size of 394 participants across
the three groups was required.
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Randomisation procedure
Randomisation (with an allocation ratio of 3 : 3 : 2 to HT, HTBF and INVEST, respectively) occurred at
one point in time following recruitment (after eligibility and baseline assessments). Randomisation was
stratified by sex (and female participants by centre) with (block size 8) randomisation implemented via
an online randomisation system developed by the PCTU. Randomisation was conducted by suitably
trained and delegated researchers at recruiting sites and followed PCTU-validated standard operating
procedures for the study.
Blinding
Patients and clinicians were necessarily aware of both INVEST and treatment allocations. To minimise
bias, where possible, a blinded researcher collected outcome data. If a blinded researcher was not
available, the participant completed the questionnaires and placed them in a sealed envelope.
Participants were trained in completing questionnaires prior to randomisation and received a visual aid
with standardised script and training for completing questionnaires. Quantitative (but not qualitative)
outcome assessments were analysed by investigators and statisticians who were blind to allocation
status and index intervention.
Concomitant medications
It was inevitable that participants would seek recourse to laxatives and other dietary supplements
during the course of the programme. Experience shows that complete prohibition can lead to
unreported laxative use, which might confound findings. Although we strongly discouraged ad libitum
medication and specified a defined breakthrough regimen, we also recorded (by diary) cotreatment
with sufficient fidelity and integrity to enable use as covariates in analyses.
Statistical methods
The primary outcome was analysed on an ITT basis at the 6-month time point. Descriptive statistics
(i.e. mean, SD, median and IQR) are presented by trial group. The average reduction in PAC-QoL score was
analysed using a linear mixed regression model. The two stratification variables (sex and study site) were
included in the model, with site as a random effect and sex as a fixed-effect covariate. Other fixed-effect
covariates included in the model were intervention, baseline PAC-QoL score and breakthrough medication
(i.e. use of oral and/or rectal laxatives).
Secondary outcomes were also analysed on an ITT basis and presented as descriptive statistics by trial
group: continuous variables (e.g. PAC-QoL score) were summarised by treatment group (using mean,
SD, median and IQR). For categorical variables, numbers and percentages of patients reporting each
response option were presented by trial group. Given the much smaller than target number of patients
recruited to the trial, it was agreed that adjusted analysis would be performed on secondary outcomes 1
to 3 (i.e. PAC-QoL score) only, with unadjusted treatment differences and 95% CIs for other secondary
outcomes. Results obtained using the CC-BRQ and BIPQ-CC have been omitted pending further analysis.
For cost-effectiveness, patients were randomised in parallel trial groups to (1) HT, (2) HTBF or
(3) INVEST-recommended treatment using (1) or (2). The three-way cost-effectiveness comparison
required the presentation of the cost-effectiveness acceptability frontier (CEAF) in addition to CEACs
for each trial group, as the CEAF correctly identifies the optimal decision across the range of WTP
thresholds when more than two options are being considered.143 For this trial, the baseline (0 months)
was set after completion of treatment, at the beginning of 12 months of follow-up. Treatment began an
average of 3 months before this baseline. Consequently, the duration of follow-up is 15 months, and
discounting of costs and QALYs (r = 0.035) has been applied to the last 3 months.
Recruitment
Recruitment started on 26March 2015 (first intervention 21May 2015) and ended 30 June 2018. A total of
182 patients (target 394 patients) were randomised out of 502 patients screened (36.3%) from 10 sites. Reasons
for screen failure are shown in Figure 9. Two sites opened but failed to recruit; the remainder randomised
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between 7 and 71 patients. A total of 182 patients were randomised: 68 to HT, 68 to HTBF and 46 to INVEST-
guided therapy (HT or HTBF based on results). A total of 79 participants dropped out of the study before the
primary end point, leaving 103 participants at 6 months.The CONSORT flow diagram is shown in Figure 2.
Baseline characteristics
Table 6 shows the numbers and percentages of patients with baseline characteristics presented by trial
group. Continuous variables (e.g. age) were summarised by treatment group using mean and SD (and
median and IQR if non-normally distributed). Table 7 shows the data for outcome measures at baseline.
These were comparable between three trial groups for all major characteristics.
Age (years)
Not constipated
Symptom duration < 6 months
Diet, lifestyle and laxative/prokinetics naive
Previous specialist nurse-led bowel
management
English language barrier
Not willing to consent
Significant organic colonic disease
Major colorectal resectional surgery
Overt pelvic organ prolapse or
surgery required









FIGURE 9 The CapaCiTY trial 1 screen failures. SNS, sacral nerve stimulation.












Referral method, n (%)
Primary care 18 (26.5) 8 (11.8) 26 (19.1) 11 (23.9) 37 (20.3)
Secondary care 24 (35.3) 32 (47.1) 56 (41.2) 16 (34.8) 72 (39.6)
Tertiary care 14 (20.6) 15 (22.1) 29 (21.3) 10 (21.7) 39 (21.4)
Other 11 (16.2) 12 (17.6) 23 (16.9) 8 (17.4) 31 (17.0)
Missing 1 (1.5) 1 (1.5) 2 (1.5) 1 (2.2) 3 (1.6)
Demographic characteristic
Sex, n (%)
Male 8 (11.8) 8 (11.8) 16 (11.8) 6 (13.0) 22 (12.1)
Female 60 (88.2) 59 (86.8) 119 (87.5) 39 (84.8) 158 (86.8)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Ethnicity, n (%)
Asian 11 (16.2) 10 (14.7) 21 (15.4) 5 (10.9) 26 (14.3)
Black 7 (10.3) 8 (11.8) 15 (11.0) 5 (10.9) 20 (11.0)
Mixed 1 (1.5) 0 (0.0) 1 (0.7) 2 (4.3) 3 (1.6)
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White 48 (70.6) 49 (72.1) 97 (71.3) 33 (71.7) 130 (71.4)
Other 1 (1.5) 0 (0.0) 1 (0.7) 0 (0.0) 1 (0.5)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Age (years)











Missing, n (%) 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Past medical history, n (%)
Total 50 (73.5) 52 (76.5) 102 (75.0) 35 (76.1) 137 (75.3)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Cardiovascular condition 13 (19.1) 10 (14.7) 23 (16.9) 7 (15.2) 30 (16.5)
Heart disease 1 (1.5) 2 (2.9) 3 (2.2) 0 (0.0) 3 (1.6)
Hypertension 9 (13.2) 6 (8.8) 15 (11.0) 4 (8.7) 19 (10.4)
Hypercholesterolaemia 8 (11.8) 7 (10.3) 15 (11.0) 4 (8.7) 19 (10.4)
Other 3 (4.4) 1 (1.5) 4 (2.9) 2 (4.3) 6 (3.3)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Respiratory condition 15 (22.1) 12 (17.6) 27 (19.9) 9 (19.6) 36 (19.8)
Asthma 13 (19.1) 11 (16.2) 24 (17.6) 9 (19.6) 33 (18.1)
COPD 5 (7.4) 2 (2.9) 7 (5.1) 0 (0.0) 7 (3.8)
Other 2 (2.9) 0 (0.0) 2 (1.5) 0 (0.0) 2 (1.1)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Gastrointestinal condition 23 (33.8) 19 (27.9) 42 (30.9) 20 (43.5) 62 (34.1)
IBS 11 (16.2) 14 (20.6) 25 (18.4) 16 (34.8) 41 (22.5)
Crohn’s disease 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ulcerative colitis 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Cancer 1 (1.5) 0 (0.0) 1 (0.7) 1 (2.2) 2 (1.1)
Colonic polyps 7 (10.3) 2 (2.9) 9 (6.6) 4 (8.7) 13 (7.1)
Other 8 (11.8) 5 (7.4) 13 (9.6) 5 (10.9) 18 (9.9)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Metabolic condition 9 (13.2) 8 (11.8) 17 (12.5) 7 (15.2) 24 (13.2)
Diabetes 5 (7.4) 1 (1.5) 6 (4.4) 1 (2.2) 7 (3.8)
Hypothyroidism 2 (2.9) 6 (8.8) 8 (5.9) 4 (8.7) 12 (6.6)
Hyperthyroidism 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Other 2 (2.9) 0 (0.0) 2 (1.5) 1 (2.2) 3 (1.6)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Haematological condition 3 (4.4) 4 (5.9) 7 (5.1) 3 (6.5) 10 (5.5)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Hepatic condition 1 (1.5) 1 (1.5) 2 (1.5) 0 (0.0) 2 (1.1)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
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Renal disease 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.2) 1 (0.5)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Genito-urinary condition 10 (14.7) 12 (17.6) 22 (16.2) 4 (8.7) 26 (14.3)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Neurological/CNS condition 14 (20.6) 14 (20.6) 28 (20.6) 6 (13.0) 34 (18.7)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Psychiatric condition 15 (22.1) 10 (14.7) 25 (18.4) 12 (26.1) 37 (20.3)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Dermatological condition 12 (17.6) 11 (16.2) 23 (16.9) 5 (10.9) 28 (15.4)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Musculoskeletal condition 6 (8.8) 12 (17.6) 18 (13.2) 5 (10.9) 23 (12.6)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Other condition 11 (16.2) 16 (23.5) 27 (19.9) 9 (19.6) 36 (19.8)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Past surgical history, n (%)
Total 36 (52.9) 35 (51.5) 71 (52.2) 22 (47.8) 93 (51.1)
Abdominal operation 13 (19.1) 11 (16.2) 24 (17.6) 7 (15.2) 31 (17.0)
Gynaecological procedure 23 (33.8) 24 (35.3) 47 (34.6) 17 (37.0) 64 (35.2)
Proctological or perineal procedure 10 (14.7) 8 (11.8) 18 (13.2) 6 (13.0) 24 (13.2)
Neuromodulation 1 (1.5) 1 (1.5) 2 (1.5) 0 (0.0) 2 (1.1)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Duration (months) of constipation symptoms
Mean (SD) 72.1 (51.9) 76.8 (56.3) 74.5 (54.0) 75.7 (55.2) 74.8 (54.1)
Missing, n (%) 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Previous lifestyle modifications, n (%)
Total 67 (98.5) 67 (98.5) 134 (98.5) 45 (97.8) 179 (98.4)
Diet 67 (98.5) 65 (95.6) 132 (97.1) 44 (95.7) 176 (96.7)
Fluid 62 (91.2) 64 (94.1) 126 (92.6) 41 (89.1) 167 (91.8)
Exercise 54 (79.4) 58 (85.3) 112 (82.4) 39 (84.8) 151 (83.0)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Alternative therapies, n (%)
Total 7 (10.3) 1 (1.5) 8 (5.9) 1 (2.2) 9 (4.9)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Laxatives, n (%)
Total 67 (98.5) 65 (95.6) 132 (97.1) 45 (97.8) 177 (97.3)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Antidiarrhoeals, n (%)
Total 3 (4.4) 4 (5.9) 7 (5.1) 2 (4.3) 9 (4.9)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
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Total 9 (13.2) 15 (22.1) 24 (17.6) 7 (15.2) 31 (17.0)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Nurse-led bowel management, n (%)
Total 12 (17.6) 11 (16.2) 23 (16.9) 12 (26.1) 35 (19.2)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Family history of bowel disease, n (%)
IBS 15 (22.1) 11 (16.2) 26 (19.1) 10 (21.7) 36 (19.8)
IBD 1 (1.5) 3 (4.4) 4 (2.9) 5 (10.9) 9 (4.9)
Gastrointestinal cancer 3 (4.4) 7 (10.3) 10 (7.4) 4 (8.7) 14 (7.7)
Other 2 (2.9) 5 (7.4) 7 (5.1) 2 (4.3) 9 (4.9)
Missing 1 (1.5) 2 (2.9) 3 (2.2) 2 (4.3) 5 (2.7)
Sexual history (female participants only), n (%)
Sexually active 43 (71.7) 40 (67.8) 83 (69.7) 29 (74.4) 112 (70.9)
Child-bearing potential 38 (63.3) 32 (54.2) 70 (58.8) 25 (64.1) 95 (60.1)
> 1 year post menopausal 21 (35.0) 24 (40.7) 45 (37.8) 9 (23.1) 54 (34.2)
Surgically sterile 13 (21.7) 13 (22.0) 26 (21.8) 8 (20.5) 34 (21.5)
Contraceptive use (female participants only), n (%)
Total 25 (41.7) 19 (32.2) 44 (37.0) 18 (46.2) 62 (39.2)
Barrier 10 (16.7) 8 (13.6) 18 (15.1) 6 (15.4) 24 (15.2)
Non-barrier 15 (25.0) 12 (20.3) 27 (22.7) 12 (30.8) 39 (24.7)
Missing 2 (3.3) 4 (6.8) 6 (5.0) 5 (12.8) 11 (7.0)
Past obstetric history (female participants only)
Total, n (%) 38 (63.3) 37 (62.7) 75 (63.0) 27 (69.2) 102 (64.6)
Number of vaginal deliveries,
mean (SD)
1.9 (1.4) 1.8 (1.3) 1.8 (1.4) 1.7 (1.3) 1.8 (1.4)
Number of caesareans, mean (SD) 0.2 (0.5) 0.4 (0.6) 0.3 (0.6) 0.4 (0.8) 0.3 (0.6)
Number of forceps/ventouse
deliveries, mean (SD)
0.1 (0.3) 0.2 (0.4) 0.2 (0.4) 0.1 (0.6) 0.1 (0.4)
Number of episiotomies, mean (SD) 0.5 (0.8) 0.4 (0.8) 0.4 (0.8) 0.6 (0.7) 0.5 (0.8)
Number of obstetric tears, mean (SD) 0.6 (0.8) 0.5 (0.7) 0.5 (0.8) 0.8 (0.9) 0.6 (0.8)
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Faecal incontinence symptoms, n (%)
Total 38 (55.9) 33 (48.5) 71 (52.2) 29 (63.0) 100 (54.9)
Faecal urgency 30 (44.1) 20 (29.4) 50 (36.8) 19 (41.3) 69 (37.9)
Urge faecal incontinence 14 (20.6) 9 (13.2) 23 (16.9) 11 (23.9) 34 (18.7)
Passive faecal incontinence 9 (13.2) 10 (14.7) 19 (14.0) 10 (21.7) 29 (15.9)
Postdefaecation leakage 10 (14.7) 10 (14.7) 20 (14.7) 15 (32.6) 35 (19.2)
Difficulty wiping clean 24 (35.3) 16 (23.5) 40 (29.4) 24 (52.2) 64 (35.2)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
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Pelvic organ prolapse symptoms, n (%)
Total 13 (19.1) 14 (20.6) 27 (19.9) 14 (30.4) 41 (22.5)
Vaginal bulging 11 (16.2) 14 (20.6) 25 (18.4) 13 (28.3) 38 (20.9)
External rectal prolapse 1 (1.5) 0 (0.0) 1 (0.7) 0 (0.0) 1 (0.5)
External uterine prolapse 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 2 (4.3) 3 (1.6)
Urinary symptoms, n (%)
Total 26 (38.2) 17 (25.0) 43 (31.6) 16 (34.8) 59 (32.4)
Urinary incontinence 19 (27.9) 7 (10.3) 26 (19.1) 14 (30.4) 40 (22.0)
Urinary urgency 16 (23.5) 13 (19.1) 29 (21.3) 13 (28.3) 42 (23.1)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 1 (2.2) 2 (1.1)
Joint hypermobility,b n (%)
Total 17 (25.0) 15 (22.1) 32 (23.5) 12 (26.1) 44 (24.2)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
CNS, central nervous system; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome.
a The HT and HTBF groups together form the no-INVEST group.
b Hypermobility was indicated by a response of ‘yes’ to two or more out of five questions used to assess joint hypermobility.













Overall, mean (SD) 2.3 (0.7) 2.4 (0.9) 2.4 (0.8) 2.5 (0.8) 2.4 (0.8)
Missing, n (%) 0 (0.0) 2 (2.9) 2 (1.5) 2 (4.3) 4 (2.2)
Dissatisfaction, mean (SD) 3.1 (0.6) 3.2 (0.8) 3.1 (0.7) 3.3 (0.7) 3.2 (0.7)
Missing, n (%) 0 (0.0) 2 (2.9) 2 (1.5) 2 (4.3) 4 (2.2)
Physical discomfort, mean (SD) 2.5 (0.8) 2.4 (1.0) 2.4 (0.9) 2.6 (0.8) 2.5 (0.9)
Missing, n (%) 0 (0.0) 2 (2.9) 2 (1.5) 2 (4.3) 4 (2.2)
Psychosocial discomfort, mean (SD) 1.8 (1.0) 1.8 (1.0) 1.8 (1.0) 2.0 (1.0) 1.8 (1.0)
Missing, n (%) 0 (0.0) 2 (2.9) 2 (1.5) 2 (4.3) 4 (2.2)
Worries and concerns, mean (SD) 2.3 (1.0) 2.4 (1.0) 2.4 (1.0) 2.6 (0.9) 2.4 (1.0)
Missing, n (%) 0 (0.0) 2 (2.9) 2 (1.5) 2 (4.3) 4 (2.2)
PAC-SYM score (points)
Overall, mean (SD) 2.1 (0.8) 2.0 (0.8) 2.1 (0.8) 2.2 (0.8) 2.1 (0.8)
Missing, n (%) 0 (0.0) 1 (1.5) 1 (0.7) 2 (4.3) 3 (1.6)
Stool symptoms, mean (SD) 2.5 (1.0) 2.4 (0.9) 2.4 (0.9) 2.6 (0.9) 2.5 (0.9)
Missing, n (%) 0 (0.0) 1 (1.5) 1 (0.7) 2 (4.3) 3 (1.6)
Abdominal symptoms, mean (SD) 2.2 (1.0) 2.0 (1.0) 2.1 (1.0) 2.2 (1.1) 2.1 (1.0)
Missing, n (%) 0 (0.0) 1 (1.5) 1 (0.7) 2 (4.3) 3 (1.6)
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Rectal symptoms, mean (SD) 1.4 (1.1) 1.5 (1.1) 1.5 (1.1) 1.7 (1.2) 1.5 (1.1)
Missing, n (%) 0 (0.0) 1 (1.5) 1 (0.7) 2 (4.3) 3 (1.6)
Bowel frequency, number reported over 14 days (diary data)
Attempts to empty bowels, mean (SD) 26.1 (19.8) 24.9 (16.4) 25.5 (18.1) 26.3 (15.1) 25.7 (17.4)
Missing, n (%) 11 (16.2) 14 (20.6) 25 (18.4) 12 (26.1) 37 (20.3)
Times stool was actually passed,
mean (SD)
14.8 (10.2) 14.7 (9.9) 14.8 (10.0) 14.3 (8.5) 14.7 (9.7)
Missing, n (%) 11 (16.2) 14 (20.6) 25 (18.4) 11 (23.9) 36 (19.8)
Nature of bowel movement, number of days out of 14 (diary data)
Laxatives used, mean (SD) 4.4 (5.4) 3.3 (5.0) 3.9 (5.2) 5.9 (6.1) 4.3 (5.5)
Missing, n (%) 12 (17.6) 14 (20.6) 26 (19.1) 12 (26.1) 38 (20.9)
Glycerine suppositories used,
mean (SD)
0.8 (2.6) 0.7 (1.7) 0.7 (2.2) 1.1 (2.8) 0.8 (2.4)
Missing, n (%) 12 (17.6) 14 (20.6) 26 (19.1) 13 (28.3) 39 (21.4)
EQ-5D-5L: problems indicated, n (%)
Mobility 16 (23.5) 21 (31.3) 37 (27.4) 11 (25.0) 48 (26.8)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 2 (4.3) 3 (1.6)
Self-care 8 (11.8) 5 (7.5) 13 (9.6) 6 (13.6) 19 (10.6)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 2 (4.3) 3 (1.6)
Usual activities 20 (29.4) 24 (36.4) 44 (32.8) 23 (52.3) 67 (37.6)
Missing 0 (0.0) 2 (2.9) 2 (1.5) 2 (4.3) 4 (2.2)
Pain/discomfort 56 (82.4) 55 (82.1) 111 (82.2) 39 (88.6) 150 (83.8)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 2 (4.3) 3 (1.6)
Anxiety/depression 42 (61.8) 33 (49.3) 75 (55.6) 28 (63.6) 103 (57.5)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 2 (4.3) 3 (1.6)
EQ-VAS score (points)
Total, mean (SD) 67.1 (20.8) 66.6 (18.6) 66.8 (19.7) 61.9 (18.2) 65.6 (19.4)
Missing, n (%) 0 (0.0) 1 (1.5) 1 (0.7) 2 (4.3) 3 (1.6)
PHQ-9 depression severity, n (%)
None 25 (36.8) 26 (38.8) 51 (37.8) 10 (22.7) 61 (34.1)
Mild 22 (32.4) 20 (29.9) 42 (31.1) 17 (38.6) 59 (33.0)
Moderate 11 (16.2) 11 (16.4) 22 (16.3) 11 (25.0) 33 (18.4)
Moderately severe 4 (5.9) 7 (10.4) 11 (8.1) 3 (6.8) 14 (7.8)
Severe 6 (8.8) 3 (4.5) 9 (6.7) 3 (6.8) 12 (6.7)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 2 (4.3) 3 (1.6)
GAD-7 anxiety severity, n (%)
None 29 (42.6) 28 (41.8) 57 (42.2) 17 (38.6) 74 (41.3)
Mild 21 (30.9) 16 (23.9) 37 (27.4) 8 (18.2) 45 (25.1)
Moderate 7 (10.3) 13 (19.4) 20 (14.8) 10 (22.7) 30 (16.8)
Severe 11 (16.2) 10 (14.9) 21 (15.6) 9 (20.5) 30 (16.8)
Missing 0 (0.0) 1 (1.5) 1 (0.7) 2 (4.3) 3 (1.6)
a The HT and HTBF groups together form the no-INVEST group.
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Table 8 shows the results for the primary outcome.
Secondary outcomes
Table 9 shows changes in PAC-QoL score analysed as binary variables (adjusted analyses) and Table 10
shows data for individual PAC-QoL domains. All other secondary outcomes are shown in Tables 11 and 12.
Figure 10 provides a summary of the similar decrease in PAC-QoL score in all intervention groups.
Supplementary analyses for secondary outcomes included:
1. Binary responses (i.e. responder vs. non-responder) to treatment defined as a ≥ 0.4-point reduction in
PAC-QoL score (at 3, 6 and 12 months post end of treatment). A logistic regression model was fitted
using the ‘xtmelogit’ (with logit link) command in Stata. Two stratification variables (sex and study site)
are included in the model; sex was included as a fixed-effect covariate in the regression model and
site as a random effect. Other covariates in the model were fixed effects for intervention, baseline
PAC-QoL score and breakthrough medication (i.e. use of oral and/or rectal laxatives).
2. Binary responses to treatment defined as a ≥ 1.0-point reduction in PAC-QoL score (at 3, 6 and 12 months
post end of treatment). A logistic regression model was fitted in Stata using the ‘xtmelogit’ (with logit
link) command.Two stratification variables (sex and study site) were included in the model; sex was
included as a fixed-effect covariate in the regression model and site as random effect. Other covariates
included the model were fixed effects for intervention, baseline PAC-QoL score and breakthrough
medication (i.e. use of oral and/or rectal laxatives).
Subgroup analyses
Planned subgroup analyses showed no difference in response (e.g. reduction in PAC-QoL score) between
patients with or without depression (baseline PHQ-9 score ≥ 5 points), anxiety (baseline GAD-7 score
≥ 4.5 points) or joint hypermobility (baseline joint hypermobility syndrome score ≥ 2 points). However,
there was a significant interaction between depression and the INVEST treatment and anxiety and the
INVEST treatment.
Safety analyses
The study (not being of a medicinal product) did not record unrelated AEs. Serious adverse events
(SAEs) and related AEs were small in number, with only two (both unrelated) SAEs reported (Table 13).
TABLE 8 Mean PAC-QoL score by randomised group at 6 months and mean differences between HT and HTBF and
between no-INVEST and INVEST groups for those included in the final analysis model
Intervention
Mean score (points)
Treatment differencea (95% CI) p-valueBaseline (SD) 6 months (SD)
HT vs. HTBF
HT (n = 38) 2.26 (0.69) 1.49 (0.85) Reference
HTBF (n= 30) 2.41 (0.81) 1.65 (1.03) –0.03 (–0.33 to 0.27) 0.8445
No INVEST vs. INVEST
No INVEST (n = 68) 2.33 (0.74) 1.56 (0.93) Reference
INVEST (n = 22) 2.36 (0.78) 1.81 (1.03) 0.22 (–0.11 to 0.55) 0.1871
a Adjusted for sex, baseline PAC-QoL score and breakthrough medication (i.e. use of oral and/or rectal laxatives).
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Results: cost-effectiveness
Summary and completeness of data
Participants were allocated randomly to HT, HTBF or INVEST-guided treatment. The average duration of
training and support visits for HTBF was greater than for HT, as expected, with the INVEST group falling
between these two, reflecting the split allocation. Patients allocated to HTBF completed an average of 2.1
biofeedback training sessions; 43 (93%) patients allocated to INVEST completed the INVEST procedure.
The cost of intervention procedures was the predominant determinant of overall cost (Table 14) and the
only variable differing significantly between groups [one-way analysis of variance (ANOVA), p < 0.001].
Use of prescription drugs and community health-care was relatively low and similar between groups.
Hence, cost differences were driven by the intervention costs. Societal costs reflected a minority of
patients (≈ 20%) reporting substantial time away from work. Completeness of cost data diminished as
follow-up progressed from 86% in the first period to 36% in the last period. Quality-of-life scores at each
follow-up point and summary QALYs were similar between groups. Similarly, completeness of EQ-5D-5L
data diminished as follow-up proceeded from 98% to 35%. An apparent trend of improving quality-of-life
in all groups may be confounded by increasing missingness of data.
TABLE 9 Binary PAC-QoL score at 3, 6 and 12 months by randomised group and ORs for HT and HTBF and no-INVEST
and INVEST groups for those included in the final analysis model
Intervention
PAC-QoL score













HT (N = 43) 2.3 (0.7) 1.7 (0.8) 26 (60.5) Reference 15 (34.9) Reference
HTBF
(N= 34)
2.3 (0.9) 1.7 (1.0) 18 (52.9) 0.74 (0.3 to 1.9) 11 (32.4) 0.94 (0.3 to 2.7)
No INVEST
(N= 77)
2.3 (0.8) 1.7 (0.9) 44 (57.1) Reference 15 (34.9) Reference
INVEST
(N= 26)
2.5 (0.8) 1.9 (1.0) 15 (57.7) 0.95 (0.4 to 2.4) 11 (32.4) 0.34 (0.1 to 1.1)
6 months
HT (N = 38) 2.3 (0.7) 1.5 (0.8) 26 (68.4) Reference 14 (36.8) Reference
HTBF
(N= 30)
2.4 (0.8) 1.7 (1.0) 21 (70.0) 1.09 (0.4 to 3.2) 10 (33.3) 0.91 (0.3 to 2.8)
No INVEST
(N= 68)
2.3 (0.7) 1.6 (0.9) 47 (69.1) Reference 14 (36.8) Reference
INVEST
(N= 22)
2.4 (0.8) 1.8 (1.0) 12 (54.5) 0.48 (0.2 to 1.4) 10 (33.3) 0.66 (0.2 to 1.9)
12 months
HT (N = 29) 2.2 (0.7) 1.5 (0.8) 16 (55.2) Reference 9 (31.0) Reference
HTBF
(N= 23)
2.2 (0.9) 1.4 (1.2) 16 (69.6) 1.68 (0.5 to 5.6) 7 (30.4) 0.84 (0.2 to 3.0)
No INVEST
(N= 52)
2.2 (0.8) 1.4 (1.0) 32 (61.5) Reference 9 (31.0) Reference
INVEST
(N= 13)
2.4 (0.8) 1.7 (0.9) 9 (69.2) 1.60 (0.4 to 6.3) 7 (30.4) 1.37 (0.3 to 6.5)
OR, odds ratio.
a Odds ratio comparing HTBF to HT or INVEST to No-INVEST, adjusted for sex, baseline PAC-QoL score and
breakthrough medication (i.e. use of oral and/or rectal laxatives).
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TABLE 10 Overall PAC-QoL score for individual domains at 3, 6 and 12 months by randomised group and mean differences between HT and HTBF and between no-INVEST and
INVEST groups for those included in each analysis model at the relevant time point
Intervention
























HT 43 2.3 (0.1) 1.7 (0.1) Reference 38 2.3 (0.1) 1.5 (0.1) Reference 29 2.2 (0.1) 1.5 (0.1) Reference
HTBF 34 2.3 (0.2) 1.7 (0.1) –0.02 (–0.3 to 0.3) 30 2.4 (0.1) 1.7 (0.1) –0.03 (–0.3 to 0.3) 23 2.2 (0.2) 1.4 (0.2) –0.01 (–0.4 to 0.4)
No INVEST 77 2.3 (0.1) 1.7 (0.1) Reference 68 2.3 (0.1) 1.6 (0.1) Reference 52 2.2 (0.1) 1.4 (0.1) Reference
INVEST 26 2.5 (0.2) 1.9 (0.1) 0.09 (–0.2 to 0.4) 22 2.4 (0.2) 1.8 (0.1) 0.22 (–0.1 to 0.5) 13 2.4 (0.2) 1.7 (0.2) –0.02 (–0.4 to 0.4)
Dissatisfaction score (points)
HT 43 3.1 (0.1) 2.1 (0.1) Reference 38 3.1 (0.1) 2.2 (0.0) Reference 29 3.1 (0.1) 2.2 (0.0) Reference
HTBF 34 3.1 (0.1) 2.2 (0.1) 0.17 (–0.3 to 0.6) 30 3.3 (0.1) 2.3 (0.1) –0.04 (–0.5 to 0.4) 22 3.2 (0.1) 2.0 (0.1) –0.17 (–0.7 to 0.3)
No INVEST 77 3.1 (0.1) 2.2 (0.0) Reference 68 3.2 (0.1) 2.2 (0.1) Reference 51 3.2 (0.1) 2.1 (0.1) Reference
INVEST 26 3.4 (0.1) 2.4 (0.1) 0.09 (–0.3 to 0.5) 22 3.3 (0.1) 2.3 (0.1) 0.04 (–0.4 to 0.5) 13 3.2 (0.2) 2.0 (0.2) –0.31 (–0.9 to 0.2)
Physical discomfort score (points)
HT 43 2.5 (0.1) 1.8 (0.1) Reference 38 2.5 (0.1) 1.7 (0.1) Reference 29 2.4 (0.1) 1.6 (0.1) Reference
HTBF 34 2.3 (0.2) 1.8 (0.2) 0.10 (–0.3 to 0.5) 30 2.4 (0.2) 1.7 (0.2) 0.06 (–0.3 to 0.5) 23 2.2 (0.2) 1.5 (0.2) 0.14 (–0.4 to 0.7)
No INVEST 77 2.4 (0.1) 1.8 (0.1) Reference 68 2.5 (0.1) 1.7 (0.1) Reference 52 2.3 (0.1) 1.6 (0.1) Reference








































































































































































































































































































TABLE 10 Overall PAC-QoL score for individual domains at 3, 6 and 12 months by randomised group and mean differences between HT and HTBF and between no-INVEST and
INVEST groups for those included in each analysis model at the relevant time point (continued )
Intervention























Psychosocial discomfort score (points)
HT 43 1.8 (0.1) 1.3 (0.1) Reference 38 1.7 (0.2) 1.1 (0.1) Reference 29 1.5 (0.2) 1.1 (0.1) Reference
HTBF 34 1.8 (0.2) 1.3 (0.2) –0.05 (–0.4 to 0.3) 30 1.9 (0.2) 1.4 (0.1) 0.07 (–0.3 to 0.4) 23 1.8 (0.2) 1.1 (0.2) –0.17 (–0.6 to 0.2)
No INVEST 77 1.8 (0.1) 1.3 (0.1) Reference 68 1.8 (0.1) 1.2 (0.1) Reference 52 1.6 (0.1) 1.1 (0.1) Reference
INVEST 26 1.9 (0.2) 1.6 (0.2) 0.21 (–0.1 to 0.6) 22 1.7 (0.2) 1.4 (0.2) 0.24 (–0.1 to 0.6) 13 1.9 (0.3) 1.3 (0.3) 0.02 (–0.4 to 0.5)
Worries and concerns score (points)
HT 43 2.3 (0.1) 1.7 (0.1) Reference 38 2.2 (0.2) 1.4 (0.1) Reference 29 2.3 (0.2) 1.3 (0.1) Reference
HTBF 34 2.3 (0.2) 1.6 (0.1) –0.08 (–0.4 to 0.3) 30 2.4 (0.2) 1.6 (0.2) –0.01 (–0.4 to 0.4) 23 2.2 (0.2) 1.4 (0.2) 0.15 (–0.3 to 0.6)
No INVEST 77 2.3 (0.1) 1.7 (0.1) Reference 68 2.3 (0.1) 1.5 (0.1) Reference 52 2.2 (0.1) 1.4 (0.1) Reference
INVEST 26 2.5 (0.2) 2.0 (0.2) 0.08 (–0.3 to 0.4) 22 2.4 (0.2) 1.9 (0.2) 0.33 (–0.1 to 0.7) 13 2.4 (0.3) 1.7 (0.2) 0.12 (–0.4 to 0.6)
a Observed baseline PAC-QoL score (mean and SD) for those with data at both baseline and follow-up time point. (Statistics only for those included in model.)
b Adjusted for sex, baseline PAC-QoL score and breakthrough medication (i.e. use of oral and/or rectal laxatives).
Note































TABLE 11 Other continuous secondary outcomes at 3, 6 and 12 months by randomised group and mean differences between HT and HTBF and between no-INVEST and INVEST
groups for those included in each of the final analysis models at the relevant time point
Continuous
outcome

























HT 43 2.2 (0.8) 1.6 (0.8) Reference 38 2.2 (0.8) 1.5 (0.8) Reference 29 2.0 (0.8) 1.3 (0.7) Reference
HTBF 34 2.1 (0.9) 1.7 (1.1) –0.1 (–0.5 to 0.3) 30 2.1 (0.8) 1.5 (1.1) –0.1 (–0.5 to 0.3) 23 2.1 (0.9) 1.3 (1.1) 0.0 (–0.5 to 0.5)
No INVEST 77 2.2 (0.8) 1.6 (0.9) Reference 68 2.1 (0.8) 1.5 (0.9) Reference 52 2.1 (0.8) 1.3 (0.9) Reference
INVEST 26 2.3 (0.9) 1.7 (0.9) –0.1 (–0.5 to 0.3) 22 2.2 (0.9) 1.7 (0.8) –0.2 (–0.6 to 0.2) 13 2.0 (0.9) 1.4 (0.8) –0.1 (–0.6 to 0.4)
Stool symptoms
HT 43 2.6 (0.9) 1.8 (0.9) Reference 38 2.5 (0.9) 1.8 (1.0) Reference 29 2.5 (0.7) 1.5 (0.7) Reference
HTBF 34 2.5 (0.8) 1.8 (1.2) –0.0 (–0.5 to 0.5) 30 2.5 (0.9) 1.7 (1.3) 0.1 (–0.4 to 0.6) 23 2.5 (0.9) 1.4 (1.2) 0.1 (–0.4 to 0.6)
No INVEST 77 2.6 (0.9) 1.8 (1.0) Reference 68 2.5 (0.9) 1.8 (1.1) Reference 52 2.5 (0.8) 1.5 (0.9) Reference
INVEST 26 2.7 (1.0) 2.0 (1.1) –0.2 (–0.7 to 0.3) 22 2.6 (1.0) 2.0 (1.0) –0.3 (–0.8 to 0.2) 13 2.4 (1.2) 1.6 (0.8) –0.1 (–0.7 to 0.5)
Abdominal symptoms
HT 43 2.2 (1.0) 1.6 (1.1) Reference 38 2.2 (0.9) 1.3 (0.9) Reference 29 2.0 (1.0) 1.4 (1.0) Reference
HTBF 34 2.0 (1.1) 1.7 (1.1) –0.1 (–0.6 to 0.4) 30 2.0 (1.0) 1.5 (1.2) –0.2 (–0.7 to 0.3) 23 1.9 (1.1) 1.3 (1.3) 0.1 (–0.6 to 0.8)
No INVEST 77 2.1 (1.0) 1.6 (1.1) Reference 68 2.1 (1.0) 1.4 (1.0) Reference 52 2.0 (1.0) 1.4 (1.1) Reference
INVEST 26 2.2 (1.0) 1.9 (1.0) –0.2 (–0.7 to 0.3) 22 2.0 (1.1) 1.7 (1.0) –0.3 (–0.8 to 0.2) 13 1.7 (0.9) 1.3 (1.0) 0.0 (–0.7 to 0.7)
Rectal symptoms
HT 42 1.5 (1.1) 1.2 (0.9) Reference 37 1.5 (1.1) 1.0 (0.8) Reference 29 1.3 (1.0) 0.7 (0.7) Reference
HTBF 34 1.6 (1.2) 1.3 (1.3) –0.1 (–0.6 to 0.4) 30 1.6 (1.1) 1.2 (1.2) –0.2 (–0.7 to 0.3) 23 1.5 (1.1) 0.9 (1.0) –0.1 (–0.6 to 0.4)
No INVEST 76 1.5 (1.2) 1.2 (1.1) Reference 67 1.5 (1.1) 1.1 (1.0) Reference 52 1.4 (1.0) 0.8 (0.8) Reference








































































































































































































































































































TABLE 11 Other continuous secondary outcomes at 3, 6 and 12 months by randomised group and mean differences between HT and HTBF and between no-INVEST and INVEST
groups for those included in each of the final analysis models at the relevant time point (continued )
Continuous
outcome
























Bowel frequency: mean number of attempts to empty bowels over 2 weeks
HT 42 27.9 (22.4) 22.4 (11.9) Reference 34 29.0 (24.1) 21.8 (11.0) Reference 25 31.6 (26.1) 24.2 (12.7) Reference
HTBF 33 23.4 (12.6) 21.7 (12.9) 0.7 (–5.0 to 6.4) 29 26.6 (18.1) 22.6 (13.8) –0.7 (–7.0 to 5.6) 22 27.4 (19.7) 24.5 (15.0) –0.3 (–8.4 to 7.8)
No INVEST 75 25.9 (18.7) 22.1 (12.3) Reference 63 27.9 (21.4) 22.2 (12.3) Reference 47 29.6 (23.2) 24.4 (13.7) Reference
INVEST 26 29.9 (15.0) 26.3 (13.6) –4.2 (–9.9 to 1.5) 22 28.4 (15.6) 23.0 (11.5) –0.8 (–6.8 to 5.2) 12 24.4 (12.4) 23.0 (11.2) 1.4 (–7.2 to 10.0)
Bowel frequency: mean number of times stool was passed over 2 weeks
HT 42 15.1 (10.9) 15.9 (10.8) Reference 34 15.8 (11.7) 14.2 (8.3) Reference 25 16.2 (11.9) 17.6 (11.1) Reference
HTBF 33 14.8 (7.6) 16.5 (10.8) –0.6 (–5.6 to 4.4) 28 14.8 (8.9) 15.4 (11.3) –1.2 (–6.2 to 3.8) 22 16.2 (9.1) 18.6 (13.0) –1.0 (–8.1 to 6.1)
No INVEST 75 14.9 (9.5) 16.1 (10.7) Reference 62 15.3 (10.4) 14.8 (9.7) Reference 47 16.2 (10.6) 18.1 (11.9) Reference
INVEST 26 15.0 (9.7) 16.7 (10.9) –0.5 (–5.4 to 4.4) 22 13.8 (7.7) 14.3 (8.2) 0.5 (–4.1 to 5.1) 12 15.2 (11.4) 17.0 (10.7) 1.1 (–6.4 to 8.6)
Nature of bowel movement: mean number of days (out of 14) laxatives used
HT 42 4.3 (5.2) 1.0 (3.0) Reference 34 3.6 (4.5) 0.5 (1.6) Reference 25 3.8 (4.9) 1.3 (2.5) Reference
HTBF 33 3.6 (5.0) 1.0 (3.1) –0.0 (–1.4 to 1.4) 29 3.5 (4.8) 1.0 (2.7) –0.4 (–1.5 to 0.7) 22 3.6 (5.0) 0.9 (2.2) 0.4 (–1.0 to 1.8)
No INVEST 75 4.0 (5.1) 1.0 (3.0) Reference 63 3.5 (4.6) 0.7 (2.2) Reference 47 3.7 (4.9) 1.1 (2.3) Reference
INVEST 26 6.2 (6.0) 1.7 (4.1) –0.6 (–2.1 to 0.9) 22 6.2 (6.1) 0.6 (3.0) 0.1 (–1.1 to 1.3) 12 5.1 (5.9) 2.6 (5.4) –1.5 (–3.5 to 0.5)
Nature of bowel movement: mean number of days (out of 14) glycerine suppositories used
HT 42 0.8 (2.5) 1.1 (2.3) Reference 34 0.2 (0.7) 0.8 (2.0) Reference 25 0.1 (0.3) 0.5 (1.1) Reference
HTBF 32 0.5 (1.5) 0.9 (2.3) 0.2 (–0.9 to 1.3) 29 0.9 (2.1) 1.2 (2.8) –0.4 (–1.6 to 0.8) 22 0.6 (1.9) 0.1 (0.3) 0.4 (–0.1 to 0.9)
No INVEST 74 0.7 (2.1) 1.0 (2.3) Reference 63 0.5 (1.5) 1.0 (2.4) Reference 47 0.4 (1.3) 0.3 (0.9) Reference































TABLE 11 Other continuous secondary outcomes at 3, 6 and 12 months by randomised group and mean differences between HT and HTBF and between no-INVEST and INVEST
groups for those included in each of the final analysis models at the relevant time point (continued )
Continuous
outcome
























HT 43 68.4 (21.0) 71.0 (21.6) Reference 39 69.9 (19.7) 69.0 (23.8) Reference 29 69.7 (18.1) 73.8 (20.2) Reference
HTBF 34 66.7 (20.1) 71.2 (21.1) –0.2 (–10.0 to 9.6) 29 66.1 (20.1) 71.0 (20.1) –2.0 (–12.9 to 8.9) 23 68.8 (17.4) 74.7 (18.8) –0.9 (–11.9 to 10.1)
No INVEST 77 67.6 (20.5) 71.1 (21.2) Reference 68 68.3 (19.8) 69.8 (22.1) Reference 52 69.3 (17.6) 74.2 (19.4) Reference
INVEST 26 65.3 (17.4) 66.8 (17.6) 4.3 (–4.9 to 13.5) 22 68.1 (16.6) 71.1 (17.3) –1.3 (–11.6 to 9.0) 13 71.5 (17.4) 71.2 (19.9) 3.0 (–9.1 to 15.1)
PHQ-9 score (points)
HT 43 8.4 (7.0) 7.8 (7.1) Reference 38 7.5 (6.5) 7.7 (7.4) Reference 29 6.7 (6.8) 7.2 (6.5) Reference
HTBF 34 6.8 (6.4) 6.4 (6.2) 1.4 (–1.7 to 4.5) 30 6.8 (6.4) 7.2 (6.9) 0.5 (–3.0 to 4.0) 23 6.4 (6.8) 5.9 (7.6) 1.3 (–2.6 to 5.2)
No INVEST 77 7.7 (6.8) 7.2 (6.7) Reference 68 7.2 (6.4) 7.5 (7.1) Reference 52 6.6 (6.8) 6.6 (6.9) Reference
INVEST 26 10.0 (6.0) 9.5 (7.4) –2.3 (–5.4 to 0.8) 22 8.8 (4.8) 8.8 (5.6) –1.4 (–4.7 to 1.9) 13 8.2 (7.0) 8.2 (7.1) –1.6 (–5.9 to 2.7)
GAD-7 score (points)
HT 43 7.4 (6.8) 7.1 (6.9) Reference 38 6.9 (6.4) 5.8 (6.3) Reference 29 6.4 (6.4) 6.5 (6.5) Reference
HTBF 34 7.6 (6.5) 6.6 (6.1) 0.6 (–2.4 to 3.6) 30 7.0 (6.4) 6.4 (6.0) –0.6 (–3.6 to 2.4) 23 6.2 (6.0) 5.1 (6.3) 1.4 (–2.2 to 5.0)
No INVEST 77 7.5 (6.6) 6.9 (6.5) Reference 68 7.0 (6.4) 6.1 (6.1) Reference 52 6.3 (6.2) 5.9 (6.4) Reference
INVEST 26 8.8 (6.5) 9.2 (6.5) –2.3 (–5.2 to 0.6) 22 8.4 (6.0) 8.7 (6.4) –2.6 (–5.6 to 0.4) 13 6.8 (6.1) 7.4 (7.1) –1.5 (–5.6 to 2.6)
Global patient satisfaction score (points)
HT 42 – 2.5 (1.0) Reference 37 – 2.8 (0.9) Reference 29 – 2.7 (0.8) Reference
HTBF 32 – 2.4 (1.1) 0.1 (–0.4 to 0.6) 29 – 2.3 (1.3) 0.4 (–0.1 to 0.9) 23 – 2.5 (1.5) 0.2 (–0.5 to 0.9)
No INVEST 74 – 2.5 (1.0) Reference 66 – 2.6 (1.1) Reference 52 – 2.6 (1.2) Reference








































































































































































































































































































TABLE 11 Other continuous secondary outcomes at 3, 6 and 12 months by randomised group and mean differences between HT and HTBF and between no-INVEST and INVEST
groups for those included in each of the final analysis models at the relevant time point (continued )
Continuous
outcome























Global patient improvement score (points)
HT 43 – 61.5 (27.8) Reference 38 – 65.8 (23.1) Reference 29 – 69.8 (23.2) Reference
HTBF 34 – 44.9 (34.3) 16.7 (2.6 to 30.8) 28 – 52.7 (35.2) 13.0 (–1.4 to 27.4) 23 – 59.8 (38.0) 10.0 (–7.2 to 27.2)
No INVEST 77 – 54.2 (31.7) Reference 66 – 60.2 (29.4) Reference 52 – 65.4 (30.7) Reference
INVEST 26 – 45.0 (30.8) 9.2 (–5.0 to 23.4) 22 – 45.7 (30.2) 14.5 (0.0 to 29.0) 13 – 62.2 (32.3) 3.2 (–16.0 to 22.4)
Note































TABLE 12 Binary secondary outcomes (EQ-5D-5L) at 3, 6 and 12 months by randomised group and mean differences between HT and HTBF and no-INVEST and INVEST groups for
































HT 43 14 (32.6) 12 (27.9) Reference 38 11 (28.9) 12 (31.6) Reference 29 7 (24.1) 5 (17.2) Reference
HTBF 34 9 (26.5) 12 (35.3) –0.1 (–0.3 to 0.1) 30 9 (30.0) 12 (40.0) –0.1 (–0.3 to 0.1) 23 6 (26.1) 8 (34.8) –0.2 (–0.4 to 0.1)
No
INVEST
77 23 (29.9) 24 (31.2) Reference 68 20 (29.4) 24 (35.3) Reference 52 13 (25.0) 13 (25.0) Reference
INVEST 26 9 (34.6) 8 (30.8) 0.0 (–0.2 to 0.2) 22 8 (36.4) 7 (31.8) 0.0 (–0.2 to 0.3) 13 5 (38.5) 4 (30.8) –0.1 (–0.3 to 0.2)
Self-care
HT 43 8 (18.6) 8 (18.6) Reference 38 4 (10.5) 4 (10.5) Reference 29 2 (6.9) 4 (13.8) Reference
HTBF 34 4 (11.8) 7 (20.6) –0.0 (–0.2 to 0.2) 29 4 (13.8) 5 (17.2) –0.1 (–0.2 to 0.1) 23 4 (17.4) 3 (13.0) 0.0 (–0.2 to 0.2)
No
INVEST
77 12 (15.6) 15 (19.5) Reference 67 8 (11.9) 9 (13.4) Reference 52 6 (11.5) 7 (13.5) Reference
INVEST 26 5 (19.2) 4 (15.4) 0.0 (–0.1 to 0.2) 22 4 (18.2) 3 (13.6) –0.0 (–0.2 to 0.2) 13 1 (7.7) 0 (0.0) 0.1 (0.0 to 0.2)
Usual activities
HT 43 14 (32.6) 20 (46.5) Reference 38 10 (26.3) 15 (39.5) Reference 29 6 (20.7) 8 (27.6) Reference
HTBF 34 14 (41.2) 15 (44.1) 0.0 (–0.2 to 0.2) 30 13 (43.3) 11 (36.7) 0.0 (–0.2 to 0.3) 22 8 (36.4) 9 (40.9) –0.1 (–0.4 to 0.1)
No
INVEST
77 28 (36.4) 35 (45.5) Reference 68 23 (33.8) 26 (38.2) Reference 51 14 (27.5) 17 (33.3) Reference








































































































































































































































































































TABLE 12 Binary secondary outcomes (EQ-5D-5L) at 3, 6 and 12 months by randomised group and mean differences between HT and HTBF and no-INVEST and INVEST groups for
































HT 43 37 (86.0) 32 (74.4) Reference 38 33 (86.8) 27 (71.1) Reference 29 25 (86.2) 20 (69.0) Reference
HTBF 34 28 (82.4) 27 (79.4) –0.0 (–0.2 to 0.1) 30 25 (83.3) 24 (80.0) –0.1 (–0.3 to 0.1) 23 18 (78.3) 13 (56.5) 0.1 (–0.1 to 0.4)
No
INVEST
77 65 (84.4) 59 (76.6) Reference 68 58 (85.3) 51 (75.0) Reference 52 43 (82.7) 33 (63.5) Reference
INVEST 26 24 (92.3) 22 (84.6) –0.1 (–0.2 to 0.1) 22 19 (86.4) 17 (77.3) –0.0 (–0.2 to 0.2) 13 12 (92.3) 12 (92.3) –0.3 (–0.5 to –0.1)
Anxiety/depression
HT 43 26 (60.5) 24 (55.8) Reference 38 23 (60.5) 20 (52.6) Reference 29 18 (62.1) 16 (55.2) Reference
HTBF 33 15 (45.5) 14 (42.4) 0.1 (–0.1 to 0.4) 30 12 (40.0) 14 (46.7) 0.1 (–0.2 to 0.3) 23 8 (34.8) 11 (47.8) 0.1 (–0.2 to 0.3)
No
INVEST
76 41 (53.9) 38 (50.0) Reference 68 35 (51.5) 34 (50.0) Reference 52 26 (50.0) 27 (51.9) Reference
INVEST 26 17 (65.4) 17 (65.4) –0.2 (–0.4 to 0.1) 22 15 (68.2) 16 (72.7) –0.2 (–0.4 to –0.0) 13 8 (61.5) 8 (61.5) –0.1 (–0.4 to 0.2)
Note
















































































FIGURE 10 Average PAC-QoL score over time in months for (a) all participants (n = 178); and (b) those with no missing
data (n = 54). Both show reductions in score (i.e. improvement) over time.













Number of patients reporting AE 4 4 8 5 13
Number of AEs reported by category
Abdominal pain 0 0 0 0 0
Anal/rectal pain or discomfort 0 2 2 1 3
Bloating 0 0 0 0 0
Constipation 0 0 0 0 0
Haemorrhoids 0 0 0 0 0
Loose motions 0 2 2 0 2
Rectal bleeding 3 2 5 5 10
Vaginal/perineal bulge 0 0 0 0 0
Miscellaneous 1 0 1 2 3
Severity
Mild 2 2 4 5 9
Moderate 2 4 6 3 9
Severe 0 0 0 0 0
continued
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No action taken 1 3 4 5 9
Withdrawal 0 0 0 1 1
Concomitant medication 1 1 2 2 4
Non-drug therapy 1 2 3 0 3
SAEsa
Number of patients reporting SAE 0 0 0 2 2
Number of SAEs reported that require hospitalisation
or prolongation of existing hospitalisation
0 0 0 2 2
Causality
Unlikely to be related 0 0 0 2 2
Related 0 0 0 0 0
Expectedness
Expected 0 0 0 0 0
Unexpected 0 0 0 2 2
Action taken
Withdrawal 0 0 0 1 1
None 0 0 0 1 1
a None of the SAEs was identified as related to a treatment; no unresolved SAEs were reported.
TABLE 14 The CapaCiTY trial 1 economic analysis variables (£, 2018)
Variable
HT (N= 68 patients) HTBF (N= 68 patients) INVEST (N= 46 patients)





140 80 57 152 102 61 143 85 39
Number of biofeedback
sessions
– – – 2.09 1.43 67 0.93 1.35 44
Invest procedure
completed
– – – – – – 0.93 0.33 46
Number of prescriptions 2.00 1.98 48 1.43 1.97 46 1.53 1.62 40
0–3 months
Number of prescriptions 0.48 0.70 44 0.83 1.42 36 0.52 1.09 27
GP visits 0.02 0.15 44 0.14 0.35 36 0.11 0.32 27
District nurse visits 0.02 0.15 44 0.00 0.00 36 0.00 0.00 27
Pharmacist visits 0.05 0.21 44 0.06 0.23 36 0.15 0.46 27
A&E visits 0.00 0.00 44 0.03 0.17 36 0.00 0.00 27
Outpatient visits 0.20 0.51 44 0.08 0.28 36 0.15 0.46 27
Days from work 0.98 2.65 44 0.64 1.73 36 2.59 5.80 27
Inpatient visits 0.00 0.00 43 0.11 0.68 35 0.00 0.00 27
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TABLE 14 The CapaCiTY trial 1 economic analysis variables (£, 2018) (continued )
Variable
HT (N= 68 patients) HTBF (N= 68 patients) INVEST (N= 46 patients)
Mean SD n Mean SD n Mean SD n
4–6 months
Number of prescriptions 0.54 1.00 39 0.37 0.61 30 0.32 0.78 22
GP visits 0.18 0.60 39 0.17 0.59 30 0.14 0.47 22
District nurse visits 0.00 0.00 39 0.00 0.00 30 0.00 0.00 22
Pharmacist visits 0.08 0.35 39 0.17 0.59 30 0.05 0.21 22
A&E visits 0.00 0.00 39 0.00 0.00 30 0.00 0.00 22
Outpatient visits 0.18 0.72 39 0.10 0.31 30 0.14 0.35 22
Days from work 3.51 12.72 39 0.86 2.26 29 1.95 5.72 22
Inpatient visits 0.03 0.16 39 0.00 0.00 30 0.00 0.00 21
7–12 months
Number of prescriptions 0.48 0.89 31 0.33 0.64 24 1.15 1.46 13
GP visits 0.27 0.64 30 0.29 0.91 24 0.46 1.66 13
District nurse visits 0.07 0.37 30 0.00 0.00 24 0.00 0.00 13
Pharmacist visits 0.03 0.18 30 0.00 0.00 24 0.54 1.66 13
A&E visits 0.10 0.55 30 0.00 0.00 24 0.08 0.28 13
Outpatient visits 0.10 0.55 30 0.42 1.32 24 0.38 1.39 13
Days from work 2.30 6.72 30 1.08 3.08 24 4.00 11.48 13
Inpatient visits 0.00 0.00 30 0.04 0.21 23 0.00 0.00 13
Health-care cost
–3 to 0 months
(intervention)
326 186 57 493 322 61 804 351 39
0–3 months 42 87 43 55 137 35 35 75 27
4–6 months 59 152 39 26 51 30 25 51 21
7–12 months 57 142 30 132 320 23 147 283 13
Overall 506 205 19 815 411 17 988 269 9
Societal cost
Overall 1187 1866 19 1231 1016 17 1312 665 9
EQ-5D-5L
–3 months 0.664 0.308 68 0.693 0.247 66 0.679 0.223 45
3 months 0.652 0.329 43 0.708 0.261 33 0.665 0.211 26
6 months 0.733 0.251 38 0.681 0.272 29 0.642 0.256 22
12 months 0.737 0.262 29 0.734 0.289 22 0.713 0.136 13
QALYs
–3 to 12 months 0.874 0.357 23 0.842 0.345 19 0.897 0.171 11
Notes
Subtotals may not sum to totals because of different numbers of participants contributing.
Intervention occurred in the 3 months preceding the trial baseline, when follow-up commenced.
Days from work included in societal cost but not NHS cost.
The QALY estimates reported cover 15 months and are undiscounted in this table.
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Cost-effectiveness analyses
The base-case model is reported in Table 15. Compared with HT, both HTBF and INVEST-guided
treatment were estimated to be associated with higher costs and lower QoL, making HT the dominant
strategy. In both instances cost increases were significant (HTBF vs. HT: £239, 95% CI £133 to £354;
INVEST vs. HT: £543, 95% CI £403 to £685), and QoL decrements were small for HTBF (–0.010
QALYs, 95% CI –0.053 to 0.03 QALYs) and more significant for INVEST (–0.047 QALYs, 95% CI –0.093
to –0.001 QALYs), compared with HT. These findings are presented in Figure 11. On the ICER plane,
credible regions are plotted around median ICERs reflecting where 95% of bootstrapped estimates lie.
Incremental differences comparing HTBF and INVEST are not presented because both are dominated
by HT. NMB values were negative for HTBF and INVEST across the commonly used range of WTP
thresholds, indicating lack of cost-effectiveness (see Table 15). These findings are presented as CEACs
at varying WTP thresholds, showing the probability of each intervention being cost-effective. At the
NICE threshold of £30,000 per QALY, the probability that HT is the most cost-effective alternative is
83%. The EVPI values the opportunity loss of ongoing uncertainty. At a WTP threshold of £30,000 per
QALY, the EVPI per subject is £59. There are no reliable British figures for the incidence, prevalence or
chronic idiopathic constipation requiring hospital management or a future timeline for relevant new
research. Assuming that an approximate cost of a further definitive RCT is £1M, the research would
need to benefit only ≈ 17,000 patients, which might indicate that further research is merited,
particularly if the findings have international relevance.












































































































a Probability cost-effective at WTP threshold of £15,000 per QALY.
b Probability cost-effective at WTP threshold of £30,000 per QALY.
c Denotes a dominated strategy: increase in cost and decrease in QALYs.
d Non-recoverable cost assumption.
e Non-participants (zero intervention cost patients) excluded.
Notes
Bootstrapped 95% CIs; median ICERs.
Base-case and sensitivity analyses: imputed with 60 draws; assuming MAR.
Complete case: includes only participants with complete cost and QALY data; assuming missing completely at random.
APPENDIX 1



































































FIGURE 11 The CapaCiTY trial 1 cost-effectiveness analysis: base case. (a) ICER plane [the average ICER for each
intervention (compared with HT) is shown as a line from the origin and the credible regions (dashed circles) show where
95% of estimates lie]; (b) incremental NMB (the shaded regions are the corresponding 95% CIs); (c) CEACs and CEAF;
and (d) EVPI. (continued )
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In Figure 11a the ICER plane shows the bootstrapped distribution of estimated incremental costs and QALYs
comparing HTBF or INVESTwith HT. Bootstrapping is a method of resampling the trial data to mimic
conducting many trials; the range of findings reflects the uncertainty in the trial. The average ICER for each
intervention (compared with HT) is shown as a line from the origin.The credible regions (dashed circles) show
where 95% of estimates lie. Compared with HT, average costs increase for both HTBF and INVEST and
QALYs decrease, meaning that HT is the dominant treatment strategy. In Figure 11b the incremental NMB
describes the resource gain (or loss) when investing in HTBF or INVEST.The shaded regions are the
corresponding 95% CIs. Investing in HTBF or INVEST at any thresholdWTP would impose a loss to the
health system when compared with other alternative choices. In Figure 11c the presentation of CEACs
re-presents the incremental NMB findings as the probability that each intervention is cost-effective at
differentWTP thresholds.The CEAF is a necessary further analysis when three or more interventions are
compared. Although HT is the dominant strategy the finding is uncertain, being estimated to be correct with
a probability of 83% at aWTP threshold of £30,000 per QALY. In Figure 11d the EVPI indicates the value to
a health-care system of further research to eliminate uncertainty, asWTP varies.
The complete-case analysis is also presented in Table 15. Although the numbers contributing are small,
the findings are similar to the base case, if less precise. The base-case analysis costed the intervention
received by each participant in terms of the number of scheduled visits attended, time taken and
equipment used. This assumes no resource losses due to non-attendance or cancellation. A first post hoc
sensitivity analysis costed each intervention fully per protocol, assuming that these were non-recoverable
costs. The consequence is that the incremental cost of HTBF and INVEST increases, increasing the
probability that HT is cost-effective (p > 99% at a WTP threshold of £30,000 per QALY). A minority of
patients (12%) had no record of engaging in the trial intervention. In a second post hoc sensitivity
analysis, these subjects were removed to explore a participant analysis and reduce the imputation
burden. Findings were similar to and thus supportive of the base-case findings.
Results: patient experience and qualitative analysis
Emergent themes are presented in this section. Numbers in square brackets refer to the numbered
quotations in Appendix 2, Quotations from participants contributing to qualitative analysis in all three
trials, CapaCiTY trial 1: habit training with or without biofeedback with or without standardised
radiophysiological investigations.
INVEST compared with no INVEST
For those randomised to the INVEST tests, some felt embarrassment, especially if the health-care




















FIGURE 11 The CapaCiTY trial 1 cost-effectiveness analysis: base case. (a) ICER plane [the average ICER for each
intervention (compared with HT) is shown as a line from the origin and the credible regions (dashed circles) show where
95% of estimates lie]; (b) incremental NMB (the shaded regions are the corresponding 95% CIs); (c) CEACs and CEAF;
and (d) EVPI.
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tests, particularly because they felt that the health-care team managed the investigations professionally
and with dignity. Several were relieved to have been in the INVEST group because they felt that the
tests provided more information about potential sources of their constipation. The tests also gave some
reassurance that no underlying diseases were the root cause of their constipation, providing a sense of
closure and peace of mind [1].
Many patients randomised to the no-INVEST group were disappointed not to have received the tests
because they felt that the investigations would aid in pinpointing underlying issues that were contributing
to their CC. In addition, some patients thought that having visualisation of their gut would help them to
better understand their bodily issues. The desire of patients to have the tests was also noticed by staff
delivering the intervention.
For a few patients, not having the prior testing was not an issue. Some patients had mixed feelings
in terms of not being allocated to the INVEST group; some were pleased that they did not have to
experience the embarrassment or invasiveness of the procedures. They also initially believed that they
would have received better care had they been in the INVEST group [2]. Others felt some regret at not
having tests but appeared to accept it and move on.
Habit training only
Some patients were initially disappointed when they discovered that they were in the HT group
because they did not believe that HT on its own would be of benefit. For others, being placed in this
group provided a sense of encouragement. For many patients the best thing about HT was being able
to talk to an interested professional during the sessions about their constipation, particularly because
they considered this a taboo subject [3]. Being able to speak about their issues helped to normalise the
experience of CC [4].
A number of patients found that the HT helped them to better understand how diet and fluids influence
their constipation [5]. Those who had the additional biofeedback element often felt that the HT elements
were the most important [6]. Patients reported better knowledge of the types of foods that helped or
worsened constipation. However, a few patients did not find changes in their diet beneficial or their diet
already followed the HT advice. Some patients noted that learning to breathe and push correctly during
defaecation helped them to pass stools more easily [7]. However, a few struggled with utilising this
breathing technique.
Some patients also noted that learning how their bowels worked allowed them to better understand
their own bodies [8]. Learning was enhanced by visual aids in the booklet; staff echoed the usefulness
of the booklet [9]. HT also allowed more time than HTBF for education during the sessions. Some
patients stated that being taught how to sit on the toilet and for how long, and/or using a stool to
elevate their legs, was helpful [9]. Others did not find the advice about sitting worked for them, or they
did not comply with the advice.
Several patients stated how helpful and supportive they found the staff. Many found that the programme
helped them to focus on their constipation and the potential solutions without reverting to over-reliance
on laxatives [11]. Some felt that HT took considerable time and dedication to start seeing improvements;
others stated that carrying out the HT methods on a regular basis was difficult or painful to maintain
without laxatives. For those who found HT helpful, benefits ranged from some improvement [12] to
substantial improvement [13].
Habit training with biofeedback
For patients who had the additional biofeedback element, some stated that they found the visual
information on the screen helpful [13]; some staff echoed the visual benefit of biofeedback. Some
patients in the HTBF group saw a substantial improvement, whereas others did not appear to see
much benefit.
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Staff opinions were mixed regarding the HTBF intervention, with some suggesting that biofeedback helped
patients improve more than HT. However, others felt that biofeedback machines offered little in terms of
improving patient symptoms [14]. Some patients found the HTBF sessions a little embarrassing because a
probe needed to inserted into the anus [15]. For others the worst thing about biofeedback was that they
did not find that it helped their symptoms. Therefore, a few of the patients seem to believe that their
constipation would never improve. For clinical staff, seeing patients’ constipation problems improve was
the most satisfying aspect for them, whether that was with HT or HTBF. However, it was frustrating for
staff when interventions did not work, particularly for patients who had had symptoms for many years.
Maintaining learning
Many patients who saw benefits from HT or HTBF are continuing to implement what they learned,
whether that is diet and fluid maintenance, using a footstool and/or utilising breathing exercises. A few
patients reported that they still took laxatives either on occasion or regularly to help their constipation.
However, others reported that they no longer needed laxatives [16].
When asked whether or not they would recommend HT, many stated that they would. Some people
would recommend HTBF [17] and a few would recommend HT but not HTBF. A few would recommend
one HT session but not multiple sessions because they did not find it beneficial enough. For others,
even if the programme did not work for them in the way that they had hoped, they would still
recommend to others with constipation that they try it.
Staff experience of delivering the intervention
Many staff indicated that the intervention was not difficult to deliver, particularly the HT aspect for
nursing staff, because this was their main clinical role prior to the study. However, time spent filling in
paperwork, setting up rooms, arranging biofeedback machines and organising a clinical scientist to be
present (if one was needed to help with setting up and operating the biofeedback machine) had an
impact on their workload, adding 10–20 minutes to their usual consultation time per patient [18].
Regarding the use of biofeedback machines, staff ranged in their confidence levels depending on
whether or not they had:
l additional professional support such as a clinical scientist
l enough previous experience using the same biofeedback machine [19]
l used the machine on a regular basis
l received formal training.
Although training sessions were provided to staff, a few staff did not receive formal biofeedback
training at their site and had to rely on the protocol description. Missing formal training may have
contributed to the reduction in confidence levels among some staff members. Staff lack of confidence
utilising the machines may have affected the patient experience during biofeedback.
Feedback on the study/treatment design
Some patients felt that the study/treatment plan was well designed and did not believe that the
intervention could be improved in any way, even if it did not address their needs specifically. Many
patients stated that the number and duration of sessions were right. However, some reported that the
time between sessions felt like long periods without support. A few mentioned that they would have
liked more information about their INVEST results.
Many patients and staff mentioned stress and psychological issues related to constipation, and specific
recommendations were made about addressing this aspect more directly in future roll-outs of the
intervention. A number of patients and staff mentioned that lying down during the biofeedback
sessions seemed counterintuitive to retraining their muscles for a bowel emptying process that is
carried out sitting up. Some patients found the information in the HT sessions too basic for their
situation or felt patronised and would have preferred a more tailored approach.
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Patient discontinuation
Four of the 24 patients interviewed for CapaCiTY trial 1 reported that they had discontinued their
participation in the intervention because of:
l unsuitability for the study (e.g. having an anal fissure)
l misunderstanding what the study could provide, such as expecting to be placed into a group
for surgery
l the intervention not appearing to work/constipation symptoms returning
l fear of stopping laxative and suppository use.
CapaCiTY trial 2: pragmatic randomised trial of low-volume compared
with high-volume initiated transanal irrigation therapy in adults with
chronic constipation
Intervention
Transanal irrigation training was provided by a trained nurse or physiotherapist with experience in
delivering care for CC. A standardised approach and intervention was provided via use of an
intervention manual.
The course of therapy included a nurse-led training session (or multiple sessions if required to ensure
that the device was being used effectively) followed by patient-led home TAI therapy. The low-volume
system commonly used in practice was Qufora® IrriSedo Mini (MacGregor Healthcare Ltd, Tranent, UK).
Various commercially available high-volume systems could be used, including Peristeen® Anal Irrigation
System (Coloplast A/S, Humlebæk, Denmark) and Qufora IrriSedo Balloon (MacGregor Healthcare Ltd).
Low-volume transanal irrigation
This system consists of a small reservoir attached to a cone. The reservoir holds approximately 70 ml
of water and is squeezed to inject water into the rectum. The regimen used will be as follows: initial
TAI once daily for 14 days using one–three insufflations (each of ≈ 70 ml). This may then be reduced to
alternate days depending on response. Patients may then adjust the frequency and volume depending
on response. They may irrigate as much and as often as they feel is necessary to give them benefit and
this information should be captured on the CRF, with the aid of an irrigation journal.
High-volume transanal irrigation
High-volume systems consist of an irrigation bag connected to a tube. The water flows into the rectum
either by gravity or using a pump. Some systems employ a balloon to hold the device in place during
irrigation; others require the patient to hold it in place. The mechanism of action is the same for all
systems. Initial frequency of TAI is the same as for low-volume TAI (i.e. daily for 14 days, then on
alternate days). Patients will commence with irrigations of 300 ml and increase this by 100 ml every
2 days until satisfactory defaecation is achieved or the procedure becomes uncomfortable, up to a
maximum of 1500 ml. Patients may adjust therapy depending on response, as for low-volume TAI.
Design features
Basic design
Robust data for the use of irrigation therapy in chronic (idiopathic) constipation are lacking. In addition,
there are no data demonstrating superiority of high-volume over low-volume systems. Given differences
in cost between the two systems, a randomised study of well-characterised patients comparing the two
methods would provide useful information on whether or not one system holds a clear advantage over the
other. In addition, the short- and long-term efficacy and acceptability of therapy in CC could be evaluated.
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Patients used one system only (plus defined ‘rescue therapies’) for a minimum of 3 months. After this
time point they could switch to the other system if their initial therapy was ineffective/unsatisfactory.
Thus, consenting patients were randomised to initiate therapy with one of these systems but had the
option of switching to the other after an initial 3-month period. This allowed identification of response
rates to each system in the short term (3 months) and thereafter a comparison between treatment
strategies (low-volume vs. high-volume initiated therapy) rather than a pure comparison of the two
techniques. This was a patient-centred study design aiming to limit the time patients spent using
ineffective therapy without being allowed to try an alternative. Reasons for switching were captured
qualitatively (see Patient experience).
Switching TAI systems before completing the 3-month waiting period was discouraged and, if it occurred,
was documented as a protocol violation, with the timing and reason documented. If symptoms were severe
despite the use of TAI and rescue therapies then other medications could be used on compassionate
grounds, but these were also recorded in the CRF/concomitant medications log.
Sample size calculation
The PAC-QoL is a 28-item disease-specific measure, with each item scoring 0–4 points, providing an
aggregate score 0.0–4.0 points. Superiority of either low-volume or high-volume TAI could be demonstrated
by a difference in effect size of 0.4 points, with a variance estimate conservatively set at SD= 1 point from
the published literature. To detect an effect size of 0.4 points (mean/SD= 0.4 points) between the two
groups with 90% power and 5% significance at 3 months requires 133 patients per group and 266 in total.
Allowing for an anticipated 10% loss to follow-up, we planned to recruit 300 patients.
Randomisation procedure
Patients were randomised 1 : 1 into two groups: those to commence therapy with a low-volume device
and those to commence therapy with a high-volume device. Because male patients represent a minority
of patients with CC (≈ 10%) and there may be differences in pathophysiology (and therefore possibly
response) between male and females patients, patients were stratified by sex and female patients by centre.
Blinding
Patients and clinicians were necessarily aware of treatment allocations. The need to collect data on
frequency and volume of TAI, as well as reasons for discontinuing or switching between systems, meant
that assessor blinding was not possible with respect to these outcomes. Any researcher collecting CRFs or
handling journals was therefore unblinded. However, the primary outcome (PAC-QoL score at 3 months)
was concealed: patients completed this questionnaire without a researcher present and placed it in a
sealed envelope.
Concomitant medications
Methods as in CapaCiTY trial 1, with recorded ad libitum usage.
Statistical methods
The primary outcome, PAC-QoL score, was analysed as a continuous variable on an ITT basis; that is,
all patients for whom an outcome was available at 3 months were included in the analysis, and analysed
according to the treatment group to which they were originally randomised (even though two patients
crossed over before the primary outcome was measured).
We present descriptive statistics (i.e. mean, SD, median and IQR) by trial group. Owing to the small
numbers of patients providing the outcome data at follow-up, no statistical comparisons were performed.
All secondary outcomes were also analysed on an ITT basis. For each outcome we present descriptive
statistics (as appropriate) by trial group; continuous variables (e.g. PAC-QoL score) have been
summarised by treatment group using mean, SD, median and IQR. For categorical variables, numbers
and percentages of patients reporting each response option have been presented by trial group.
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Note that irrigation volume transgresses the ITT rule, being reported as that actually being used despite
original allocation. Results obtained using the CC-BRQ and BIPQ-CC have been omitted pending
further analysis.
Time to cessation of TAI is presented using Kaplan–Meier graphs, and where available reasons for
cessation of each system presented.
For cost-effectiveness, patients were randomised in parallel trial groups to low-volume or high-volume
TAI therapy. Days of use of low-volume and high-volume TAI were not recorded directly but approximated
from available data for using evidence of use in each follow-up period, frequency of use (days per week) in
each period and withdrawal data. No discounting was applied to economic data reflecting the follow-up
period of 1 year.
Recruitment
First recruitment and intervention was on 11 November 2015; recruitment ended 30 June 2018.
A total of 65 patients (target 300 patients) were randomised out of 150 screened (21.7%) from seven sites.
Reasons for screen failure are shown in Figure 12. Three sites opened but failed to recruit; the remainder
randomised 1–33 patients, with approximately half of the patients recruited from secondary care and half
from tertiary care. A total of 65 patients were randomised. A total of 14 patients withdrew from the study
before the primary end point (51 completed the 3-month follow-up). A total of 30 patients were randomised
to low-volume TAI and 35 to high-volume TAI.The CONSORT flow diagram is shown in Figure 4.
Baseline characteristics
Table 16 shows the numbers and percentages of patients with baseline characteristics presented by
trial group. Continuous variables (e.g. age) were summarised by treatment group using mean and SD
(median and IQR if non-normally distributed). The data show that half of the patients were in tertiary
care and that, as would be expected, all had tried lifestyle measures and laxatives. The age and sex
distribution are as would be expected from a hospital-based constipation cohort. The prevalence of
other medical conditions was fairly typical for any hospital-attending patient group of this age range with a
chronic illness. One-quarter of patients had hypermobility, higher than reported in the general population.
Age (years)
Not constipated
Diet, lifestyle and laxative/prokinetics naive
Previous specialist nurse-led bowel
management naive
Previous pelvic floor surgery including SNS
Significant neurological disease













FIGURE 12 The CapaCiTY trial 2 screen failures. SNS, sacral nerve stimulation.
DOI: 10.3310/pgfar09140 Programme Grants for Applied Research 2021 Vol. 9 No. 14
Copyright © 2021 Knowles et al. This work was produced by Knowles et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
85
TABLE 16 The CapaCiTY trial 2 baseline data
Characteristic Low-volume TAI (N= 30) High-volume TAI (N= 35) Total (N= 65)
Referral method, n (%)
Secondary care 11 (36.7) 16 (45.7) 27 (41.5)
Tertiary care 16 (53.3) 18 (51.4) 34 (52.3)
Other 3 (10.0) 1 (2.9) 4 (6.2)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Demographic characteristic
Sex, n (%)
Male 3 (10.0) 4 (11.4) 7 (10.8)
Female 27 (90.0) 31 (88.6) 58 (89.2)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Ethnicity, n (%)
Asian 1 (3.3) 1 (2.9) 2 (3.1)
Black 2 (6.7) 1 (2.9) 3 (4.6)
Mixed 0 (0.0) 2 (5.7) 2 (3.1)
White 26 (86.7) 31 (88.6) 57 (87.7)
Missing 1 (3.3) 0 (0.0) 1 (1.5)
Age (years)
Mean (SD) 43.3 (15.0) 44.9 (11.8) 44.2 (13.3)
Median (IQR) 41.5 (37.0–55.0) 43.0 (40.0–53.0) 43.0 (39.0–54.0)
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Past medical history, n (%)
Total 27 (90.0) 28 (80.0) 55 (84.6)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Cardiovascular condition 8 (26.7) 6 (17.1) 14 (21.5)
Heart disease 1 (3.3) 0 (0.0) 1 (1.5)
Hypertension 5 (16.7) 4 (11.4) 9 (13.8)
Hypercholesterolaemia 5 (16.7) 3 (8.6) 8 (12.3)
Other 1 (3.3) 1 (2.9) 2 (3.1)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Respiratory condition 10 (33.3) 7 (20.0) 17 (26.2)
Asthma 9 (30.0) 7 (20.0) 16 (24.6)
COPD 3 (10.0) 1 (2.9) 4 (6.2)
Other 1 (3.3) 1 (2.9) 2 (3.1)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Gastrointestinal condition 15 (50.0) 12 (34.3) 27 (41.5)
IBS 11 (36.7) 7 (20.0) 18 (27.7)
Crohn’s disease 0 (0.0) 0 (0.0) 0 (0.0)
Ulcerative colitis 0 (0.0) 0 (0.0) 0 (0.0)
Cancer 0 (0.0) 1 (2.9) 1 (1.5)
Colonic polyps 3 (10.0) 3 (8.6) 6 (9.2)
Other 4 (13.3) 3 (8.6) 7 (10.8)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
86
TABLE 16 The CapaCiTY trial 2 baseline data (continued )
Characteristic Low-volume TAI (N= 30) High-volume TAI (N= 35) Total (N= 65)
Metabolic condition 8 (26.7) 4 (11.4) 12 (18.5)
Diabetes 5 (16.7) 2 (5.7) 7 (10.8)
Hypothyroidism 2 (6.7) 3 (8.6) 5 (7.7)
Hyperthyroidism 1 (3.3) 0 (0.0) 1 (1.5)
Other 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Haematological condition 2 (6.7) 0 (0.0) 2 (3.1)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Hepatic condition 2 (6.7) 3 (8.6) 5 (7.7)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Renal disease 1 (3.3) 0 (0.0) 1 (1.5)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Genito-urinary condition 6 (20.0) 7 (20.0) 13 (20.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Neurological/CNS condition 10 (33.3) 7 (20.0) 17 (26.2)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Psychiatric condition 12 (40.0) 12 (34.3) 24 (36.9)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Dermatological condition 6 (20.0) 6 (17.1) 12 (18.5)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Musculoskeletal condition 4 (13.3) 5 (14.3) 9 (13.8)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Other condition 3 (10.0) 1 (2.9) 4 (6.2)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Past surgical history, n (%)
Total 17 (56.7) 17 (48.6) 34 (52.3)
Abdominal operation 10 (33.3) 7 (20.0) 17 (26.2)
Gynaecological procedure 10 (33.3) 11 (31.4) 21 (32.3)
Proctological or perineal procedure 2 (6.7) 5 (14.3) 7 (10.8)
Neuromodulation 1 (3.3) 0 (0.0) 1 (1.5)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Duration (months) of constipation symptoms
Mean (SD) 90.4 (79.1) 120.7 (76.3) 106.7 (78.5)
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Previous lifestyle modifications, n (%)
Total 30 (100.0) 35 (100.0) 65 (100.0)
Diet 30 (100.0) 35 (100.0) 65 (100.0)
Fluid 30 (100.0) 35 (100.0) 65 (100.0)
Exercise 27 (90.0) 31 (88.6) 58 (89.2)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
continued
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TABLE 16 The CapaCiTY trial 2 baseline data (continued )
Characteristic Low-volume TAI (N= 30) High-volume TAI (N= 35) Total (N= 65)
Alternative therapies, n (%)
Total 5 (16.7) 8 (22.9) 13 (20.0)
Missing 0 (0.0) 1 (2.9) 1 (1.5)
Laxatives, n (%)
Total 30 (100.0) 34 (97.1) 64 (98.5)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Antidiarrhoeals, n (%)
Total 1 (3.3) 2 (5.7) 3 (4.6)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Prokinetics, n (%)
Total 18 (60.0) 23 (65.7) 41 (63.1)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Nurse-led bowel management, n (%)
Total 30 (100.0) 35 (100.0) 65 (100.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Family history of bowel disease, n (%)
IBS 7 (23.3) 5 (14.3) 12 (18.5)
IBD 2 (6.7) 3 (8.6) 5 (7.7)
Gastrointestinal cancer 7 (23.3) 5 (14.3) 12 (18.5)
Other 4 (13.3) 5 (14.3) 9 (13.8)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Sexual history (female participants only), n (%)
Sexually active 14 (51.9) 23 (74.2) 37 (63.8)
Child-bearing potential 18 (66.7) 19 (61.3) 37 (63.8)
> 1 year post menopausal 4 (14.8) 7 (22.6) 11 (19.0)
Surgically sterile 7 (25.9) 9 (29.0) 16 (27.6)
Contraceptive use (female participants only), n (%)
Barrier 12 (44.4) 14 (45.2) 26 (44.8)
Non-barrier 2 (7.4) 6 (19.4) 8 (13.8)
Missing 11 (40.7) 8 (25.8) 19 (32.8)
Past obstetric history (female participants only)
Total, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Number of vaginal deliveries, mean (SD) 19 (70.4) 25 (80.6) 44 (75.9)
Number of caesareans, mean (SD) 0 (0.0) 0 (0.0) 0 (0.0)
Number of forceps/ventouse
deliveries, mean (SD)
1.9 (1.1) 2.3 (1.3) 2.1 (1.3)
Number of episiotomies, mean (SD) 0.2 (0.4) 0.2 (0.5) 0.2 (0.4)
Number of obstetric tears, mean (SD) 0.5 (0.7) 0.4 (0.9) 0.4 (0.8)
Missing, n (%) 0.7 (0.9) 0.3 (0.5) 0.5 (0.7)
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Table 17 shows the data for outcome measures at baseline. These were comparable between the two
groups for all major characteristics.
Results: clinical effectiveness
Owing to the low numbers of patients recruited, only descriptive statistics are presented (Table 18).
At 3 months there was a modest reduction of mean PAC-QoL score from 2.4 to 2.2 points (0.2-point
reduction) in the low-volume irrigation group and a larger reduction of 0.5 points in the high-volume
TAI group. Although the difference is not large there was consistency of findings across some of the
other outcome measures. Secondary outcomes are shown in Tables 19 and 20. For example, global
satisfaction, global improvement and EQ-VAS scores were more improved in the high-volume TAI
group. These results were based on an ITT analysis and, therefore, included two patients who crossed
over before 3 months (possibly diluting the difference in effect).
TABLE 16 The CapaCiTY trial 2 baseline data (continued )
Characteristic Low-volume TAI (N= 30) High-volume TAI (N= 35) Total (N= 65)
Faecal incontinence symptoms, n (%)
Total 0.6 (1.0) 0.6 (0.9) 0.6 (0.9)
Faecal urgency 0 (0.0) 0 (0.0) 0 (0.0)
Urge faecal incontinence 17 (56.7) 17 (48.6) 34 (52.3)
Passive faecal incontinence 9 (30.0) 14 (40.0) 23 (35.4)
Post defaecation leakage 5 (16.7) 7 (20.0) 12 (18.5)
Difficulty wiping clean 2 (6.7) 8 (22.9) 10 (15.4)
Missing 4 (13.3) 8 (22.9) 12 (18.5)
Pelvic organ prolapse symptoms, n (%)
Total 7 (23.3) 9 (25.7) 16 (24.6)
Vaginal bulging 0 (0.0) 0 (0.0) 0 (0.0)
External rectal prolapse 0 (0.0) 0 (0.0) 0 (0.0)
External uterine prolapse 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
In what proportion of bowel motions does the patient experience spontaneous rectal urge to defaecate (without laxatives)?, n (%)
Never 10 (33.3) 9 (25.7) 19 (29.2)
< 25% 10 (33.3) 12 (34.3) 22 (33.8)
25–75% 5 (16.7) 7 (20.0) 12 (18.5)
> 75% 2 (6.7) 1 (2.9) 3 (4.6)
Always 2 (6.7) 5 (14.3) 7 (10.8)
Missing 1 (3.3) 1 (2.9) 2 (3.1)
Joint hypermobility,a n (%)
Total 8 (26.7) 9 (25.7) 17 (26.2)
Missing 1 (3.3) 2 (5.7) 3 (4.6)
COPD, chronic obstructive pulmonary disease; IBD, inflammatory bowel disease.
a Hypermobility was indicated by a response of ‘yes’ to two or more out of five questions used to assess
joint hypermobility.
DOI: 10.3310/pgfar09140 Programme Grants for Applied Research 2021 Vol. 9 No. 14
Copyright © 2021 Knowles et al. This work was produced by Knowles et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
89
TABLE 17 The CapaCiTY trial 2 outcome measure data at baseline
Outcome measure Low-volume TAI (N= 30) High-volume TAI (N= 35) Total (N= 65)
PAC-QoL score (points)
Overall, mean (SD) 2.5 (0.8) 2.4 (0.7) 2.4 (0.8)
Missing, n (%) 2 (6.7) 2 (5.7) 4 (6.2)
Dissatisfaction, mean (SD) 3.3 (0.6) 3.2 (0.6) 3.3 (0.6)
Missing, n (%) 2 (6.7) 3 (8.6) 5 (7.7)
Physical discomfort, mean (SD) 2.7 (0.9) 2.7 (0.8) 2.7 (0.8)
Missing, n (%) 2 (6.7) 2 (5.7) 4 (6.2)
Psychosocial discomfort, mean (SD) 1.8 (1.0) 1.8 (1.0) 1.8 (1.0)
Missing, n (%) 2 (6.7) 2 (5.7) 4 (6.2)
Worries and concerns, mean (SD) 2.5 (1.0) 2.5 (0.9) 2.5 (0.9)
Missing, n (%) 2 (6.7) 2 (5.7) 4 (6.2)
PAC-SYM score (points)
Overall, mean (SD) 2.1 (0.8) 2.1 (0.7) 2.1 (0.8)
Missing, n (%) 2 (6.7) 2 (5.7) 4 (6.2)
Stool symptoms, mean (SD) 2.3 (1.0) 2.4 (1.1) 2.3 (1.0)
Missing, n (%) 2 (6.7) 2 (5.7) 4 (6.2)
Abdominal symptoms, mean (SD) 2.4 (1.2) 2.4 (0.8) 2.4 (1.0)
Missing, n (%) 2 (6.7) 2 (5.7) 4 (6.2)
Rectal symptoms, mean (SD) 1.3 (1.2) 1.3 (0.8) 1.3 (1.0)
Missing, n (%) 2 (6.7) 2 (5.7) 4 (6.2)
Bowel frequency, number reported over 14 days (diary data)
Attempts to empty bowels, mean (SD) 20.3 (10.6) 21.2 (13.2) 20.8 (12.0)
Missing, n (%) 6 (20.0) 6 (17.1) 12 (18.5)
Times stool was actually passed, mean (SD) 12.1 (9.5) 11.3 (9.9) 11.6 (9.6)
Missing, n (%) 7 (23.3) 6 (17.1) 13 (20.0)
Nature of bowel movement, number of days out of 14 (diary data)
Laxatives used, mean (SD) 21.7 (5.8) 23.7 (5.2) 22.8 (5.6)
Missing, n (%) 6 (20.0) 6 (17.1) 12 (18.5)
Glycerine suppositories used, mean (SD) 26.0 (4.0) 26.5 (3.3) 26.3 (3.6)
Missing, n (%) 7 (23.3) 6 (17.1) 13 (20.0)
EQ-5D-5L: ‘no problem’ indicated, n (%)
Mobility 6 (20.0) 9 (25.7) 15 (23.1)
Missing 3 (10.0) 2 (5.7) 5 (7.7)
Self-care 4 (13.3) 4 (11.4) 8 (12.3)
Missing 3 (10.0) 2 (5.7) 5 (7.7)
Usual activities 11 (36.7) 17 (48.6) 28 (43.1)
Missing 3 (10.0) 2 (5.7) 5 (7.7)
Pain/discomfort 24 (80.0) 30 (85.7) 54 (83.1)
Missing 3 (10.0) 2 (5.7) 5 (7.7)
Anxiety/depression 15 (50.0) 20 (57.1) 35 (53.8)
Missing 3 (10.0) 2 (5.7) 5 (7.7)
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Further evidence of the greater benefit of high-volume TAI could be inferred from the fact that
15 patients switched from low-volume to high-volume TAI but only four patients switched from high-
volume to low-volume TAI and two of these six switched back again to high-volume TAI (Table 21).
Many of the treatment responses improved over time, suggesting a possible beneficial effect of TAI.
This improvement cannot be definitively assigned to the treatment owing to confounding factors such
as regression to the mean, loss of participants and the absence of a sham control. However, it is
reasonable to postulate that survival rate of therapy (being both cumbersome and unpleasant)
indicated ongoing patient perception that it had clinical benefit.
A secondary aim of CapaCiTY trial 2 was to observe the survival rate of TAI therapy against time, this
being a surrogate of ongoing perceived patient benefit (given the invasive and time-consuming nature
of self-administering the therapy). Figure 13 shows that three-quarters of patients were still using TAI
at 12 months – an impressively high number. Concomitant medicine usage was roughly equal in both
groups (Table 22).
TABLE 18 The CapaCiTY trial 2 primary outcome: PAC-QoL score, low-volume vs. high-volume TAI and difference in














2.4 (0.8) 2.4 (1.9–2.9) 2.2 (0.8) 2.0 (1.5–2.8) Reference
High-volume TAI
(n = 25)
2.3 (0.7) 2.4 (1.8–2.8) 1.8 (0.9) 1.8 (1.1–2.3) –0.37 (–0.89 to 0.15)
TABLE 17 The CapaCiTY trial 2 outcome measure data at baseline (continued )
Outcome measure Low-volume TAI (N= 30) High-volume TAI (N= 35) Total (N= 65)
EQ-VAS score (points)
Total, mean (SD) 63.9 (20.3) 70.9 (19.1) 67.8 (19.8)
Missing, n (%) 3 (10.0) 2 (5.7) 5 (7.7)
PHQ-9 depression severity, n (%)
None 2 (6.7) 2 (5.7) 4 (6.2)
Mild 14 (46.7) 16 (45.7) 30 (46.2)
Moderate 5 (16.7) 8 (22.9) 13 (20.0)
Moderately severe 3 (10.0) 2 (5.7) 5 (7.7)
Severe 6 (20.0) 7 (20.0) 13 (20.0)
Missing 2 (6.7) 2 (5.7) 4 (6.2)
GAD-7 anxiety severity, n (%)
None 8 (26.7) 15 (42.9) 23 (35.4)
Mild 8 (26.7) 5 (14.3) 13 (20.0)
Moderate 6 (20.0) 9 (25.7) 15 (23.1)
Severe 3 (10.0) 1 (2.9) 4 (6.2)
Missing 3 (10.0) 3 (8.6) 6 (9.2)
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TABLE 19 The CapaCiTY trial 2 continuous secondary outcomes at baseline and follow-up for participants with data collected at 3, 6 and 12 months by randomised treatment group
Intervention




























Low-volume TAI 19 2.4 (0.8) 2.2 (0.8) 2.4 (1.9–2.9) 2.0 (1.5–2.8) 19 2.4 (0.7) 1.8 (0.9) 2.4 (1.9–2.9) 1.4 (1.1–2.6) 14 2.5 (0.7) 2.1 (0.9) 2.5 (2.0–2.9) 1.9 (1.4–2.7)
High-volume TAI 25 2.3 (0.7) 1.8 (0.9) 2.4 (1.8–2.8) 1.8 (1.1–2.3) 21 2.2 (0.7) 1.4 (0.8) 2.4 (1.8–2.8) 1.2 (0.9–1.9) 18 2.3 (0.7) 1.5 (0.9) 2.3 (1.8–2.8) 1.1 (0.9–2.1)
Dissatisfaction
Low-volume TAI 19 3.4 (0.4) 2.8 (0.7) 3.4 (3.2–3.8) 3.0 (2.2–3.4) 19 3.4 (0.4) 2.2 (0.9) 3.4 (3.2–3.6) 2.2 (1.8–2.8) 14 3.4 (0.4) 2.5 (1.0) 3.4 (3.2–3.6) 2.5 (2.0–3.2)
High-volume TAI 24 3.1 (0.7) 2.5 (0.9) 3.2 (2.8–3.6) 2.8 (2.1–3.1) 20 3.0 (0.7) 2.1 (1.1) 3.1 (2.6–3.6) 2.1 (1.3–3.0) 17 3.1 (0.7) 2.2 (1.1) 3.2 (2.8–3.6) 2.2 (1.4–2.4)
Physical discomfort
Low-volume TAI 18 2.7 (0.9) 2.4 (0.9) 2.9 (2.3–3.3) 2.3 (2.0–3.0) 19 2.6 (0.9) 1.8 (1.0) 2.8 (2.0–3.3) 1.8 (1.0–2.8) 14 2.6 (0.9) 2.1 (1.2) 2.9 (2.3–3.3) 2.5 (1.3–2.8)
High-volume TAI 25 2.6 (0.7) 1.9 (0.9) 2.5 (2.3–3.0) 1.8 (1.3–2.3) 20 2.4 (0.6) 1.3 (0.9) 2.5 (2.1–2.8) 1.3 (0.6–2.0) 18 2.4 (0.6) 1.6 (0.9) 2.5 (2.3–2.8) 1.3 (1.0–2.0)
Psychosocial discomfort
Low-volume TAI 19 1.6 (1.0) 1.5 (1.1) 1.5 (0.8–2.8) 1.3 (0.8–2.4) 19 1.6 (1.0) 1.3 (1.1) 1.5 (0.9–2.3) 0.9 (0.5–2.3) 14 2.0 (1.1) 1.7 (1.3) 1.9 (1.1–2.9) 1.6 (0.5–3.1)
High-volume TAI 25 1.7 (1.0) 1.2 (0.9) 1.8 (0.8–2.6) 0.9 (0.6–1.9) 21 1.5 (1.1) 0.8 (0.8) 1.3 (0.6–2.4) 0.6 (0.3–1.1) 18 1.5 (1.1) 1.0 (0.9) 1.2 (0.6–2.5) 0.6 (0.4–1.8)
Worries and concerns
Low-volume TAI 19 2.4 (1.0) 2.3 (1.0) 2.6 (1.5–3.1) 2.2 (1.6–2.8) 19 2.4 (0.9) 1.8 (1.1) 2.6 (1.9–3.1) 1.5 (0.9–2.5) 14 2.5 (0.8) 2.0 (1.1) 2.8 (2.1–3.1) 2.0 (1.2–2.5)
High-volume TAI 25 2.4 (1.0) 1.9 (1.1) 2.4 (1.8–3.1) 1.8 (1.0–2.4) 21 2.3 (0.9) 1.4 (1.1) 2.3 (1.8–3.0) 1.0 (0.6–1.9) 18 2.4 (0.9) 1.5 (1.1) 2.2 (1.8–3.0) 1.0 (0.6–2.6)
PAC-SYM score (points)
Overall
Low-volume TAI 19 2.0 (0.8) 1.8 (0.8) 2.0 (1.4–2.6) 1.8 (1.2–2.1) 19 2.0 (0.8) 1.4 (0.8) 2.0 (1.4–2.4) 1.4 (0.8–1.7) 14 2.0 (0.9) 1.6 (0.8) 1.8 (1.3–2.4) 1.5 (0.8–2.3)
High-volume TAI 25 2.0 (0.7) 1.4 (0.7) 2.1 (1.4–2.5) 1.4 (1.0–1.8) 21 1.9 (0.6) 1.2 (0.6) 1.9 (1.4–2.4) 1.3 (0.7–1.7) 18 1.9 (0.6) 1.3 (0.6) 1.9 (1.4–2.4) 1.3 (0.8–1.7)
Stool symptoms
Low-volume TAI 19 2.2 (1.0) 2.0 (1.0) 2.2 (1.6–3.0) 2.0 (1.0–2.4) 19 2.1 (1.0) 1.5 (0.9) 2.2 (1.4–3.0) 1.6 (0.8–2.0) 14 2.0 (0.8) 1.7 (0.9) 2.0 (1.4–2.4) 1.6 (1.2–2.4)
High-volume TAI 25 2.2 (1.1) 1.6 (0.8) 2.4 (1.6–3.0) 1.8 (1.2–2.0) 21 2.1 (1.1) 1.4 (0.8) 2.4 (1.4–3.0) 1.4 (0.8–2.0) 18 2.1 (1.0) 1.6 (0.9) 2.3 (1.4–3.0) 1.8 (0.8–2.4)
Abdominal symptoms
Low-volume TAI 19 2.3 (1.2) 2.0 (0.9) 2.0 (2.0–3.5) 2.0 (1.3–2.8) 19 2.5 (1.1) 1.7 (1.0) 2.3 (2.0–3.5) 1.5 (0.8–2.3) 14 2.5 (1.2) 1.9 (1.1) 2.4 (2.0–4.0) 2.0 (0.8–2.8)































TABLE 19 The CapaCiTY trial 2 continuous secondary outcomes at baseline and follow-up for participants with data collected at 3, 6 and 12 months by randomised treatment group
(continued )
Intervention



























Low-volume TAI 19 1.1 (1.1) 1.0 (1.3) 1.0 (0.3–1.7) 0.3 (0.3–1.7) 19 1.1 (1.0) 0.8 (0.8) 1.0 (0.3–1.7) 1.0 (0.0–1.3) 14 1.2 (1.1) 1.0 (1.1) 0.8 (0.3–1.7) 0.7 (0.3–1.3)
High-volume TAI 25 1.1 (0.7) 0.6 (0.7) 1.0 (0.7–1.7) 0.3 (0.0–1.0) 21 1.0 (0.7) 0.5 (0.6) 1.0 (0.3–1.3) 0.3 (0.0–1.0) 18 1.1 (0.7) 0.8 (0.9) 1.2 (0.3–1.7) 0.3 (0.0–1.3)
Irrigation journal
Average number of times per week that the patient has used their anal irrigation
Low-volume TAI 19 – 5.2 (7.5) – 4.0 (1.0–7.0) 19 – 3.3 (2.5) – 3.0 (2.0–6.0) 17 – 2.3 (2.1) – 2.0 (1.0–3.0)
High-volume TAI 21 – 3.1 (2.1) – 3.0 (2.0–4.0) 22 – 2.8 (2.5) – 3.0 (0.0–4.0) 19 – 2.6 (2.1) – 3.0 (0.0–4.0)
Average volume (ml) of water used per irrigationa
Low-volume TAI 16 – 147.8 (94.2) – 143.5
(70.0–210.0)
13 – 97.8 (92.6) – 70.0 (0.0–170.0) 11 – 83.2 (102.9) – 70.0 (0.0–210.0)






25 – 535.7 (381.7) – 500.0 (373.0–703.0)
Diary data
Bowel frequency: mean number of attempts to empty bowels over 2 weeks
Low-volume TAI 19 19.7 (11.3) 17.3 (10.6) 18.0 (11.0–28.0) 20.0 (7.0–23.0) 15 18.1 (8.3) 19.5 (22.6) 18.0 (11.0–22.0) 11.0 (10.0–22.0) 12 21.8 (12.2) 19.2 (13.7) 20.5 (12.0–30.0) 17.5 (10.5–23.0)
High-volume TAI 18 23.1 (14.1) 19.3 (9.8) 21.5 (13.0–33.0) 16.5 (12.0–26.0) 17 25.0 (13.8) 16.6 (9.1) 23.0 (17.0–34.0) 16.0 (10.0–22.0) 13 24.1 (16.5) 18.4 (12.8) 20.0 (13.0–37.0) 13.0 (7.0–25.0)
Bowel frequency: mean number of times stool was passed over 2 weeks
Low-volume TAI 18 11.8 (10.2) 10.9 (6.9) 9.5 (5.0–15.0) 10.0 (7.0–13.0) 16 8.8 (5.3) 12.8 (13.9) 8.0 (4.5–13.0) 9.5 (6.0–15.0) 13 12.2 (11.6) 11.2 (8.7) 9.0 (5.0–13.0) 10.0 (5.0–15.0)
High-volume TAI 18 13.1 (11.2) 13.3 (8.2) 10.0 (6.0–17.0) 11.5 (8.0–16.0) 17 14.2 (11.0) 11.7 (5.3) 11.0 (7.0–17.0) 9.0 (8.0–15.0) 13 12.2 (12.6) 12.5 (9.0) 10.0 (4.0–15.0) 9.0 (7.0–18.0)
Nature of bowel movement: mean number of days (out of 14) laxatives used
Low-volume TAI 19 21.7 (6.2) 22.7 (5.5) 23.0 (14.0–28.0) 25.0 (17.0–28.0) 16 22.4 (5.7) 22.4 (5.5) 24.0 (16.5–28.0) 23.0 (18.5–28.0) 13 20.8 (6.0) 22.8 (6.5) 23.0 (14.0–26.0) 25.0 (20.0–28.0)








































































































































































































































































































TABLE 19 The CapaCiTY trial 2 continuous secondary outcomes at baseline and follow-up for participants with data collected at 3, 6 and 12 months by randomised treatment group
(continued )
Intervention


























Nature of bowel movement: mean number of days (out of 14) glycerine suppositories used
Low-volume TAI 18 26.5 (3.5) 26.7 (3.7) 28.0 (27.0–28.0) 28.0 (28.0–28.0) 15 26.7 (3.6) 27.5 (1.4) 28.0 (27.0–28.0) 28.0 (28.0–28.0) 12 26.3 (4.2) 26.1 (5.3) 28.0 (27.5–28.0) 28.0 (28.0–28.0)
High-volume TAI 18 26.6 (2.7) 26.8 (3.3) 28.0 (26.0–28.0) 28.0 (27.0–28.0) 17 25.6 (4.1) 27.4 (1.5) 28.0 (24.0–28.0) 28.0 (28.0–28.0) 13 26.7 (2.9) 27.6 (1.0) 28.0 (27.0–28.0) 28.0 (28.0–28.0)
EQ-VAS score (points)
Low-volume TAI 19 60.8 (22.7) 56.1 (26.0) 65.0 (45.0–75.0) 60.0 (40.0–75.0) 18 61.1 (21.2) 63.3 (22.4) 67.5 (50.0–75.0) 68.5 (60.0–80.0) 13 62.7 (21.9) 49.6 (19.6) 70.0 (60.0–75.0) 50.0 (40.0–64.0)
High-volume TAI 25 72.5 (19.0) 70.0 (25.9) 80.0 (65.0–90.0) 80.0 (62.0–90.0) 21 69.7 (19.2) 67.7 (22.4) 80.0 (50.0–80.0) 70.0 (49.0–85.0) 17 67.2 (20.4) 69.2 (22.1) 70.0 (50.0–80.0) 80.0 (50.0–85.0)
PHQ-9 score (points)
Low-volume TAI 19 9.7 (7.1) 9.1 (6.9) 10.0 (3.0–17.0) 6.0 (4.0–15.0) 19 9.4 (7.0) 9.3 (7.6) 8.0 (3.0–17.0) 5.0 (4.0–11.0) 14 9.6 (8.3) 11.4 (8.5) 6.5 (3.0–17.0) 9.5 (4.0–21.0)
High-volume TAI 24 6.6 (6.4) 8.1 (8.1) 5.0 (1.5–11.0) 4.0 (1.0–17.0) 21 6.0 (5.8) 6.6 (6.8) 3.0 (2.0–10.0) 4.0 (1.0–9.0) 18 6.4 (5.7) 7.1 (6.7) 5.0 (2.0–10.0) 6.0 (2.0–10.0)
GAD-7 score (points)
Low-volume TAI 19 7.8 (6.5) 6.9 (6.5) 6.0 (3.0–13.0) 6.0 (2.0–12.0) 19 7.6 (6.4) 7.4 (6.2) 5.0 (3.0–13.0) 7.0 (3.0–9.0) 14 7.7 (7.5) 9.9 (8.1) 4.5 (1.0–13.0) 9.0 (3.0–18.0)
High-volume TAI 24 6.0 (5.8) 6.9 (6.9) 4.0 (2.0–8.0) 4.0 (1.0–13.1) 21 4.8 (4.3) 5.9 (6.7) 4.0 (2.0–6.0) 4.0 (0.0–12.0) 18 4.9 (4.5) 6.6 (7.4) 4.0 (2.0–6.0) 3.5 (0.0–14.0)
Global patient satisfaction score (points)
Low-volume TAI 19 – 2.0 (1.2) – 2.0 (1.0–3.0) 19 – 2.5 (1.0) – 3.0 (2.0–3.0) 14 – 2.0 (1.2) – 2.0 (2.0–3.0)
High-volume TAI 24 – 2.6 (1.1) – 2.5 (2.0–3.5) 21 – 2.9 (0.9) – 3.0 (3.0–3.0) 18 – 2.8 (0.9) – 3.0 (3.0–3.0)
Global patient improvement score (points)
Low-volume TAI 19 – 40.4 (31.0) – 40.0 (11.0–70.0) 19 – 51.7 (30.1) – 56.0 (20.0–80.0) 14 – 46.4 (31.2) – 50.0 (20.0–70.0)
High-volume TAI 25 – 53.6 (28.7) – 60.0 (35.0–70.0) 21 – 70.2 (25.7) – 80.0 (70.0–85.0) 18 – 66.1 (24.6) – 75.0 (65.0–80.0)
a Data for this outcome was collected by treatment used and not treatment assigned.
Note































TABLE 20 The CapaCiTY trial 2 binary secondary outcomes (EQ-5D-5L score) at baseline and follow-up for patients with
data collected at 3, 6 and 12 months by randomised treatment group
Intervention



























Low-volume TAI 19 3 (15.8) 4 (21.1) 18 3 (16.7) 4 (22.2) 13 4 (30.8) 3 (23.1)
High-volume TAI 25 8 (32.0) 6 (24.0) 21 7 (33.3) 6 (28.6) 17 6 (35.3) 4 (23.5)
Self-care
Low-volume TAI 19 4 (21.1) 2 (10.5) 18 3 (16.7) 3 (16.7) 13 3 (23.1) 2 (15.4)
High-volume TAI 25 4 (16.0) 3 (12.0) 21 4 (19.0) 5 (23.8) 17 4 (23.5) 4 (23.5)
Usual activities
Low-volume TAI 19 9 (47.4) 7 (36.8) 18 8 (44.4) 6 (33.3) 13 8 (61.5) 8 (61.5)
High-volume TAI 25 12 (48.0) 9 (36.0) 21 10 (47.6) 7 (33.3) 17 7 (41.2) 6 (35.3)
Pain/discomfort
Low-volume TAI 19 16 (84.2) 19 (100.0) 18 15 (83.3) 14 (77.8) 13 11 (84.6) 10 (76.9)
High-volume TAI 25 22 (88.0) 18 (72.0) 21 18 (85.7) 13 (61.9) 17 14 (82.4) 10 (58.8)
Anxiety/depression
Low-volume TAI 19 12 (63.2) 12 (63.2) 18 11 (61.1) 10 (55.6) 13 6 (46.2) 11 (84.6)
High-volume TAI 24 13 (54.2) 13 (54.2) 21 11 (52.4) 10 (47.6) 17 9 (52.9) 9 (52.9)
Note
The results under each time point summarise only the data from participants with recorded outcomes at both baseline
and that follow-up time point.








Number of patients who switched from
low-volume to high-volume TAI
15 0 15
Number of patients who switched from
high-volume to low-volume TAI
4a 4 8
Number of patients who discontinued therapy 4 11 15




Sensation of incomplete evacuation 1 3 4
Frequent trips to the toilet 0 2 2
Satisfactory defaecation achieved with very low
volumes (< 300 ml)
0 1 1
No significant effect on symptoms or QoL 2 5 7
Treatment not acceptable to patient 0 1 1
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Safety analyses
The anal irrigation systems used in CapaCiTY trial 2 are widespread and established in clinical use throughout
the NHS, with known AEs (22%) being mostly low grade and reversible. All trial interventions were as
per the standard care provided in the NHS for CC. Related AEs and SAEs were recorded on the CRF and
in the medical notes to enable assessment and reporting in line with sponsor and regulatory requirements.
Causality was at the discretion of the health-care provider (e.g. research nurse, physiotherapist, principal
investigator, delegated member of team).
Serious adverse events that were considered ‘related’ and ‘unexpected’ were reported to the sponsor
within 24 hours of learning of the event and to the main REC within 15 days, in line with the required
time frame. The number of patients reporting AEs/SAEs was presented by trial group.









Excess bloating 0 1 1
Excess pain 0 3 3
Other AE 0 1 1
Other reason 1 1 2
Total 4 18 22
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FIGURE 13 Survival rate of TAI therapy: Kaplan–Meier plot for time to cessation of treatment (all participants).








Number of patients reporting the use of
concomitant medications
28 28 56
Number of concomitant medications reported 171 156 327
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The study (not being of a medicinal product) did not record unrelated AEs. SAEs and related AEs were
small in number, with six SAEs reported (Table 23). None of these was related to trial treatment and all
were resolved.
Results: cost-effectiveness
Summary and completeness of data
Participants were allocated randomly to low-volume or high-volume TAI. Variables used to estimate
costs and QALYs are described in Table 24. The average training time for the two methods was similar.
Participants were instructed to make daily use of their allocated method for the first 14 days, reducing
to alternate days depending on response. Estimated use of TAI was similar in the two groups during
the first month, but thereafter a difference emerged. Average daily use in the high-volume group
diminished over time, due primarily to the number of users diminishing, and there was very little
crossover to low-volume TAI. There was a similar decrease in low-volume TAI use but substantial
crossover to high-volume TAI over the duration of follow-up. The cost of TAI was the predominant
determinant of overall cost in each period. TAI treatment was provided as a prescription and the
baseline analysis estimated the number of prescriptions of TAI equipment received (see Table 24).
Levels of use of (non-irrigation) prescription drugs and community health-care were relatively low and
similar comparing groups. Hence, cost differences were driven by the intervention costs. Societal costs
reflected a minority (≈ 20%) of patients reporting substantial time away from work. Reported days
away from work in the periods 4–6 and 7–12 months suggest more return to work in the high-volume
group, contributing to a lower societal cost, although the cost difference is not statistically significant
(p = 0.34). Completeness of cost data diminishes as follow-up progresses from 86% in the first period
to 48% in the last period. Comparing QoL scores, there is an apparent trend of improving QoL in the
high-volume TAI group not apparent in the low-volume TAI group, although this may be confounded
by increasing missingness of data. Again, completeness of EQ-5D-5L data decreases as follow-up
proceeds, from 94% to 62%.
Cost-effectiveness analyses
The base-case model is reported in Table 25. Compared with low-volume TAI, high-volume TAI featured
similar costs (median difference –£8, 95% CI –£240 to £221) and significantly higher QoL (0.093 QALYs,
95% CI 0.016 to 0.175 QALYs); these findings are visualised in Figure 14. Incremental NMB values are
positive across the commonly used range ofWTP thresholds, indicating that high-volume TAI is cost-effective
and appears to deliver a gain to the health system compared with alternative choices.These findings are
presented as a CEAC showing the probability of being cost-effective at varyingWTP thresholds. At the
NICE-recommendedWTP threshold of £30,000 per QALY, the probability that high-volume TAI is a
cost-effective alternative to low-volume TAI is 99%.The EVPI (per subject) reflects the opportunity loss
of ongoing uncertainty. At a WTP threshold of £30,000 per QALY, EVPI per subject is just £2, reflecting
the certainty of the finding. Assuming that the finding is robust, this would indicate that further research
is not merited.
The complete-case analysis is also presented (see Table 26). Although numbers contributing are small,
the findings are similar to the base case, if less precise. The base-case analysis costed the number of
irrigation prescriptions received by each participant, assuming that unused portions of prescriptions
were lost. As a sensitivity analysis the number of daily uses was costed to provide greater granularity
to the costing. This marginally increased the incremental costs, but the overall finding remained robust.
Given the small numbers of participants in the trial, as a second sensitivity analysis the base-case
model was re-estimated as a univariate regression (NMB at varying WTP thresholds) to explore
distributional assumptions. Qualitatively, the finding was similar, although at a WTP threshold of
£30,000 per QALY the probability that high-volume TAI is cost-effective reduced to 91%.
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Number of patients reporting AE 11 5 16
Number of AEs reported
Abdominal cramping 1 0 1
Abdominal pain 3 3 6
Anal/rectal pain or discomfort 17 9 26
Constipation 1 0 1
Loose motions 1 0 1
Pain 1 4 5
Rectal bleeding 10 12 22
Miscellaneous 2 4 6
Severity
Mild 22 18 40
Moderate 8 12 20
Severe 4 2 6
Life-threatening 2 0 2
Action
No action taken 23 22 45
Withdrawal 0 3 3
Concomitant medication 5 5 10
Non-drug therapy 6 2 8
SAE, n
Number of patients reporting SAE 6 0 6
Number of SAEs reported
Life-threatening, unlikely to be related
Life-threatening, related
Required hospitalisation or prolongation of existing
hospitalisation, unlikely to be related
6 0 6
Required hospitalisation or prolongation of existing
hospitalisation, related
Expectedness
Expected 3 0 3
Unexpected 3 0 3
Action taken
No action taken 1 0 1
Non-drug therapy 1 0 1
Hospitalisation 4 0 4
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TABLE 24 The CapaCiTY trial 2 economic analysis variables (£, 2018)
Characteristic
Low-volume TAI (N= 30) High-volume TAI (N= 35)
Mean SD n Mean SD n
Resource use
0–1 months
Training time, hours 1.53 0.51 29 1.60 0.46 34
Low-volume TAI, days 21.90 0.00 24 0.00 0.00 32
High-volume TAI, days 0.00 0.00 30 19.29 6.70 35
Number of prescriptions 1.85 1.83 26 1.19 1.20 32
1–3 months
Low-volume TAI, days 22.23 14.41 21 0.00 0.00 26
High-volume TAI, days 3.54 9.17 30 14.30 12.86 35
Number of prescriptions 0.91 1.11 22 0.96 0.93 23
GP visits 0.05 0.22 21 0.00 0.00 22
District nurse visits 0.00 0.00 21 0.00 0.00 22
Pharmacist visits 0.05 0.22 21 0.50 1.47 22
A&E visits 0.19 0.68 21 0.00 0.00 22
Outpatient visits 0.05 0.22 21 0.18 0.39 22
Days from work 3.52 9.87 21 4.59 21.09 22
Inpatient visits 0.00 0.00 20 0.00 0.00 22
4–6 months
Low-volume TAI, days 16.82 20.88 22 0.33 1.60 32
High-volume TAI, days 12.87 17.24 30 15.28 17.90 35
Number of prescriptions 1.36 2.48 22 0.71 1.30 24
GP visits 0.05 0.22 20 0.04 0.21 23
District nurse visits 0.00 0.00 20 0.00 0.00 23
Pharmacist visits 0.40 1.19 20 0.00 0.00 23
A&E visits 0.05 0.22 20 0.04 0.21 23
Outpatient visits 0.55 0.60 20 0.17 0.39 23
Days from work 8.20 21.47 20 0.68 2.01 22
Inpatient visits 0.15 0.67 20 0.00 0.00 22
7–12 months
Low-volume TAI, days 10.50 22.50 20 1.84 10.55 33
High-volume TAI, days 16.23 29.92 30 22.20 31.84 35
Number of prescriptions 0.62 1.07 21 0.65 1.11 23
GP visits 0.29 0.69 17 0.05 0.23 19
District nurse visits 0.00 0.00 17 0.00 0.00 19
Pharmacist visits 0.06 0.24 17 0.05 0.23 19
A&E visits 0.00 0.00 17 0.00 0.00 19
Outpatient visits 0.24 0.44 17 0.26 0.65 19
Days from work 7.24 23.93 17 1.16 4.00 19
Inpatient visits 0.00 0.00 17 0.00 0.00 18
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TABLE 24 The CapaCiTY trial 2 economic analysis variables (£, 2018) (continued )
Characteristic
Low-volume TAI (N= 30) High-volume TAI (N= 35)
Mean SD n Mean SD n
NHS cost (£)
Treatment period (0–1 months) 370 110 24 462 69 32
1–3 months 294 132 18 284 152 21
4–6 months 525 340 19 435 277 20
7–12 months 556 359 14 565 305 17
Overall 1995 796 10 1816 629 15
Societal cost (£)
Overall 4985 6425 10 2803 3246 14
EQ-5D-5L
Baseline (0 months) 0.64 0.28 27 0.63 0.29 34
3 months 0.68 0.24 24 0.73 0.26 29
6 months 0.58 0.31 20 0.70 0.31 24
12 months 0.65 0.35 19 0.74 0.23 21
QALYs
0–12 months 0.62 0.37 10 0.72 0.26 15
Notes
Subtotals may not sum to totals because of different numbers of participants contributing.
Days from work included in societal cost but not in NHS cost.
Number of prescriptions includes all non-irrigation prescribed medication.























































a Probability cost-effective at WTP threshold of £15,000 per QALY.
b Probability cost-effective at WTP threshold of £30,000 per QALY.
c Denotes a dominant strategy: negative change in cost and positive change in QALYs.
d Irrigation cost per use.
e Univariate regression (NMB) of base case.
Notes
Bootstrapped 95% CIs; median ICERs.
Base-case and sensitivity analyses: imputed with 50 draws; assuming MAR.
Complete case: includes only participants with complete cost and QALY data; assuming missing completely at random.
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FIGURE 14 The CapaCiTY trial 2 cost-effectiveness analysis: base case. (a) ICER plane [the credible region (dashed circle)
shows where 95% of estimates lie]; (b) incremental NMB; (c) CEAC; and (d) EVPI. (continued )
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Results
Patient experience and qualitative analysis
Emergent themes are presented in this section. Numbers in square brackets refer to the numbered
quotations in Appendix 2, Quotations from participants contributing to qualitative analysis in all three trials,
CapaCiTY trial 2: transanal irrigation.
Rapport with nurse
Several patients mentioned the importance of the positive rapport that they had with the TAI nurse.
Staff echoed the importance of rapport and also indicated that demonstrating enthusiasm and belief in
the TAI system appeared to assist patients [1].
Transanal irrigation training
Patients recalled the TAI training as a positive experience and particularly liked that they had the option to
try the device either in clinic (for the first time) with the nurse close to hand or at home on their own [2].
Patients also found the telephone follow-up support reassuring [3, 4]. Staff noted the importance of these
follow-up support telephone calls and how they helped instil confidence in the patients.
Although the information about how to use the TAI system was clear, for some patients it was still a
lot of information to take in at once [5]. Therefore, the follow-up telephone calls allowed patients to
troubleshoot with the TAI nurse. Staff and patients both felt that the follow-up timings seemed
appropriate. For some patients it took a little getting used to the device [6]. However, several found
both high-volume and low-volume TAI devices relatively easy to use [7].
Initial expectations of transanal irrigation compared with actual experience
A number of patients spoke about their initial fears about whether or not TAI would be painful, and
several found that the device was more comfortable and easier to use than they initially thought. For a
few, the TAI system could be uncomfortable, particularly at the beginning [8].
Patient views on randomisation group
Patients views about which group they were randomised to varied. For some, because they had
struggled with constipation for years they wanted to have what they considered to be the most
effective intervention (i.e. high-volume TAI). Others, particularly if they had a fear of TAI being painful,
were pleased to have been in the low-volume TAI group [9]. However, initial trepidation often




















FIGURE 14 The CapaCiTY trial 2 cost-effectiveness analysis: base case. (a) ICER plane [the credible region (dashed circle)
shows where 95% of estimates lie]; (b) incremental NMB; (c) CEAC; and (d) EVPI.
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Practical experiences of using transanal irrigation
The time taken to use the TAI device ranged from 10 minutes with the low-volume device to 20–30 minutes
with the high-volume device. Patients reported using the TAI systems from once per week to several times
per week. Many appeared to have a relatively easy time obtaining the devices.
Some people found TAI relatively easy to fit into their daily routine [10], whereas for others it was
more difficult to factor into daily living [11]. A few patients noticed an improvement in their symptoms
immediately on using TAI, whereas for others the process took longer (up to a few months) to see
results [12]. Some (particularly in the high-volume TAI group) needed to get to grips with the technical
elements of using the device before they started to see results.
Impact of transanal irrigation on quality of life
Several patients chose to continue using their TAI device and have found it to be of great benefit in
terms of improving their overall health, mood and activity levels [13, 14]. They noted the psychological
impact of not having to worry about when they use the toilet, as they now have more control over
their bowels through using the TAI device. This means that they are able to plan their days more than
they could prior to TAI use. Some patients have noticed that if they did not use the device their
constipation symptoms began to return. Some stated that, because of their continued use of TAI, they
no longer considered themselves chronically constipated [15]. Others mentioned that, although they
did not feel that their bowels were ‘normal’, the TAI device had brought them back to their own sense
of ‘normal’. Irrigating daily allowed them to remove a little stool each day, relieving many of the
debilitating effects of CC.
For many, the freedom from the ongoing discomfort of CC was the best thing about using the TAI system.
Many stated that they would recommend TAI to someone experiencing CC. Some specifically stated
that TAI was preferrable to laxatives because of the side effects from these medicines (e.g. bloating,
uncontrolled bowels). A few had concerns about their ability to use the device in their later years, whereas
others were happy to continue use it indefinitely.
Frustrations with transanal irrigation
Although the devices appeared to work for the most part, there were occasions when TAI was not
as effective, which was frustrating for some. Many patients described that, at times, using the device
felt like a bit of a chore, but ultimately a chore worth doing because of the beneficial effects. Some
indicated that the most difficult part of the treatment was leakage [16]. For others the most difficult
part was finding a routine that worked for them.
One patient with no success with low-volume TAI switched to high-volume TAU. The high-volume TAI
system did not appear to relieve another patient’s symptoms and she chose to discontinue usage.
Suggestions from patients
Suggestions included:
l additional pages in the booklet to fill in thoughts and experiences of usage
l putting the kit together themselves at clinic
l having the same sex as the intervention nurse.
Staff experience of delivering the intervention
Intervention staff found TAI intervention delivery relatively easy because they typically provided
similar TAI support in their clinic. However, they also noted that they needed to be mindful of the
way that they delivered even the most seemingly straightforward information because assumptions
and miscommunication could contribute towards patients misusing the devices.
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Some nurses indicated that they believed that the low-volume TAI is easier for patients to learn and
usually quicker to use, but for this particular patient group it may be less effective. By contrast, the
high-volume system may seem more onerous, with more steps to learn, and may require perseverance,
but is usually more effective for this patient cohort [17].
For nurses, the most satisfying element of the intervention was when it benefited the patient. Likewise,
it was frustrating when nurses felt restricted to the research protocol.
These views highlight the clash between clinical agendas (to manage patient concerns with the most
suitable treatment) and research agendas (to test which treatments are most effective through
randomisation, which may not always be in the best interest of the individual patient).
Staff were often under the impression that high-volume TAI was the most appropriate and most
effective treatment for patients.
It was particularly difficult to convince patients who were allocated to low-volume TAI to ‘stick with’ a
treatment that nurses believed would not work. Specifically, it was difficult to persuade frustrated patients
with a long history of constipation to maintain an intervention that was not currently providing benefits.
However, a few nurses did indicate that it may have been helpful to start some patients on low-volume TAI
first, because the kit is somewhat easier to use, and then graduate patients up to high-volume TAI after
their confidence has increased.
At times participants were removed from the study in the best interest of the patient (e.g. if interventions
were not working). Furthermore, at times patients and/or staff did not believe that they could delay
treatment any longer, which affected recruitment rates.
CapaCiTY trial 3: stepped-wedge randomised trial of laparoscopic ventral
mesh rectopexy in adults with chronic constipation
Intervention
Participants attended for surgery at their allocated time, with admissions procedures as per routine
clinical care with normal preparation, for example bowel cleansing.
Surgical procedure
Perioperative care used normal adjuncts [including informed NHS consent, World Health Organization
surgical checklists, appropriate broad-spectrum antibiotic prophylaxis, venous thromboembolism
prevention, patient warming and urinary catheter insertion]. Surgery could be performed as a day case
procedure in an enhanced recovery programme, although most patients had an overnight stay. Consent
included discussion of the risks of conversion to open surgery and specific complications. A phosphate
enema or similar (optional) could be used to clear the rectum.
Figure 15 illustrates lapVMR surgical technique. Exact surgical technique was surgeon specific (i.e. based
on individual preference) but in accord with expert guidance and training. All participating surgeons
required sign-off by a delegated surgical team provided by the Pelvic Floor Society, an affiliate of the
Association of Coloproctology of Great Britain and Ireland. Where required, preceptorship was provided
to meet sign-off requirements.
In brief, after positioning the patient (in a modified lithotomy position on a non-slip mat) and port site
insertion (using standard equipment and technique), the rectosigmoid junction is retracted to the left
and a peritoneal incision is made over the right side of the sacral promontory and extended in an
inverted J form along the rectum and over the deepest part of the pouch of Douglas. Special care is
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taken not to damage the right hypogastric nerve. Denonvillier’s fascia is incised and the rectovaginal
septum is broadly opened. Limited rectal mobilisation and lateral dissection are performed as required
to expose the distal rectum and pelvic floor. A strip of trimmed mesh (biologic or synthetic) is inserted.
Using slowly absorbable sutures (polydioxanone recommended), the mesh is sutured to the ventral
aspect of the distal rectum and further fixed to the lateral seromuscular borders of the rectum
proximal and distal to the incised pouch of Douglas and/or pelvic floor. The proximal end of the mesh is
fixed on the sacral promontory using either sutures or an endofascia stapler. Limited traction is exerted
on the rectum as required to obliterate the intussusception and/or rectocele. If deemed necessary, the
posterior vaginal fornix may be elevated and sutured to the anterior aspect of the mesh; this allows
closure of the rectovaginal septum and correction of a mid-compartment prolapse, if present. The
lateral borders of the incised peritoneum are then closed over the mesh. This elevates the new pouch
of Douglas over the colpopexy and completely covers the mesh with peritoneum. No drain is usually
required. Ports should be closed directly [using an Endoclose™ device (Medtronic Ltd, Watford, UK) for
lateral ports] owing to the high risk of early and late port site hernias in this group of patients with
potential connective tissue laxity.
FIGURE 15 Laparoscopic ventral mesh rectopexy surgical technique. Reprinted by permission from Springer Nature:
Surgical Endoscopy, Laparoscopic ventral recto(colpo)pexy for rectal prolapse: surgical technique and outcome for
109 patients, D’Hoore et al.144 © 2006.
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Postoperative management
Postoperative management was as per routine clinical care, usually an overnight hospital stay followed
by urinary catheter removal, mobilisation and discharge. Postoperative laxative use was standardised
to a weaning course of Movicol (Macrogol, Norgine) or Laxido (Macrogol, Galen) three times per day
immediately postoperatively for 1 day, then reduced according to ease of bowel movements. This
prevented postoperative constipation from immobility, narcotics or general anaesthesia, which if left
untreated may cause painful straining on the mesh and thus protraction of the sacral promontory
periosteum, potentially leading to readmission. Surgeons aimed to discharge patients 1 day postoperatively.
However, length of stay was determined by clinical evaluation and could be longer if required.
Laparoscopic ventral mesh rectopexy 30-day follow-up
At 30 days, clinical recurrence of rectal prolapse was determined based on physical examination.
Morbidity and mortality data were collected and treatment administered for any complications arising
from lapVMR surgery. The 30-day readmission rates were also recorded. A CRF was used to capture
intra-operative and postoperative data for surgery-specific outcomes.
Surgical quality assessment
Monitoring and quality control were conducted remotely via video submission and assessed against the
standardised lapVMR protocol and defined assessment criteria. Monitoring took the form of planned,
random and triggered sessions.
Potential principal investigators had to record and submit two unedited and anonymised videos of lapVMR
performed in non-study patients. Each video was allocated to two peer reviewers of a three-member expert
panel. Based on blinded assessment of unedited and anonymised videos by expert review, the panel then
decided whether or not the principal investigator was ‘adherent’ to the standardised technique. Any
disagreement was resolved by consensus after consulting a third independent expert. If deemed ‘non-
adherent’ to the standardised technique, the site was notified that a step needed to be corrected and invited
to submit another video for similar review. An unedited video of the first patient at each site enrolled in
CapaCiTY trial 3 was also reviewed in this manner. Any ‘failure’ to comply with the standardised surgical
technique for lapVMR in any submitted video of a study patient would trigger the request for a further
submission of the next recruited patient from that centre. A second judgement of ‘non-adherence’ to the
standardised technique would trigger an onsite training and monitoring session for the site. Monitoring
would continue until adherence was achieved. A third ‘non-adherence’ or ‘failure’would result in withdrawal
of the site/principal investigator from the trial.
Random monitoring
All principal investigators had to record and submit the unedited and anonymised video of the lapVMR
performed in a randomly selected patient enrolled in CapaCiTY trial 3 (one in five at site level). The adherence
to the standardised technique was established by consensus as described for the planned monitoring.
Triggered monitoring
The DMC reviewed the morbidity and mortality rates and AEs and SAEs from all sites. Safety concerns
could trigger additional monitoring or onsite training and mentorship visits to take place by expert
panel. Repeated ‘non adherence’ or ‘failure’ to comply would result in withdrawal of the site/principal
investigator from the trial.
Standardisation of UK patient selection practice for surgery and laparoscopic ventral mesh
rectopexy technique
The CapaCiTY trial 3 required the recruitment of 80 patients to undergo lapVMR. At the time of
starting the programme this seemed easily achievable, with several UK centres performing > 100 such
operations per annum. It became abundantly clear, however, that many centres’ view of selecting
patients for surgery did not agree with expert opinion (even at that time) in terms of defining surgical target
pathophysiology (defined by INVEST) or in excluding patients with relative contraindications to surgery.
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The development of consensus in respect to this and other surgical approaches to patients with CC
was timely because it coincided with the rapid evolution of a media storm against the placement of
pelvic mesh and worldwide class actions against surgeons and manufacturers of mesh. Although
detrimental to recruitment, the increased rigour invoked by the programme in patient selection
probably protected some patients (and their surgeons) from further harm.
Selection of surgeons to participate in CapaCiTY trial 3 also required submission of two videos for
quality assurance of surgical technique. This highlighted not only unnecessary variation in technique
but also some practices that could promote harm from mesh (e.g. use of polyester sutures). Again,
although this actually delayed the study, it was probably beneficial to patients.
In regard to subsequent national and international scrutiny of mesh, work performed as part of this
programme has featured in national guidance by learned bodies,134 patient-facing information on
consent for surgery and several news reports.145
Design features
Basic design
We used a stepped-wedge randomised trial design to permit observer-masked data comparisons between
patients awaiting intervention and those who had undergone surgery. Contrary to most stepped-wedge trials,
individual patients rather than clusters were randomised. In brief, eligible participants were randomised to
three groups, with different delays before surgery (see Figure 6). In all groups there was a period of
4 weeks post eligibility to arrange the logistics of surgery (T–4 weeks to T0) and ensure that patients had
returned to their normal life routine after various assessments. LapVMR was performed at T0 in group 1,
T12 in group 2 and T24 in group 3. Unavoidably, participants were aware when surgery was undertaken;
however, this fortuitously met the assumptions of the stepped-wedge design (i.e. no effect of treatment
is expected until surgery has been performed). Efficacy outcome data were collected at equally stepped
time points (T0, T12, T24, T36 and T48).
This was, in effect, a modification of a standard parallel-group, waiting-list control design, but with
several advantages. First, a stepped-wedge design is more efficient and thus improves recruitment
feasibility (the major hurdle of nearly all surgical trials). Despite the multicentre approach of this study,
the problems of recruitment were manifest. Simulation demonstrated that a parallel-group design
required a much larger sample size than that proposed for the current study at the same power.
Second, the trial design meant that there was only a one-in-three chance (rather than one-in-two
chance for a parallel group) of waiting 6 months for surgery, which was more acceptable to patients
(see Work programme 5, Patient and public involvement).
Sample size calculation
Sample size was calculated using the primary clinical outcome (PAC-QoL score), but with a 1.0-point change
deemed clinically important and sufficient to justify the cost and invasive nature of lapVMR. Previous surgical
trials had shown a 1-point decrease in PAC-QoL score from pre surgery to 48 weeks (approximately 1 year)
post surgery.131 Using a stepped-wedge design, we hypothesised that PAC-QoL score at any time point
during follow-up would be approximately 1.0 points lower than in preoperative participants.
Sample size was calculated by simulation using the ‘simsam’ package in Stata. We assumed that PAC-QoL
score followed a normal distribution over all time points with a SD of 1.5 points and with a correlation
between repeated assessments equal to 0.5 points. Simulation showed that detection of a 1.0-point
difference in 6-month PAC-QoL score, with 95% power (purposely chosen to reflect the magnitude and
risk of intervention) at the 5% significance level, required 34 participants in each of the three groups.
Allowing for a 10% loss to follow-up, a sample size of 38 was needed per group (i.e. a total sample size
of 114 patients across the three groups). Should the correlation between repeated assessments be
< 0.5 points, a sample size of 114 will still provide at least 90% power for the study. This was calculated
using the same simulation procedure with correlations of 0.3 and 0.1 points.
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Randomisation procedure
Randomisation to the three trial groups (1 : 1 : 1) was stratified by sex, and female participants further
stratified by centre (for the reasons outlined for CapaCiTY trial 2; in fact, only females were recruited).
Blinding
Patients and clinicians were necessarily aware of allocation to different waiting times. Quantitative
outcomes were collected by investigators unaware of the before or after status of the patient in
respect of surgery, and analysis was performed blind to allocation status.
Concomitant medications
Methods as for CapaCiTY trial 1, with recorded ad libitum use.
Statistical methods
Primary outcome
Total PAC-QoL scores at the time points T0, T12, T24, T36, T48, T60 and T72 in the three groups were
analysed using a mixed linear regression model, with random effects for participants and a fixed effect of
time since randomisation (potentially considering a random effect for time as well to relax the assumption
of same time trend for each participant) to estimate mean differences between PAC-QoL score before and
after lapVMR. The comparison of primary interest was between PAC-QoL score at 24 weeks after surgery
and PAC-QoL score at baseline. A correction was included in the model to account for the small sample
size. Missing data were imputed through multiple imputation by chained equations.
Secondary outcomes
Total PAC-SYM scores were analysed using the approach described in the paragraph above. All other
secondary clinical outcomes derived from the standardised outcome framework were analysed only
at 24 and 48 weeks post operatively. We present mostly descriptive statistics, with simple regression
models used to obtain CIs for the results. Results obtained using the CC-BRQ and BIPQ-CC have been
omitted pending further analysis.
Because of the nature of the intervention (i.e. pelvic surgery), a further outcome was included in
CapaCiTY trial 3 (not included in CapaCiTY trials 1 and 2). The Pelvic Organ Prolapse/Urinary
Incontinence Sexual Questionnaire-12 (PISQ-12) is a self-administered questionnaire that evaluates
sexual function in heterosexual women with urinary incontinence and/or pelvic organ prolapse. It has
12 items; responses are graded on a 5-point Likert scale from ‘never’ to ‘always’. Scores are calculated
by totalling the scores for each question, with 0 indicating never and 4 indicating always. Reverse
scoring is used for items 1–4. It can be used with up to two missing responses. To handle missing
values, the sum is calculated by multiplying the number of items by the mean of answered items.
The PISQ-12 scores can be reported only as a total or on a per-item basis.
All participants randomised to the three groups were analysed according to their allocation ± 2 weeks
from the scheduled intervention date.
Cost-effectiveness
Patients were randomised in a stepped-wedge design to (1) immediate lapVMR, (2) lapVMR after a
12-week delay or (3) lapVMR after a 24-week delay. The design was chosen because of efficiency
considerations and the logistical constraint of participants wanting surgery. The stepped-wedge design
we adopted has three steps and features a closed cohort in which all patients spend time as controls
and treated patients. Although the within-patient design is efficient, the step ‘placing’ creates particular
challenges for the cost-effectiveness analysis. Economic analysis requires balanced time receiving
alternatives to estimate incremental costs and QALYs. The value of surgery may be demonstrated over
time frames of 1 or 2 years, and require a balanced pre-surgery period. Patient follow-ups were
between 48 and 72 weeks post surgery. However, even using the screening visit as an approximate
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–12-week time point, each patient had between only 12 and 36 weeks’ pre-surgery follow-up. As has
been reported, this trial was also severely hampered by under-recruitment. In an exploratory analysis,
the trial was analysed as a simple pre–post within-patient design. Data were too sparse to use
multiple imputation to cover an adequate pre-surgery period or postsurgery period beyond 48 weeks.
Consequently, growth curve analyses (hierarchical generalised linear model) were used to describe and
model pre-surgery and postsurgery trends. These models suggest that pre-surgery EQ-5D-5L scores
and costs were constant and could reasonably be used to estimate EQ-5D-5L scores and costs at
48 weeks pre surgery using a ‘first observation carried back’ (FOCB) approach. The pre-surgery
period was then conflated into a single period in subsequent analyses to reduce spurious precision.
Postsurgery growth curve analysis found stable (non-surgery) costs and that EQ-5D-5L scores,
although initially improving, returned to pre-surgery levels by 48 weeks, obviating the need for further
extrapolation post surgery. An assumption of the approach taken is that there is no confounding with
time (secular change). Although delay to surgery was to be explored in regression of costs and QALYs,
the available sample is too underpowered to detect differences. No discounting was applied to economic
data in CapaCiTY trial 3, reflecting the within-patient comparison of 48 weeks pre surgery and 48 weeks
post surgery.
Recruitment
First recruitment occurred on 1 March 2016 and first intervention on 15 June 2016. Recruitment
ended on 31 January 2019. A total of 28 (target 114) patients were randomised out of 81 screened
(30.9%) from six sites. Reasons for screen failure are shown in Figure 16. Two sites opened but failed to
recruit and one site failed to randomise; the remaining sites (n = 6) randomised 1–11 patients. Among
the 28 patients randomised, nine patients were randomised to immediate surgery, 10 patients were
randomised to a 12-week waiting list and nine patients were randomised to a 24-week waiting list. Six
patients failed to complete the primary outcome at 24 weeks, among whom two dropped out of the
study, which was therefore completed by 19 patients. The CONSORT flow diagram is shown in Figure 7.
Baseline characteristics
Table 26 shows the numbers and percentages of patients with baseline characteristics by trial group.
Continuous variables (e.g. age) were summarised by treatment group using mean and SD (median and
IQR if non-normally distributed). Table 27 shows the data for outcome measures at baseline. These
were comparable between the two groups for all major characteristics.
Age (years)
Diet, lifestyle and laxative/prokinetics naive
Previous specialist nurse-led bowel
management naive
English language barrier
Overt pelvic organ prolapse or
surgery required
Previous pelvic floor surgery including SNS;
previous rectopexy
Significant neurological disease












FIGURE 16 The CapaCiTY trial 3 screen failures. SNS, sacral nerve stimulation.
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(N= 9) Total (N= 28)
Referral method, n (%)
Secondary care 5 (55.6) 6 (60.0) 4 (44.4) 15 (53.6)
Tertiary care 3 (33.3) 4 (40.0) 5 (55.6) 12 (42.9)
Other 1 (11.1) 0 (0.0) 0 (0.0) 1 (3.6)
Demographic characteristic
Sex, n (%)
Female 9 (100.0) 10 (100.0) 9 (100.0) 28 (100.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ethnicity, n (%)
Asian 0 (0.0) 0 (0.0) 1 (11.1) 1 (3.6)
Black 0 (0.0) 1 (10.0) 0 (0.0) 1 (3.6)
Mixed 1 (11.1) 0 (0.0) 0 (0.0) 1 (3.6)
White 8 (88.9) 9 (90.0) 8 (88.9) 25 (89.3)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Age (years)
Mean (SD) 52.7 (14.3) 52.9 (14.4) 53.4 (9.8) 53.0 (12.6)
Median (IQR) 59.0 (39.0–66.0) 56.0 (42.0–64.0) 55.0 (49.0–58.0) 55.0 (42.0–64.5)
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Past medical history, n (%)
Total 7 (77.8) 9 (90.0) 6 (66.7) 22 (78.6)
Cardiovascular condition 4 (44.4) 3 (30.0) 1 (11.1) 8 (28.6)
Heart disease 0 (0.0) 1 (10.0) 0 (0.0) 1 (3.6)
Hypertension 3 (33.3) 2 (20.0) 1 (11.1) 6 (21.4)
Hypercholesterolaemia 2 (22.2) 1 (10.0) 1 (11.1) 4 (14.3)
Other 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Respiratory condition 0 (0.0) 2 (20.0) 1 (11.1) 3 (10.7)
Asthma 0 (0.0) 2 (20.0) 1 (11.1) 3 (10.7)
COPD 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Gastrointestinal condition 5 (55.6) 3 (30.0) 2 (22.2) 10 (35.7)
IBS 3 (33.3) 3 (30.0) 1 (11.1) 7 (25.0)
Crohn’s disease 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ulcerative colitis 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Cancer 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Colonic polyps 1 (11.1) 0 (0.0) 0 (0.0) 1 (3.6)
Other 2 (22.2) 0 (0.0) 1 (11.1) 3 (10.7)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110










(N= 9) Total (N= 28)
Metabolic condition 0 (0.0) 3 (30.0) 4 (44.4) 7 (25.0)
Diabetes 0 (0.0) 1 (10.0) 1 (11.1) 2 (7.1)
Hypothyroidism 0 (0.0) 2 (20.0) 3 (33.3) 5 (17.9)
Hyperthyroidism 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other 0 (0.0) 0 (0.0) 1 (11.1) 1 (3.6)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Haematological condition 2 (22.2) 1 (10.0) 0 (0.0) 3 (10.7)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hepatic condition 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Renal disease 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Genito-urinary condition 2 (22.2) 0 (0.0) 2 (22.2) 4 (14.3)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Neurological/CNS
condition
2 (22.2) 4 (40.0) 3 (33.3) 9 (32.1)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Psychiatric condition 2 (22.2) 5 (50.0) 4 (44.4) 11 (39.3)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Dermatological condition 1 (11.1) 3 (30.0) 1 (11.1) 5 (17.9)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Musculoskeletal condition 3 (33.3) 2 (20.0) 3 (33.3) 8 (28.6)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other condition 0 (0.0) 1 (10.0) 0 (0.0) 1 (3.6)
Past surgical history, n (%)
Total 5 (55.6) 10 (100.0) 7 (77.8) 22 (78.6)
Abdominal operation 2 (22.2) 3 (30.0) 2 (22.2) 7 (25.0)
Gynaecological procedure 4 (44.4) 9 (90.0) 5 (55.6) 18 (64.3)
Proctological or perineal
procedure
0 (0.0) 4 (40.0) 1 (11.1) 5 (17.9)
Neuromodulation 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Duration (months) of constipation symptoms
Mean (SD) 68.7 (36.9) 63.3 (31.6) 76.6 (55.4) 69.5 (41.3)
Missing, n (%) 0 (0.0) 1 (10.0) 0 (0.0) 1 (3.6)
Previous lifestyle modifications, n (%)
Total 9 (100.0) 10 (100.0) 9 (100.0) 28 (100.0)
Diet 9 (100.0) 10 (100.0) 9 (100.0) 28 (100.0)
Fluid 9 (100.0) 10 (100.0) 9 (100.0) 28 (100.0)
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(N= 9) Total (N= 28)
Exercise 7 (77.8) 10 (100.0) 7 (77.8) 24 (85.7)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Alternative therapies, n (%)
Total 1 (11.1) 1 (10.0) 1 (11.1) 3 (10.7)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Laxatives, n (%)
Total 9 (100.0) 10 (100.0) 9 (100.0) 28 (100.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Antidiarrhoeals, n (%)
Total 0 (0.0) 2 (20.0) 1 (11.1) 3 (10.7)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Prokinetics, n (%)
Total 1 (11.1) 3 (30.0) 2 (22.2) 6 (21.4)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nurse-led bowel management, n (%)
Total 9 (100.0) 10 (100.0) 9 (100.0) 28 (100.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Family history of bowel disease, n (%)
IBS 2 (22.2) 2 (20.0) 2 (22.2) 6 (21.4)
IBD 0 (0.0) 0 (0.0) 1 (11.1) 1 (3.6)
Gastrointestinal cancer 1 (11.1) 3 (30.0) 2 (22.2) 6 (21.4)
Other 1 (11.1) 2 (20.0) 0 (0.0) 3 (10.7)
Missing 0 (0.0) 1 (10.0) 0 (0.0) 1 (3.6)
Sexual history (female participants only), n (%)
Sexually active 5 (55.6) 6 (60.0) 3 (33.3) 14 (50.0)
Child-bearing potential 4 (44.4) 4 (40.0) 4 (44.4) 12 (42.9)
> 1 year post menopausal 3 (33.3) 6 (60.0) 4 (44.4) 13 (46.4)
Surgically sterile 3 (33.3) 5 (50.0) 4 (44.4) 12 (42.9)
Contraceptive use (female participants only), n (%)
Total 2 (22.2) 2 (20.0) 3 (33.3) 7 (25.0)
Barrier 0 (0.0) 1 (10.0) 0 (0.0) 1 (3.6)
Non-barrier 2 (22.2) 1 (10.0) 3 (33.3) 6 (21.4)
Missing 4 (44.4) 3 (30.0) 1 (11.1) 8 (28.6)
Past obstetric history (female participants only)
Total, n (%) 9 (100.0) 10 (100.0) 9 (100.0) 28 (100.0)
Number of vaginal
deliveries, mean (SD)
2.1 (1.1) 2.5 (1.1) 2.7 (1.0) 2.4 (1.0)
Number of caesareans,
mean (SD)
1.0 (1.1) 0.1 (0.3) 0.4 (1.0) 0.5 (0.9)
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0.2 (0.7) 0.5 (0.7) 0.3 (0.7) 0.4 (0.7)
Number of episiotomies,
mean (SD)
1.1 (1.1) 0.2 (0.4) 1.0 (1.2) 0.8 (1.0)
Number of obstetric
tears, mean (SD)
0.6 (0.7) 0.4 (0.5) 0.6 (0.5) 0.5 (0.6)
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Faecal incontinence symptoms, n (%)
Total 7 (77.8) 9 (90.0) 7 (77.8) 23 (82.1)
Faecal urgency 4 (44.4) 8 (80.0) 5 (55.6) 17 (60.7)
Urge faecal incontinence 5 (55.6) 6 (60.0) 3 (33.3) 14 (50.0)
Passive faecal
incontinence
4 (44.4) 6 (60.0) 3 (33.3) 13 (46.4)
Postdefaecation leakage 5 (55.6) 4 (40.0) 4 (44.4) 13 (46.4)
Difficulty wiping clean 6 (66.7) 5 (50.0) 4 (44.4) 15 (53.6)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Pelvic organ prolapse symptoms, n (%)
Total 6 (66.7) 5 (50.0) 7 (77.8) 18 (64.3)
Vaginal bulging 6 (66.7) 5 (50.0) 7 (77.8) 18 (64.3)
External rectal prolapse 1 (11.1) 0 (0.0) 0 (0.0) 1 (3.6)
External uterine prolapse 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
COPD, chronic obstructive pulmonary disease; IBD, inflammatory bowel disease.
a One patient dropped out before surgery (see Figure 7).














Overall, mean (SD) 2.7 (0.6) 2.7 (0.6) 2.5 (0.8) 2.6 (0.6)
Missing, n (%) 1 (11.1) 0 (0.0) 1 (11.1) 2 (7.1)
Dissatisfaction,
mean (SD)
3.1 (0.6) 3.1 (0.4) 3.2 (0.9) 3.1 (0.6)
Missing, n (%) 1 (11.1) 0 (0.0) 1 (11.1) 2 (7.1)
Physical discomfort,
mean (SD)
2.7 (0.6) 2.9 (0.6) 2.7 (0.5) 2.8 (0.6)
Missing, n (%) 1 (11.1) 0 (0.0) 1 (11.1) 2 (7.1)
Psychosocial
discomfort, mean (SD)
2.3 (0.9) 2.3 (0.9) 2.1 (0.9) 2.2 (0.9)
Missing, n (%) 1 (11.1) 0 (0.0) 1 (11.1) 2 (7.1)
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2.7 (0.7) 2.8 (0.7) 2.5 (1.0) 2.7 (0.8)
Missing, n (%) 1 (11.1) 0 (0.0) 1 (11.1) 2 (7.1)
PAC-SYM score (points)
Overall, mean (SD) 2.3 (0.4) 2.1 (0.6) 2.3 (0.7) 2.2 (0.6)
Missing, n (%) 1 (11.1) 1 (10.0) 0 (0.0) 2 (7.1)
Stool symptoms,
mean (SD)
2.7 (0.7) 2.1 (0.9) 2.5 (1.3) 2.4 (1.0)
Missing, n (%) 1 (11.1) 1 (10.0) 0 (0.0) 2 (7.1)
Abdominal symptoms,
mean (SD)
2.3 (0.6) 2.5 (0.8) 2.4 (0.8) 2.4 (0.7)
Missing, n (%) 1 (11.1) 1 (10.0) 0 (0.0) 2 (7.1)
Rectal symptoms,
mean (SD)
1.5 (0.7) 1.6 (1.2) 2.0 (1.2) 1.7 (1.0)
Missing, n (%) 1 (11.1) 1 (10.0) 0 (0.0) 2 (7.1)
Bowel frequency, number reported over 14 days (diary data)
Attempts to empty
bowels, mean (SD)
41.3 (16.2) 43.9 (27.6) 45.1 (23.2) 43.5 (22.0)




21.3 (14.5) 36.5 (18.7) 24.4 (20.8) 27.8 (18.6)
Missing, n (%) 2 (22.2) 2 (20.0) 2 (22.2) 6 (21.4)
Nature of bowel movement, number of days out of 14 (diary data)
Laxatives used,
mean (SD)
20.4 (5.7) 24.1 (6.6) 22.3 (6.6) 22.3 (6.2)




27.7 (0.8) 27.7 (0.8) 27.6 (0.8) 27.7 (0.7)
Missing, n (%) 2 (22.2) 3 (30.0) 2 (22.2) 7 (25.0)
EQ-5D-5L: ‘no problem’ indicated, n (%)
Mobility 4 (44.4) 2 (20.0) 4 (44.4) 10 (35.7)
Missing 2 (22.2) 1 (10.0) 0 (0.0) 3 (10.7)
Self-care 1 (11.1) 1 (10.0) 1 (11.1) 3 (10.7)
Missing 2 (22.2) 1 (10.0) 0 (0.0) 3 (10.7)
Usual activities 5 (55.6) 7 (70.0) 6 (66.7) 18 (64.3)
Missing 2 (22.2) 1 (10.0) 0 (0.0) 3 (10.7)
Pain/discomfort 7 (77.8) 9 (90.0) 9 (100.0) 25 (89.3)
Missing 2 (22.2) 1 (10.0) 0 (0.0) 3 (10.7)
Anxiety/depression 6 (66.7) 4 (40.0) 6 (66.7) 16 (57.1)
Missing 2 (22.2) 1 (10.0) 0 (0.0) 3 (10.7)
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Results: clinical effectiveness
Results for the primary outcome (i.e. PAC-QoL score) at 24 weeks (the primary end point) and at other
time points are shown in Table 28. There was a substantive reduction in estimated PAC-QoL score at
24 weeks compared with the baseline of 1.09 points (p = 0.0019), exceeding that sought by design
(1.0 points). A similar magnitude of change was observed for the modelled secondary outcome (i.e.
PAC-SYM score). Reductions in scores were sustained at later time points, accepting a strong chance
of attrition bias.
Secondary outcomes are shown in Tables 29 (continuous) and 30 (binary). These show positive directional
effects for nearly all outcomes, with some quite substantial improvements in measures, including > 25%
scalar improvements in psychological measures (PHQ-9 score, GAD-7 score, St Mark’s Incontinence Score
and EQ-VAS score). Global patient satisfaction was 2.7 points at 24 weeks (i.e. closest to ‘very satisfied’),
although this dropped to 2.2 points (i.e. closest to ‘moderately satisfied’) at 48 weeks. This result was
mirrored in the global patient improvement score (EQ-VAS score 0–100 points between ‘no effect’ and
‘complete cure’), which was 72.2 points at 24 weeks and 56.5 points at 48 weeks.














Total, mean (SD) 59.3 (14.3) 53.4 (23.0) 63.3 (17.3) 58.6 (18.6)
Missing, n (%) 2 (22.2) 1 (10.0) 0 (0.0) 3 (10.7)
PHQ-9 depression severity, n (%)
None 5 (55.6) 2 (20.0) 3 (33.3) 10 (35.7)
Mild 1 (11.1) 4 (40.0) 3 (33.3) 8 (28.6)
Moderate 2 (22.2) 1 (10.0) 1 (11.1) 4 (14.3)
Moderately severe 0 (0.0) 0 (0.0) 2 (22.2) 2 (7.1)
Severe 0 (0.0) 2 (20.0) 0 (0.0) 2 (7.1)
Missing 1 (11.1) 1 (10.0) 0 (0.0) 2 (7.1)
GAD-7 anxiety severity, n (%)
None 4 (44.4) 4 (40.0) 4 (44.4) 12 (42.9)
Mild 3 (33.3) 1 (10.0) 3 (33.3) 7 (25.0)
Moderate 0 (0.0) 2 (20.0) 1 (11.1) 3 (10.7)
Severe 1 (11.1) 2 (20.0) 1 (11.1) 4 (14.3)
Missing 1 (11.1) 1 (10.0) 0 (0.0) 2 (7.1)
St Mark’s Incontinence Score (points)
Total, mean (SD) 12.4 (3.6) 11.7 (5.9) 11.3 (4.7) 11.8 (4.7)
Missing, n (%) 1 (11.1) 0 (0.0) 1 (11.1) 2 (7.1)
PISQ-12 score (points)
Total, mean (SD) 19.3 (7.1) 21.4 (6.7) 20.8 (5.4) 20.5 (6.1)
Missing, n (%) 2 (22.2) 3 (30.0) 0 (0.0) 5 (17.9)
Note that, owing to the lack of male participants, male sexual health outcomes are not summarised in this report.
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TABLE 28 The PAC-QoL and PAC-SYM scores at baseline and follow-up points post surgery, with 95% CI and p-value for
















Baseline 26 2.63 – – –
12 weeks 23 1.35 –1.04 –1.54 to –0.55 0.0001
24 weeks 19 1.26 –1.09 –1.76 to –0.41 0.0019
36 weeks 19 1.47 –0.98 –1.87 to –0.10 0.0296
48 weeks 17 1.43 –1.07 –2.16 to 0.02 0.0552
60 weeks 9 1.22 –1.26 –2.56 to 0.05 0.0587
72 weeks 5 1.11 –1.38 –2.94 to 0.19 0.0840
PAC-SYM
Baseline 26 2.24 – – –
12 weeks 23 1.15 –0.97 –1.41 to –0.53 0.0000
24 weeks 18 1.19 –0.92 –1.52 to –0.32 0.0029
36 weeks 19 1.25 –1.03 –1.80 to –0.26 0.0094
48 weeks 17 1.36 –0.97 –1.92 to –0.02 0.0444
60 weeks 9 1.19 –1.16 –2.28 to –0.03 0.0448
72 weeks 5 0.82 –1.51 –2.87 to –0.16 0.0289
All estimates are adjusted for time.
TABLE 29 Continuous secondary outcomes, with unadjusted estimate of difference in mean scores at 24 and 48 weeks
post surgery compared with baseline
Time n Mean (SD) Median (IQR) Difference in means (95% CI)
PAC-QoL score (points)
Dissatisfaction
Baseline 26 3.1 (0.6) 3.1 (2.8–3.6) Reference
24 weeks 19 1.8 (1.0) 1.8 (1.0–2.4) –1.3 (–1.8 to –0.8)
48 weeks 17 2.1 (1.0) 2.0 (1.4–2.8) –1.0 (–1.5 to –0.5)
Physical discomfort
Baseline 26 2.8 (0.6) 2.8 (2.5–3.0) Reference
24 weeks 19 1.3 (0.9) 1.3 (0.5–1.8) –1.5 (–2.0 to –1.0)
48 weeks 17 1.6 (1.1) 1.5 (0.8–2.0) –1.1 (–1.6 to –0.6)
Psychosocial discomfort
Baseline 26 2.2 (0.9) 2.2 (1.5–3.0) Reference
24 weeks 19 0.9 (0.7) 0.9 (0.3–1.5) –1.3 (–1.8 to –0.8)
48 weeks 17 1.0 (0.9) 0.6 (0.1–1.4) –1.2 (–1.8 to –0.7)
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TABLE 29 Continuous secondary outcomes, with unadjusted estimate of difference in mean scores at 24 and 48 weeks
post surgery compared with baseline (continued )
Time n Mean (SD) Median (IQR) Difference in means (95% CI)
Worries and concerns
Baseline 26 2.7 (0.8) 2.9 (2.1–3.3) Reference
24 weeks 19 1.3 (1.0) 1.2 (0.5–2.0) –1.4 (–2.0 to –0.8)
48 weeks 17 1.4 (1.2) 1.0 (0.5–1.7) –1.3 (–1.9 to –0.7)
Stool symptoms
Baseline 26 2.4 (1.0) 2.6 (2.0–3.2) Reference
24 weeks 18 1.2 (0.7) 1.3 (0.8–1.6) –1.2 (–1.8 to –0.6)
48 weeks 17 1.6 (1.0) 1.4 (0.8–2.4) –0.9 (–1.5 to –0.3)
Abdominal symptoms
Baseline 26 2.4 (0.7) 2.4 (2.0–2.8) Reference
24 weeks 18 1.4 (1.0) 1.3 (0.8–1.8) –1.0 (–1.5 to –0.5)
48 weeks 17 1.5 (0.8) 1.5 (1.0–2.0) –0.9 (–1.4 to –0.4)
Rectal symptoms
Baseline 26 1.7 (1.0) 1.7 (1.0–2.0) Reference
24 weeks 18 0.8 (0.5) 0.7 (0.3–1.0) –0.9 (–1.4 to –0.3)
48 weeks 17 0.8 (1.0) 0.7 (0.3–1.0) –0.9 (–1.4 to –0.3)
Diary data
Bowel frequency: mean number of attempts to empty bowels over 2 weeks
Baseline 22 43.5 (22.0) 45.5 (28.0–61.0) Reference
24 weeks 20 22.9 (18.1) 19.0 (11.5–25.0) –20.5 (–32.5 to –8.5)
48 weeks 15 30.6 (16.6) 30.0 (19.0–44.0) –12.9 (–25.9 to 0.1)
Bowel frequency: mean number of times stool was passed over 2 weeks
Baseline 22 27.8 (18.6) 19.5 (15.0–46.0) Reference
24 weeks 21 17.3 (12.2) 14.0 (8.0–22.0) –10.5 (–20.1 to –0.9)
48 weeks 15 21.3 (15.3) 19.0 (10.0–26.0) –6.6 (–17.1 to 4.0)
Nature of bowel movement: mean number of days (out of 14) laxatives used
Baseline 21 22.3 (6.2) 26.0 (15.0–28.0) Reference
24 weeks 21 23.7 (4.7) 24.0 (21.0–28.0) 1.4 (–2.0 to 4.7)
48 weeks 15 22.7 (5.3) 25.0 (18.0–28.0) 0.4 (–3.3 to 4.1)
Nature of bowel movement: mean number of days (out of 14) glycerine suppositories used
Baseline 21 27.7 (0.7) 28.0 (28.0–28.0) Reference
24 weeks 21 26.5 (2.7) 28.0 (26.0–28.0) –1.1 (–2.2 to –0.0)
48 weeks 15 27.4 (1.1) 28.0 (27.0–28.0) –0.3 (–1.5 to 0.9)
EQ-VAS score (points)
Baseline 25 58.6 (18.6) 60.0 (40.0–75.0) Reference
24 weeks 20 73.7 (17.1) 77.0 (60.0–90.0) 15.1 (4.1 to 26.1)
48 weeks 17 68.2 (19.3) 70.0 (60.0–80.0) 9.6 (–1.9 to 21.1)
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TABLE 29 Continuous secondary outcomes, with unadjusted estimate of difference in mean scores at 24 and 48 weeks
post surgery compared with baseline (continued )
Time n Mean (SD) Median (IQR) Difference in means (95% CI)
PHQ-9 score (points)
Baseline 26 8.0 (6.5) 5.0 (4.0–11.0) Reference
24 weeks 18 6.1 (6.0) 4.5 (2.0–9.0) –2.0 (–6.0 to 2.0)
48 weeks 17 6.7 (7.0) 3.0 (2.0–10.0) –1.3 (–5.4 to 2.7)
GAD-7 score (points)
Baseline 26 7.1 (6.4) 6.5 (2.0–10.0) Reference
24 weeks 18 5.0 (6.1) 2.5 (0.0–7.0) –2.1 (–5.9 to 1.6)
48 weeks 17 4.4 (5.7) 2.0 (1.0–6.0) –2.8 (–6.6 to 1.1)
Global patient satisfaction score (points)
Baseline NA NA NA NA
24 weeks 18 2.7 (0.8) 3.0 (2.0–3.0) NA
48 weeks 17 2.2 (1.3) 3.0 (1.0–3.0) NA
Global patient improvement score (points)
Baseline NA NA NA NA
24 weeks 18 72.2 (25.0) 80.0 (67.0–88.0) NA
48 weeks 17 56.5 (34.6) 75.0 (25.0–80.0) NA
St Mark’s Incontinence Score (points)
Baseline 26 11.8 (4.7) 13.0 (8.0–16.0) Reference
24 weeks 16 8.7 (4.5) 8.5 (4.5–13.0) –3.1 (–6.3 to 0.1)
48 weeks 17 8.7 (5.8) 8.0 (3.0–15.0) –3.1 (–6.2 to 0.1)
PISQ-12 score (points)
Baseline 23 20.5 (6.1) 21.0 (15.0–25.0) Reference
24 weeks 12 18.8 (5.9) 18.0 (15.5–22.5) –1.7 (–5.7 to 2.4)
48 weeks 12 17.3 (4.5) 17.0 (14.5–19.0) –3.2 (–7.3 to 0.9)
NA, not applicable.
Male sexual health outcomes in the Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form (MSHQ-EjD
Short Form) omitted owing to lack of male participants.
TABLE 30 Binary secondary outcomes, with unadjusted estimate of ORs, comparing scores at 24 and 48 weeks post
surgery and baseline
Time point n/N (%) OR (95% CI)
PAC-QoL score, ≥ 1-point reduction
Baseline NA/NA NA
24 weeks 11/18 (61.1) NA
48 weeks 7/16 (43.8) NA
EQ-5D-5L, problems indicated
Mobility
Baseline 10/25 (40.0) NA
24 weeks 7/20 (35.0) 0.81 (0.24 to 2.73)
48 weeks 5/17 (35.0) 0.63 (0.17 to 2.33)
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Adherence to treatment
The numbers of patients (1) undergoing surgery as planned and (2) reporting that they were taking
confounding medications, including those bought over the counter and numbers of confounding
medications used, are presented by trial group in Table 31. As shown, concomitant medication use was
high (i.e. by almost all patients).
Safety analyses
Laparoscopic ventral mesh rectopexy has a number of specific complications in addition to the general
risks of surgery. Data on these complications are in the public domain and can be considered to be
expected events. However, these were still recorded for outcome reporting. The study (not being of a
medicinal product) did not record unrelated AEs, and related AEs and SAEs were small in number, with
only two related SAEs reported (Table 32).
TABLE 30 Binary secondary outcomes, with unadjusted estimate of ORs, comparing scores at 24 and 48 weeks post
surgery and baseline (continued )
Time point n/N (%) OR (95% CI)
Self-care
Baseline 3/25 (12.0) NA
24 weeks 4/20 (20.0) 1.83 (0.36 to 9.35)
48 weeks 2/17 (11.8) 0.98 (0.15 to 6.58)
Usual activities
Baseline 18/25 (72.0) NA
24 weeks 10/20 (50.0) 0.39 (0.11 to 1.34)
48 weeks 8/17 (47.1) 0.35 (0.09 to 1.26)
Pain/discomfort
Baseline 25/25 (100.0) NA
24 weeks 18/20 (90.0) 1.00a
48 weeks 17/17 (100.0) 1.00a
Anxiety/depression
Baseline 16/25 (64.0) NA
24 weeks 11/20 (55.0) 0.69 (0.21 to 2.29)
48 weeks 9/17 (52.9) 0.63 (0.18 to 2.22)
NA, not applicable; OR, odds ratio.
a High percentages made model fitting impossible.













Number of patients who
underwent surgery
9 9 9 27
Number of patients reporting
the use of concomitant
medications
9 8 7 24
Number of concomitant
medications reported
64 80 56 200
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TABLE 32 The CapaCiTY trial 3 AEs
Variable
Group 1: lapVMR












8 7 1 16
Number of AEs reported by category
Abdominal pain 2 2 0 4
Anal/rectal pain
or discomfort
1 3 0 4
Bloating 0 1 0 1
Constipation 1 0 0 1
Haemorrhoids 1 0 0 1
Loose motions 0 1 0 1
Rectal bleeding 1 1 0 2
Vaginal/perineal
bulge
2 1 0 3
Miscellaneous 4 8 0 12
Severity
Mild 5 5 0 10




3 4 1 8
Possibly related 4 7 0 11
Definitely related 3 6 0 9
Action
No action taken 8 7 1 16
Withdrawal 1 0 0 1
Concomitant
medication
2 9 0 11
Non-drug
therapy
1 0 0 1




2 3 0 5
Number of SAEs reported that require hospitalisation or prolongation of existing hospitalisation
Unlikely to be
related
1 0 0 1
Possibly related 0 2 0 2
Definitely related 1 1 0 2
Expectedness
Expected 1 2 0 3
Unexpected 1 1 0 2
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Results: cost-effectiveness
Summary and completeness of data
Patients were allocated randomly to lapVMR with either immediate surgery or surgery after a 12-week
or 24-week delay. The trial under-recruited (25 out of a planned 114 patients), making analysis exploratory.
Variables used to estimate costs and QALYs are described in Table 33. For brevity, prescription and
community health-care resources are shown costed and aggregated by period before and after surgery.
Non-interventional costs were small and stable in the periods before and after surgery, compared with
the cost of surgery itself (£4941 per patient). All patients had a minimum follow-up period from 12 weeks
pre surgery to 48 weeks post surgery. Pre-surgery and postsurgery follow-up could be extended by up
to 24 weeks depending on the delay in allocation to surgery. Completeness of cost and QALY data
was reasonable over the period of common follow-up (–12 to 48 weeks) but diminished outside this
follow-up window, reflecting a combination of allocation and missed visits.
TABLE 32 The CapaCiTY trial 3 AEs (continued )
Variable
Group 1: lapVMR










No action 0 1 0 1
Concomitant
medication
1 1 0 2
Non-drug
therapy
1 0 0 1
Hospitalisation 0 1 0 1
a None of the SAEs was identified as related to a treatment; no unresolved SAEs were reported.
TABLE 33 The CapaCiTY trial 3 economic analysis variables (£, 2018)
Cost (£, 2018) QoL, EQ-5D-5L score (points)
Perioda Mean (SD) SD n Perioda Mean (SD) SD n
–48 to –36 weeksb – – 0 –48 weeksb – – 0
–36 to –24 weeksc 39 66 7 –36 weeksc 0.664 0.145 9
–24 to –12 weeksc 138 259 15 –24 weeksc 0.596 0.224 17
–12 to 0 weeks 82 147 23 –12 weeks 0.637 0.198 22
0 to 12 weeks 85 126 22 0 weeks 0.613 0.286 23
12 to 24 weeks 126 264 21 12 weeks 0.731 0.150 24
24 to 36 weeks 64 80 17 24 weeks 0.671 0.235 20
36 to 48 weeks 146 194 16 36 weeks 0.701 0.196 19
48 to 60 weeks 120 95 7 48 weeks 0.618 0.279 17
60 to 72 weeks 126 127 6 60 weeks 0.719 0.225 10
– – 72 weeks 0.809 0.118 5
FOCB
–48 to –36 weeks 71 191 27 –48 weeks 0.637 0.172 26
–36 to –24 weeks 71 191 27 –36 weeks 0.637 0.172 26
–24 to –12 weeks 90 210 27 –24 weeks 0.629 0.192 25
continued
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To construct an informative exploratory analysis, a simple pre–post design was employed, with the
three trial groups aligned and the time of surgery of each group becoming T0. Exploratory growth
curve analysis of the postsurgery period found a stable cost consistent with a constant value over each
period but an increasing and then decreasing EQ-5D-5L score over the 48-week period following
surgery. Using last observation carried forward (LOCF) from 48 weeks to compensate for diminishing
data, the EQ-5D-5L score was consistent with a constant value beyond 48 weeks. An incremental
analysis would then require costs and QALYs estimated 48 weeks before to 48 weeks after surgery.
Comparison of observed data and growth curve analysis using FOCB from –12 weeks found that costs
and EQ-5D-5L scores were stable and consistent with a constant value over the pre-intervention period.
Consequently, costs and EQ-5D-5L scores were estimated for the entire pre-surgery period (–48 to 0 weeks)
using the FOCB approach because data were too sparse to attempt imputation. Multiple imputation was
used in the base-case model to manage missing values in the pre-surgery period and the postsurgery
periods from 0 to 48 weeks.
Cost-effectiveness analyses
The base-case model is reported in Table 34. Comparing pre-surgery and postsurgery periods, intervention
led to a significant increase in cost (£5012, 95% CI £4446 to £5322), similar to the cost of surgery, and
a modest and imprecise increase in QoL (0.043 QALYs, 95% CI –0.005 to 0.093 QALYs). The ICER of
£115,512 per QALY is visualised using the ICER plane in Figure 17. NMB values were negative for surgery
across the commonly used range of WTP thresholds, indicating a lack of cost-effectiveness. These findings
are presented as a CEAC showing the probability of being cost-effective at various WTP thresholds. At the
NICE-recommended WTP of £30,000 per QALY, the probability that surgery is cost-effective is 0%. The
EVPI (per subject) reflects the opportunity loss of ongoing uncertainty and suggests that there is no
requirement for further research.
TABLE 33 The CapaCiTY trial 3 economic analysis variables (£, 2018) (continued )
Cost (£, 2018) QoL, EQ-5D-5L score (points)
Perioda Mean (SD) SD n Perioda Mean (SD) SD n
LOCF
36 to 48 weeks 141 189 17 48 weeks 0.627 0.257 20
48 to 60 weeks 130 137 17 60 weeks 0.627 0.283 20
60 to 72 weeks 121 124 18 72 weeks 0.635 0.278 21
Health-care cost
–48 to 0 weeksd 239 442 23 –48 to 0 weeksd 0.571 0.164 19
0 to 48 weeks 468 452 15 0 to 48 weeks 0.639 0.184 12
Δe 5252 564 14 Δe 0.018 0.121 10
Societal costf
–48 to 0 weeks 1131 1762 23 – – – –
0 to 48 weeks 2835 4474 15 – – – –
Δg 6540 4863 14 – – – –
LOCF, last observation carried forward.
Subtotals may not sum to totals because of different numbers of patients contributing.
a Includes (non-surgery) prescription drugs, hospital and community health visits.
b No patients had data observed at this time point or for this period.
c Because of the allocated delay to surgery, patients had between 12- and 36-week pre-surgery data.
d Pre-surgery costs and QALYs estimated by FOCB.
e Incremental health-care cost = cost of surgery + cost (0 to 48 weeks) – cost (–48 to 0 weeks).
f Includes days lost from usual activity/work.
g Incremental societal cost.
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a Probability cost-effective at WTP threshold of £15,000 per QALY.
b Probability cost-effective at WTP threshold of £30,000 per QALY.
c Denotes a dominated strategy: increase in cost and decrease in QALYs.
d Univariate regression (NMB) of base case.
Note












































FIGURE 17 The CapaCiTY trial 3 cost-effectiveness analysis: base case. (a) ICER plane [the credible region (dashed circle)
shows where 95% of estimates lie]; (b) incremental NMB; (c) CEAC; and (d) EVPI. (continued )
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In Figure 17a, the ICER plane shows that lapVMR resulted in a significant increase in costs but modest and
imprecise increase in QALYs. In Figure 17b, the incremental NMB shows that investing in lapVMR at
commonly usedWTP thresholds appears to deliver a loss to the health-care system compared with
alternatives. In Figure 17c, the CEAC shows that there is a very low probability that lapVMR is cost-effective.
In Figure 17d, the EVPI suggests that there is little value to the health-care system of further research in this
field unless theWTP threshold was considerably higher than commonly used thresholds.
The complete-case analysis (using the FOCB estimate of pre-surgery cost) is also presented in Table 34.
Although the numbers contributing are small, the findings are statistically similar to the base case, if
less precise. Given the very small numbers in the trial, as a sensitivity analysis the base-case model was
re-estimated as a univariate regression (NMB at various WTP thresholds). The findings were very
similar: at a WTP of £30,000 per QALY, the probability that surgery was cost-effective was 0%.
Results: patient experience and qualitative analysis
Emergent themes are presented in this section. Numbers in square brackets refer to the numbered
quotations in Appendix 2, Quotations from participants contributing to qualitative analysis in all three trials,
CapaCiTY trial 3: laparoscopic ventral mesh rectopexy.
Making the decision for surgery
Nine out of the 10 interviewees opted for lapVMR surgery. For some, the decision to undergo surgery
was a much-welcomed pragmatic option [1]. Others appeared to go through a longer deliberation
process about potential adverse effects of the surgery, including the recently publicised issues around




































FIGURE 17 The CapaCiTY trial 3 cost-effectiveness analysis: base case. (a) ICER plane [the credible region (dashed circle)
shows where 95% of estimates lie]; (b) incremental NMB; (c) CEAC; and (d) EVPI.
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trust in the surgeon and wider bowel team, seemed to mitigate these concerns. For one patient, the
reasons for not opting for surgery at this time included several current physical and mental health
issues. This patient had chosen to manage her CC with a change in diet, TAI, suppositories and
laxatives, as advised by health-care professionals.
Patient surgical experience
A few patients experienced surgical delays, cancellations and pathway difficulties due to administration
or cross-departmental communication issues. A number reported a very good hospital stay experience
and described how they felt supported by the surgical and wider health-care team. Some patients
reported that the surgery was better than they had initially expected [3]. However, a few patients did
report negative experiences during their hospital stay. These did not appear to be related to the
surgery itself, but rather to the before and after care provided on the wards.
Patient postoperative experience
The level of postsurgical pain seemed to vary. For some, pain was not much of an issue [4], whereas for
others postoperative pain was a significant feature [5]. Recovery times also varied, with a couple of
patients going back to work within weeks. However, for several it took between 6 weeks and 9 months
to fully recover postoperatively.
Surgical results
Some patients described how their bowel functioning was better immediately after surgery [6]. For
others, it took a few weeks to start seeing improvement. However, for a few patients the surgery did
not seem to improve their constipation [7]. Some patients have reported continued success and a
better QoL both mentally and physically [8] and would recommend the surgery to someone who was
experiencing similar bowel issues.
For others, the surgery has corrected some but not all issues, such as being able to pass stools in a
timely manner. Thus, for some, it was not the ‘miracle cure’ they were hoping for [9]. A few patients
reported that, although surgery initially seemed to be addressing their problematic bowel issues, they
were now re-experiencing these problems [10].
Postoperative behavioural changes
Some patients changed their diet and fluid intake after surgery to better manage their bowels and to
promote continued success, and others had a healthy diet prior to surgery and continued to maintain
this. Some patients reported using laxatives from time to time after surgery, but that this use was
much less frequent than before.
Patient concerns
A few patients, particularly those who were re-experiencing their previous symptoms, reported concerns
about a prolapse recurring as well as new defaecation pain. For a few patients, there had been additional
concerns about whether or not mesh use played a role in continued pain following surgery.
Mesh in the media
Although the study had the full backing from national expert groups such as the Pelvic Floor Society,
negative coverage of mesh use in the media coincided with the start of the study [11]. This affected
the wider elements of the study in terms of patient participation.
Staff experiences
Because of the media coverage there was reluctance from surgeons to recruit patients for the study
and to surgery in general, or surgeons decided to no longer perform lapVMR at all. These media
concerns have led to surgeons directly expressing anxieties [12]. In addition, some hospitals erred on
overemphasising the risks involved, providing patients with multiple consent forms, which potentially
exacerbated patient anxieties about lapVMR. Equally, entire organisations chose to no longer offer the
surgery because of litigation concerns.
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Documents outlining the differences between the gynaecological mesh issues (in the media) and the
current lapVMR surgery helped to clarify some patient concerns, as did surgical mentoring and patient
tracking databases. However, recruitment continued to be severely affected by the negative media
coverage [13]. Developing one nationally recognised information sheet and lapVMR surgical
certification may assist with patient and surgeon anxieties in future.
Some staff stated that CapaCiTY trial 3 did not appear to affect current clinical practice. However,
others did acknowledge that the research affected practice and/or current practice affected the
research procedure owing to protocol restrictions and scheduling issues.
Surgeons noted that lapVMR surgery is technically challenging, particularly if the patient has additional
medical complications. Furthermore, owing to the technical nature of the operation, extensive
experience of carrying out lapVMR surgeries is deemed necessary to perform the procedure, limiting
the number of surgeons able to offer this operation. The research team attempted to mitigate any
potential surgical variation by reviewing operation videos; however, disparity still existed.
Although the surgical video review embedded in the current study attempted to solve the issue of
operational variation, it presented additional challenges around:
l patient consent deviations
l potential reluctance of sites/surgeons participating owing to feeling scrutinised
l professional feedback difficulties, which may have contributed towards administrative video
review delays.
Anxieties around potential legal issues, lack of experienced lapVMR surgeons and surgeons possibly
feeling scrutinised by video review could have contributed towards the difficulty of recruiting surgical
staff to take part in CapaCiTY trial 3 interviews (in addition to the patient recruitment issues).
However, the general sense from the interviewed staff was that lapVMR is helpful for the majority of
patients, although staff also recognise that some patients (particularly those who have multiple medical
issues) may not experience lasting beneficial results.
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Appendix 2 Other outputs arising from
the programme
CapaCiTY trial 1: intervention protocols
Habit training
Sessions (minimum 3, maximum 4; ≈ 60 minutes each).
This will use a standardised pro forma.
l Participants receive a written information leaflet covering normal bowel function, causes of
constipation, diet and fluid advice, and getting into a good bowel habit.
l Participants receive a review of written information using locally available teaching tools such as
models or diagrams.
l Participants receive advice to stop using all laxatives, including drugs that the British National
Formulary146 describes as having a laxative effect or over-the-counter herbal teas that contain strong
purgatives. Glycerine suppositories (one or two) as rescue if there is no stool for 3 days is allowed.
No use of irrigation devices or enemas.
l Participants encouraged to follow a daily routine: sit on the toilet 20–30 minutes after first meal
and/or hot drinks (sooner if urge felt).
l Participants instructed that they can attempt defaecation after meals or when urge is felt, but no
more than three times per day.
l Participants instructed that they should sit on the toilet with knees bent in a 45-degree position,
with feet elevated on stool or equivalent, and abdominal brace and breathe while performing
anal relaxation.
l Participants instructed that they must attempt to push for only 5–10 minutes maximum.
l Defaecation manoeuvres taught while the patient is positioned sitting on a chair, with verbal
coaching to breathe while pushing.
l Participants strongly discouraged from multiple attempts and prolonged straining.
l Participants instructed that there must be no digitation anally.
l Where appropriate, participants taught rectocele (vaginal), perineal and perianal splinting.
l Therapists prohibited from using digital rectal exam to train manoeuvres.
l Participants receive diet and lifestyle advice (e.g. moderate but not excessive fibre; moderate but
not excessive fluid intake; increase exercise, such as walking, if possible).
l Only participants with evacuation difficulty and/or perineal descent taught pelvic floor exercises.
l Participants receive optimistic encouragement and personal attention.
l Participants receive suggestions about what to work on until next meeting.
l Therapists to complete relevant sections in participant booklet.
Habit training and direct visual biofeedback
l Biofeedback balloon and catheter/probe connected to computer monitor. Patient lying in lateral
position facing computer screen (supine if unable to lie in lateral position). Probe taped or held
into position.
l Resting pressure noted (using event recorder). Squeeze pressure noted.
l Rectal balloon inflated with air (2 ml/second) to assess first sensation and urge volume. Volumes
noted. Maximum = 360 ml.
l Rectoanal inhibitory reflex elicited with 50-ml aliquots and rapid inflation with air (30 ml/second);
volume to first urge and the effect on resting pressure noted. Maximum = 150 ml.
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l Coaching to evacuate with 60 ml of water (one syringe full) in the balloon. Participant attempts
balloon expulsion and the effect on anal pressure noted.
l Attempts to relax while pushing to expel balloon are monitored. Participant instructed to push and
breathe, with emphasis on needing to push from the waist while relaxing the anus. Propulsive effort
noted. A minimum of three and no more than 10 attempts in total, with coaching (therapist
observes abdominal and anal activity and advises), or until balloon is expelled (not essential).
Correct pushing technique ensured.
l HRAM can be used to coach pelvic floor exercises if indicated.
l Participants undergoing biofeedback may have rectal hypersensitivity or hyposensitivity. At each
interventional visit, these participants will undergo sensitivity training. The goal will be to increase
(hypersensitive) or decrease (hyposensitive) tolerated balloon volume by gentle progressive
distension or depression of air.
Quotations from participants contributing to qualitative analysis in all
three trials
Synonyms and group allocation are indicated after each quotation.
CapaCiTY trial 1: habit training with or without biofeedback with or without standardised
radiophysiological investigations
1. It was good; indeed, to know that quite early on, that there was nothing serious [after INVEST], that
has helped.
Brian, HTBF with INVEST
2. Well, relief in one way because they didn’t sound like a lot of fun. But also, perhaps, a little regret
because I thought I might get better treatment if I had. So a mixture.
Beth, HT
3. My constipation is stress related and psychologically related and talking to somebody about it really helped.
Francesca, HT
4. Meeting people that it was OK to be like this around, and being OK to talk about it, that they
understood and not just thinking ‘is this just me?’, ‘is this just me and am I going to live like this for the
rest of my life?’
Helen, HT
5. I’d got into a very bad routine and I learned more about improving . . . the dietary side of things . . .
and that includes fluids, which I’ve always been very bad at having enough [of].
Anne-Marie, HT with INVEST
6. I’ve introduced fibre . . . fibre is more the crucial thing.
Edward, HTBF
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
128
7. One really good thing for me was becoming aware, after all these years, that I’d actually been working
against nature, in that I was given advice to be breathing – which, to me, was very, very useful, because
I had been doing the opposite, which basically means tightening . . . the rectum instead of relaxing it.
Anne-Marie, HT with INVEST
8. Having the nurse talk to me about how the bowels actually work, how the problems that my bowels
actually have – I mean that’s really helped me. It has reassured me and I don’t really get as stressed out
as I used to. I don’t have any accidents [faecal incontinence] like I used to either.
Teresa, HT with INVEST
9. I find [the booklet] very informative, especially to the patient and also to the clinician as well, especially
if they are not, you know, they are not so familiar yet with the normal evacuation process.
Bill, clinical intervention nurse
10. It’s much easier for me when I use a [foot]stool. So what I even did – I bought myself a portable stool,
and took it with me when we went on holidays.
Lauren, HTBF with INVEST
11. I guess it’s the reiteration, because a lot of the stuff that he’s telling me is stuff that I kind of know
already, insoluble and soluble fibre stuff, prune juice, I’ve been doing that for ages now. Exercise. But
again it’s just the reiteration and kind of focusing on what I need to concentrate on.
Samantha, HT
12. I certainly feel that there’s been some improvement.
Linda, HT
13. I did have some patients that really grasped using the screen and the images and that really helped
them understand their condition and enabled them to be able to use the map in the right way and
improve, so I found that really interesting to see.
Becky, physiologist
14. I personally felt that when the way that I treated the patients before CapaCiTY came along, worked
exceptionally well and patients were improving. I don’t think the machine added any benefit at all.
Maria, clinical intervention nurse
15. It was a little bit undignified . . . but I’m normally very OK about that sort of thing, I just get on with it.
Kate, HTBF
16. The fact that I’m off the [laxatives] is the best thing. I’m still having interventions and it’s not perfect,
but it’s not like it used to be.
Lauren, HTBF with INVEST
17. I have no qualms about recommending it to absolutely anybody.
Edward, HTBF
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18. It takes longer setting up and takes another 15–20 minutes.
Shaunett, clinical intervention nurse
19. I just didn’t like using [the biofeedback machine] and that might be because I’m not great with change or
adopting something new.
Maria, clinical intervention nurse
CapaCiTY trial 2: transanal irrigation
1. We’re very enthusiastic because we’ve seen the results and we know that it works. So if we’re really
positive about it, I think that really helps. And bringing the patient along with you as well, so you’ve got
to build a good rapport with the patient and bring them along with you.
Bernadette, clinical intervention nurse
2. I think the opportunity to practice during that visit with the nurse was extremely helpful, because there
were some initial ‘so I do it this way, do I do it that way?’ things I could get immediate feedback on so
that was very helpful.
Warren, high-volume TAI, continuing use
3. She offered me the chance to do it [in the clinic] but I just did it at home, it seemed quite straightforward . . .
it’s still something that I feel a bit embarrassed talking about, or doing, so I just preferred to do it at home.
Derek, high-volume TAI, continuing use
4. I was still worried about doing it, because you’re doing it once with the nurses and then you’re coming
home and you’re on your own. But as I say, I knew they were on the end of the phone, and I knew I
could phone them.
Rita, high-volume TAI, continuing use
5. You’re trying to take in a lot of information all at once with a procedure that feels really unnatural, so
I think there’s lots of kind of sequential things that could go wrong . . . not wrong, but just kind of, are
not entirely clear. So even with all that really good explanation and opportunity [to practice in clinic]
there was still a lot of confusion for a wee while.
Warren, high-volume TAI, continuing use
6. It does take a bit of time to get used to it, because it’s a strange sensation, but once you do it’s quite
straightforward to do.
Josephine, high-volume TAI, continuing use
7. It was fine; easy to do.
Lacey, low-volume TAI, continuing use
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
130
8. In the first 3 or 4 days I got what felt like period pain, in my abdomen, just the pressure of the water
being pumped up, but then after, nothing in my abdomen after that. It just feels strange. I wouldn’t say
that it’s painful, it just feels strange using a catheter.
Laurella, high-volume TAI, continuing use
9. [I was] quite happy to do the low[-volume] one . . . I thought the higher[-volume] one would be more like
the colonic irrigation, more painful or more intense.
Lacey, low-volume TAI, continuing use
10. You fit it into your daily routine easily, it’s quick to use.
Elizabeth, high-volume TAI, discontinued use
11. Sometimes it’s quite restrictive, in that it’s hard to fit it into my daily life. Sometimes I get into a routine
with the children and sort of forget about doing it.
Lacey, low-volume TAI, continuing use
12. I think for a couple of months, possibly a bit longer, maybe for a month after using it or a bit longer, it
was still hit or miss, but more recently it has been absolutely fantastic and it does work every time.
Laurella, high-volume TAI, continuing use
13. I am absolutely over the moon with it and I’m happy with how it’s all ended [up]. Compared to how I
am now to how I was I’m like a different person because I feel clean all the time.
Pamela, low-volume TAI, continuing use
14. 100% satisfied. I’ll go on holidays now . . . I’m alive again, I feel like I’m bubbly inside . . . I can go
outside, I can do a lot of walks.
Derek, high-volume TAI, continuing use
15. I don’t suffer from chronic constipation anymore. So I used to go maybe once a week and that’s how my
life was. I used to joke that every Wednesday was my poo day. So this has helped me so much, I can
only thank the team for transforming my life.
Pamela, low-volume TAI, continuing use
16. It’s the leakage, you have to change once or twice until it stops and then after that it’s fine, but there’s
always that bit of leakage coming out after and with me.
Rebecca, high-volume TAI, continuing use
17. Sometimes this group of patients are able to get results straight away, particularly with the high-volume
kit; however, some do need to persevere in order to see the results as it may take time to adapt the
system to meet the person’s particular needs.
Joyce, clinical intervention nurse
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CapaCiTY trial 3: laparoscopic ventral mesh rectopexy
1. I sort of jumped at the chance . . . I just thought if I could just empty naturally, then it would make life a
lot easier.
Rachel, post surgery
2. Obviously [I had] fears, lots of fears about having it done, whether it was the right thing to do . . . it was
all the publicity about mesh.
Camilla, post surgery
3. I think the actual surgery – afterwards, it was better because I thought I was going to be all scarred
down below but it was all done in my tummy, which was better than what I expected . . . The actual
recovery from the surgery, that went quite quickly.
Rita, post surgery
4. There wasn’t a lot of pain with it.
Peggy, post surgery
5. I did have a lot of pain post op. I had quite a severe nerve pain on my right-hand side; that gave me
more problems than the actual pain in my bottom area. That took about 3 or 4 months to calm down.
Esther, post surgery
6. The treatment was excellent and, as I say, the bowel sensation down below literally disappeared
immediately and I don’t have to use gloves and a finger to get all the poo out.
Lilian, post surgery
7. [The surgery] didn’t change anything really.
Camilla, post surgery
8. I used to get very down before the operation and then afterwards even my son noticed and said ‘you
seem cheerful mum’, and I said ‘yeah, I feel quite good actually’.
Amanda, post surgery
9. It wasn’t the miracle cure that I thought it might be, although [the surgeon] didn’t promise me a miracle
cure. But he said, you know, that it should improve my quality of life. I don’t think it has really.
Rachel, post surgery
10. My prolapse is back, the pain’s back, it was about 10 months after the surgery that my prolapse came
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11. There’s been a massive coverage in the media about the negatives of using mesh and how it introduces
long-term issues for the patient.
Angela, research team member
12. It’s a dangerous place being a pelvic floor surgeon. But you’ve got to keep yourself buoyed up by the fact
that the majority of patients do well. Otherwise you wouldn’t do it at all. There is a danger that we all
stop doing this because of the small minority of patients that are not happy.
Christopher, surgeon
13. We were just . . . getting [the study] off the ground when this all blew up and sabotaged it. And of course,
the question is more relevant than ever now with the mesh problems. The study aimed to address
[this], which is the sort of horrendous irony of it really.
Marshall, surgeon
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